Sortiert nach Autor

Publikationen - sortiert nach Autor

• Zifko U, Guendling K, Seet R, Kasper S (2024) Management of cognitive impairment associated with post-COVID-19 syndrome: recommendations for primary care Front. Pharmacol., 15: 1338235
  | Weblink |
• Bartova L, Fugger G, Dold M, Kautzky A, Bairhuber I, Kloimstein P, Fanelli G, Zanardi R, Weidenauer A, Rujescu D, Souery D, Mendlewicz J, Zohar J, Montgomery S, Fabbri C, Serretti A, Kasper S (2024) The clinical perspective on late-onset depression in European real-world treatment settings Int. J. Neuropsychopharmacol., 84: 59-68
  | Weblink |
• Kasper S, Volz H, Möller H, Schläfke S, Klement S, Anghelescu I, Seifritz E (2024) Lavender oil preparation Silexan is effective in mild-to-moderate major depression: a randomized, placebo- and reference-controlled trial Eur Arch Psychiatry Clin Neurosci,
  | Weblink |
• Oliva V, Martone A, Fanelli G, Domschke K, Minelli A, Gennarelli M, Martini P, Bortolomasi M, Maron E, Squassina A, Pisanu C, Kasper S, Zohar J, Souery D, Montgomery S, Albani D, Forloni G, Ferentinos P, Rujescu D, Mendlewicz J, De Ronchi D, Baune B, Serretti A, Fabbri C, Potier M, van Westrhenen R, Rybakowski F, Mehta D, Dierssen M, Janzing J, Liò P (2024) Polygenic scores of subcortical brain volumes as possible modulators of treatment response in depression Neuroscience Applied, 3: 103937
  | Weblink |
• Kadriu B, Deng Z, Kraus C, Johnston J, Fijtman A, Henter I, Kasper S, Zarate C (2024) The impact of body mass index on the clinical features of bipolar disorder: A STEP-BD study Bipolar Disorders, 26: 160-175
  | Weblink |

• Lochmann van Bennekom M, IntHout J, Gijsman H, Akdede B, Yağcıoğlu A, Barnes T, Galling B, Gueorguieva R, Kasper S, Kreinin A, Nielsen J, Nielsen R, Remington G, Repo-Tiihonen E, Schmidt-Kraepelin C, Shafti S, Xiao L, Correll C, Verkes R (2024) Efficacy and tolerability of antipsychotic polypharmacy for schizophrenia spectrum disorders. A systematic review and meta-analysis of individual patient data Schizophr Res, 272: 1-11
  | Weblink |

• Spies M, Silberbauer L, Kasper S (2023) Letter to the editor refers to “Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression” Decision making in treatment resistant depression: appeal for an individualized approach. N Engl J Med, 389 (10): 960
  | Weblink |
• Kasper S, Eckert A, Möller H, Volz H, Seifritz E (2023) Psychiatric manifestations of post-COVID-19 syndrome: the potential benefit of Silexan Int J Psychiatry Clin Pract, 27 (3): 285-291
  | Weblink |
• Wegener T, Edwards D, Kasper S (2023) The potential role of Rhodiola rosea L. extract WS® 1375 for patients with post-COVID-19 fatigue hb TIMES Schw Aerztej, 8 (1): 56-61
  | Weblink |
• Buchmayer F, Kasper S (2023) Overcoming the myths of esketamine administration: different and not difficult Front Psychiatry, 14
  | Weblink |
• Kasper S (2023) Cheers and a thank-you note from the founding chief-editor Int J Psychiatry Clin Pract, 27 (4): 319-322
  | Weblink |
• McIntyre R, Alsuwaidan M, Baune B, Berk M, Demyttenaere K, Goldberg J, Gorwood P, Ho R, Kasper S, Kennedy S, Ly‐Uson J, Mansur R, McAllister‐Williams R, Murrough J, Nemeroff C, Nierenberg A, Rosenblat J, Sanacora G, Schatzberg A, Shelton R, Stahl S, Trivedi M, Vieta E, Vinberg M, Williams N, Young A, Maj M (2023) Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions World Psychiatry, 22 (3): 394-412
  | Weblink |
• Kautzky A, Bartova L, Fugger G, Dold M, Souery D, Montgomery S, Zohar J, Mendlewicz J, Fabbri C, Serretti A, Rujescu D, Kasper S (2023) Age as a moderating factor of treatment resistance in depression Eur Psychiatry, 66: ahead of print
  | Weblink |
• Dold M, Bartova L, Volz H, Seifritz E, Möller H, Schläfke S, Kasper S (2023) Efficacy of Silexan in patients with anxiety disorders: a meta-analysis of randomized, placebo-controlled trials Eur Arch Psychiatry Clin Neurosci, 273 (7): 1615-1628
  | Weblink |
• Stöhrmann P, Godbersen G, Reed M, Unterholzner J, Klöbl M, Baldinger-Melich P, Vanicek T, Hahn A, Lanzenberger R, Kasper S, Kranz G (2023) Effects of bilateral sequential theta-burst stimulation on functional connectivity in treatment-resistant depression: first results J Affect Disord, 324: 660-669
  | Weblink |
• Murgaš M, Unterholzner J, Stöhrmann P, Philippe C, Godbersen G, Nics L, Reed M, Vraka C, Vanicek T, Wadsak W, Kranz G, Hahn A, Mitterhauser M, Hacker M, Kasper S, Lanzenberger R, Baldinger-Melich P (2023) Effects of bilateral sequential theta-burst stimulation on 5-HT1A receptors in the dorsolateral prefrontal cortex in treatment-resistant depression: a proof-of-concept trial Transl Psychiat, 13 (1)
  | Weblink |
• Kraus C, Kautzky A, Watzal V, Gramser A, Kadriu B, Deng Z, Bartova L, Zarate C, Lanzenberger R, Souery D, Montgomery S, Mendlewicz J, Zohar J, Fanelli G, Serretti A, Kasper S (2023) Body mass index and clinical outcomes in individuals with major depressive disorder: Findings from the GSRD European Multicenter Database J Affect Disord, 335: 349-357
  | Weblink |
• Bartova L, Fugger G, Dold M, Kautzky A, Fanelli G, Zanardi R, Albani D, Weidenauer A, Rujescu D, Souery D, Mendlewicz J, Montgomery S, Zohar J, Fabbri C, Serretti A, Kasper S (2023) Real-world characteristics of European patients receiving SNRIs as first-line treatment for major depressive disorder J Affect Disord, 332: 105-114
  | Weblink |
• Kasper S (2023) Fluch oder Segen von Benzodiazepinen: neu bewertet Jatros Neurologie & Psychiatrie , : 5
• Kasper S (2023) Evidenzbasis pflanzlicher Arzneimittel in der Psychopharmakotherapie Psychopharmakotherap, 30: 11-20
• Oliva V, Fanelli G, Kasper S, Zohar J, Souery D, Montgomery S, Albani D, Forloni G, Ferentinos P, Rujescu D, Mendlewicz J, De Ronchi D, Fabbri C, Serretti A (2023) Melancholic features and typical neurovegetative symptoms of major depressive disorder show specific polygenic patterns J Affect Disord, 320: 534-543
  | Weblink |

• Pallanti S, Zohar J, Kasper S, Möller H, Hollander E (2023) Revisiting benzodiazepines (GABA Enhancers):A transdiagnostic and precision medicine approach Psychiat Gen, 170: 65-72
  | Weblink |
• Bartova L, Lanzenberger R, Rujescu D, Kasper S (2023) Reply to: “The serotonin theory of depression: a systematic umbrella review of the evidence” published by Moncrieff J, Cooper RE, Stockmann T, Amendola S, Hengartner MP, Horowitz MA in Molecular Psychiatry (2022 Jul 20. doi: 10.1038/s41380-022-01661-0) Mol Psychiatry, 28 (8): 3153-3154
  | Weblink |
• Himmerich H, Lewis Y, Conti C, Mutwalli H, Karwautz A, Sjögren J, Uribe Isaza M, Tyszkiewicz-Nwafor M, Aigner M, McElroy S, Treasure J, Kasper S, Bailer U, Bulik C, Conti C, Zwaan M, Favaro A, Fernandez-Aranda F, Fetissov S, Hilbert A, Himmerich H, Wijbrand Hoek H, Kan C, Karpenko O, Karwautz A, Kasper S, Kaye W, Lewis Y, McElroy S, Mitchell J, Monteleone P, Mörkl S, Müller D, Mutwalli H, Nazar B, Papežová H, Sjögren J, Steiger H, Stein D, Szabo C, Tyszkiewicz-Nwafor M, Voderholzer U, Uribe Isaza M, Wade T, Wranik W, Yoshiuchi K, (2023) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines update 2023 on the pharmacological treatment of eating disorders World J Biol Psychiatry, 24: 643-706
  | Weblink |
• Bartova L, Dold M, Fugger G, Weidenauer A, Rujescu D, Kasper S (2023) Silexan for treatment of anxiety and depression in the context of COVID-19 Eur Neuropsychopharmacol, 70: 47-48
  | Weblink |

• Inada K, Yamawaki S, Kanba S, Shinozaki G, Kasper S (2023) General Principles of Pharmacologic Therapy. In: Springer Verlag, Springer Verlag Heidelberg, New York Springer Verlag, Heidelberg, New York: ahead of print
  | Weblink |

• Seifritz E, Kasper S, Möller H, Volz H, Müller W, Eckert A, Hatzinger M (2022) Effect of anxiolytic drug silexan on sleep – a narrative review World J Biol Psychiatry, 23 (7): 493-500
  | Weblink |
• Pain O,..,the GSRD Consortium, the Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium, McIntosh AM, Lewis CM (2022) Identifying the Common Genetic Basis of Antidepressant Response Biological Psychiatry GOS, 2 (2): 115-126
  | Weblink |
• Panariello F, Kasper S, Zohar J, Souery D, Montgomery S, Ferentinos P, Rujescu D, Mendlewicz J, De Ronchi D, Serretti A, Fabbri C (2022) Characterisation of medication side effects in patients with mostly resistant depression in a real-world setting World J Biol Psychiatry, 24 (5): 439-448
  | Weblink |
• Roca M, Bonelli A, Cattaneo A, Comandini A, Di Dato G, Heiman F, Pegoraro V, Kasper S, Volz H, Palao D (2022) Factors associated with sick leave duration in patients suffering from major depressive disorder initiating antidepressant treatment: a real-world evidence study in Germany and Spain Int J Psychiatry Clin Pract, 27 (1): 59-68
  | Weblink |
• Silberbauer L, Rischka L, Vraka C, Hartmann A, Godbersen G, Philippe C, Pacher D, Nics L, Klöbl M, Unterholzner J, Stimpfl T, Wadsak W, Hahn A, Hacker M, Rujescu D, Kasper S, Lanzenberger R, Gryglewski G (2022) ABCB1 variants and sex affect serotonin transporter occupancy in the brain Mol Psychiatry, 27 (11): 4502-4509
  | Weblink |
• Bandelow B, Allgulander C, Baldwin D, Costa D, Denys D, Dilbaz N, Domschke K, Eriksson E, Fineberg N, Hättenschwiler J, Hollander E, Kaiya H, Karavaeva T, Kasper S, Katzman M, Kim Y, Inoue T, Lim L, Masdrakis V, Menchón J, Miguel E, Möller H, Nardi A, Pallanti S, Perna G, Rujescu D, Starcevic V, Stein D, Tsai S, Van Ameringen M, Vasileva A, Wang Z, Zohar J (2022) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders – Version 3. Part I: Anxiety disorders World J Biol Psychiatry, 24 (2): 79-117
  | Weblink |
• Bandelow B, Allgulander C, Baldwin D, Costa D, Denys D, Dilbaz N, Domschke K, Hollander E, Kasper S, Möller H, Eriksson E, Fineberg N, Hättenschwiler J, Kaiya H, Karavaeva T, Katzman M, Kim Y, Inoue T, Lim L, Masdrakis V, Menchón J, Miguel E, Nardi A, Pallanti S, Perna G, Rujescu D, Starcevic V, Stein D, Tsai S, Van Ameringen M, Vasileva A, Wang Z, Zohar J (2022) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders – Version 3. Part II: OCD and PTSD World J Biol Psychiatry, 24 (2): 118-134
  | Weblink |
• Ludwig B, Carlberg L, Kienesberger K, Swoboda P, Swoboda M, Bernegger A, Koller R, Inaner M, Fuxjäger M, Zotter M, Schmelzle N, Senft B, Meisner L, Fischer-Hansal D, Huber J, Schoenthaler S, Kapusta N, Haslacher H, Aigner M, Weinhaeusel A, Kasper S, Schosser A (2022) Oxytocin receptor gene methylation as a molecular marker for severity of depressive symptoms in affective disorder patients BMC Psychiatry, 22 (1): 1-8
  | Weblink |
• L. Bartova, G. Fugger, M. Dold, S. Kasper (2022) Therapieoptionen bei Angsterkrankungen unter Berücksichtigung der Phyto- Psychopharmakotherapie Journal für Neurologie, Neurochirurgie und Psychiatrie, 23: 124-130
• Vanicek T, Reed M, Seiger R, Godbersen G, Klöbl M, Unterholzner J, Spurny-Dworak B, Gryglewski G, Handschuh P, Schmidt C, Kraus C, Stimpfl T, Rupprecht R, Kasper S, Lanzenberger R (2022) Increased left dorsolateral prefrontal cortex density following escitalopram intake during relearning: a randomized, placebo-controlled trial in healthy humans Ther Adv Psychopharmacol, 12: 1-15
  | Weblink |
• Zhang B, Stöhrmann P, Godbersen G, Unterholzner J, Kasper S, Kranz G, Lanzenberger R (2022) Normal component of TMS-induced electric field is correlated with depressive symptom relief in treatment-resistant depression Brain Stimul, 15 (5): 1318-1320
  | Weblink |
• Bartova L, Fugger G, Dold M, Kautzky A, Rujescu D, Kasper S (2022) Psychotherapy’s Role for Treatment-Resistant Depression? Am J Psychiatry, 179 (9): 687-687
  | Weblink |
• Spurny-Dworak B, Godbersen GM, Reed MB, Unterholzner J, Vanicek T, Baldinger-Melich P, Hahn A, Kranz GS, Bogner W, Lanzenberger R, Kasper S (2022) The impact of theta-burst stimulation on cortical GABA and glutamate in treatment-resistant depression: A surface-based MRSI analysis approach. Front Mol Neurosci, : 913274
  | Weblink |
• Bartova L, Dold M, Volz HP, Seifritz E, Möller HJ, Kasper S (2022) Beneficial effects of Silexan on co-occurring depressive symptoms in patients with subthreshold anxiety and anxiety disorders – randomized, placebo-controlled trials revisited. Eur Arch Psychiatry Clin Neurosci,
  | Weblink |
• Fanelli G, Domschke K, Minelli A, Gennarelli M, Martini P, Bortolomasi M, Maron E, Squassina A, Kasper S, Zohar J, Souery D, Montgomery S, Albani D, Forloni G, Ferentinos P, Rujescu D, Mendlewicz J, De Ronchi D, Baune BT, European College of Neuropsychopharmacology (ECNP) Pharmacogenomics & Transcriptomics Thematic Working Group, Serretti A, Fabbri C (2022) A meta-analysis of polygenic risk scores for mood disorders, neuroticism, and schizophrenia in antidepressant response. Eur Neuropsychopharmacol, 55: 86-95
  | Weblink |
• Oliva V, Fanelli G, Kasper S; Zohar J, Souery D; Montgomery S, Albani D; Forloni G, Ferentinos P, Rujescu D, Mendlewicz J, Kas M, De Ronchi D, Fabbri C, Serretti A (2022) Social withdrawal as a trans-diagnostic predictor of short-term remission. A meta-analysis of five clinical cohorts. Int Clin Psychopharmacol, 37: 38 – 45
  | Weblink |
• Fugger G, Bartova L, Dold M, Fabbri C, Fanelli G, Zanardi R, Kautzky A, Zohar J, Souery D, Mendlewicz J, Montgomery S, Rujescu D, Serretti A, Kasper S (2022) Evidence on Sociodemographic and Clinical Correlates of Antidepressant Combination or Augmentation with Second-Generation Antipsychotics in Major Depressive Disorder. Prog in Neuropsychopharmaco & Biolog. Psychiatry , 114: 110480
  | Weblink |
• Fugger G, Bartova L, Fabbri C, Fanelli G, Zanardi R, Dold M, Kautzky A, Rujescu D, Souery D, Mendlewicz J, Zohar J, Montgomery S, Serretti A, Kasper S (2022) The Sociodemographic and Clinical Phenotype of European Patients with Major Depressive Disorder Undergoing first-line Antidepressant Treatment with NaSSAs J Affect Disord, : 225-234
  | Weblink |
• Fugger G, Bartova L, Fabbri C, Fanelli G, Dold M, Swoboda MMM, Kautzky A, Zohar J, Souery D, Mendlewicz J, Montgomery S, Rujescu D, Serretti A, Kasper S (2022) The Sociodemographic and Clinical Profile of Patients with Major Depressive Disorder Receiving SSRIs as First-line Antidepressant Treatment in European Countries. Eur Arch Psychiatry Clin Neurosci,
  | Weblink |
• de Bardeci M, Greil W, Stassen H, Willms J, Köberle U, Bridler R, Hasler G, Kasper S, Rüther E, Bleich S, Toto S, Grohmann R, Seifert J (2022) Dear Doctor Letters regarding Citalopram and Escitalopram: Guidelines vs real world data. Eur Arch Psychiatry Clin Neurosci,
  | Weblink |
• Bartova L, Fugger G, Dold M, Kautzky A, Swoboda MMM, Rujescu D, Zohar J, Souery D, Mendlewicz J, Montgomery S, Fabbri C, Serretti A, Kasper S (2022) The Choice of either Quetiapine or Aripiprazole as Augmentation Treatment in a European Naturalistic Sample of Patients with Major Depressive Disorder. Int. J. Neuropsychopharmacol., 25: 118-127
  | Weblink |
• Calabrò M, Fabbri C, Kasper S, Zohar J, Souery D, Montgomery S, Albani D, Forloni G, Ferentinos P, Rujescu D, Mendlewicz J, De Ronchi D, Serretti A, Crisafulli C (2022) Metabolizing status of CYP2C19 in response and side effects to medications for depression: results from a naturalistic study. Eur Neuropsychopharmacol, 56: 100-111
  | Weblink |
• Kasper S (2022) Initiating Antidepressant Medication: What is the Most Important Factor? Adv in Therapy, : S5-S12,
  | Weblink |
• Sarris J, Ravindran A, Yatham LN, Marx W, Rucklidge J, McIntyre RS, Akhondzadeh S, Benedetti F, Caneo C, Cramer H, Cribb L, de Manincor M, Dean O, Deslandes AC, Freeman MP, Gangadhar B, Harvey BH, Kasper S, Lake J, Lopresti A, Lu L, Metri NJ, Mischoulon D, Ng C, Nishi D, Rahimi R, Seedat S, Sincliar J, Su KP, Zhang ZJ, Berk M (2022) Clinician Guidelines for the Treatment of Psychiatric Disorders with Nutraceuticals and Phytoceuticals: The World Federation of Societies of Biological Psychiatry (WFSBP) and Canadian Network for Mood and Anxiety Treatments (CANMAT) Taskforce. World J Biol Psychiatry, 23: 424-455
  | Weblink |
• Volz H, Bartečků E, Bartova L, Bessa J, De Berardis D, Dragasek J, Kozhuharov H, Ladea M, Lazáry J, Roca M, Usov G, Wichniak A, Godman B, Kasper S (2022) Sick leave duration as a potential marker of functionality and disease severity in depression Int J Psychiatry Clin Pract, 26 (4): 406-416
  | Weblink |
• Komorowski A, Murgas M, Vidal R, Singh A, Gryglewski G, Kasper S, Wiltfang J, Lanzenberger R, Goya-Maldonado R (2022) Regional gene expression patterns are associated with task-specific brain activation during reward and emotion processing measured with functional MRI Human Brain Mapping, 43: 5266-5280
  | Weblink |
• Fanelli G, Sokolowski M, Wasserman D, European College of Neuropsychopopharmacology (ECNP) Network on Suicide Research and Prevention, Kasper S, Zohar J, Souery D, Montgomery S, Albani D, Forloni G, Ferentinos P, Rujescu D, Mendlewicz J, De Ronchi D, Serretti A, Fabbri C (2022) Polygenic risk scores for neuropsychiatric, inflammatory, and cardio-metabolic traits highlight possible genetic overlap with suicide attempt and treatment-emergent suicidal ideation Am. J. Med. Genet. B Neuropsychiatr. Genet. , : 74-85
  | Weblink |
• Generoso M, Taiar I, Cordeiro Q, Shiozawa P, Kasper S (2022) Cariprazine for treating psychosis: an updated meta-analysis Int J Psychiatry Clin Pract, 27 (1): 107-109
  | Weblink |
• Friedrich ME, Grohmann R, Rabl U, Winkler D, Konstantinidis A, Engel R, Seifert J, Toto S, Stübner S, Frey R, Kasper S (2022) Incidence of drug-induced delirium during treatment with antidepressants or antipsychotics – a drug surveillance report of German-speaking countries between 1993 and 2016. Int. J. Neuropsychopharmacol., 25: 556-566
  | Weblink |
• Vanicek T, Unterholzner J, Lanzenberger R, Naderi-Heiden A, Kasper S, Praschak-Rieder N (2022) Intravenous esketamine leads to an increase in impulsive and suicidal behaviour in a patient with recurrent major depression and borderline personality disorder World J Biol Psychiatry, 23 (9): 715-718
  | Weblink |

• Kasper S (2022) Rasch wirkende Antidepressiva bei Major Depression und therapieresistenter Depression Jatros Neurologie & Psychiatrie , 5: 38
• Kasper S, Sachs G, Erfurth A, Rujescu D, Bach M, Baldinger-Melich P, Bartova L, Conca A, Dold M, Frey R, Goessler R, Hausmann A, Lan-zenberger R, Lehofer M, Marksteiner J, Naderi-Heiden A, Plener P, Praschak-Rieder N, Rados C, Schosser A, Sperner-Unterweger B, Spies M, Winkler D (2022) Angststörungen Psychopharmakotherapie Jatros Neurologie & Psychiatrie ,
• Möller HJ, Kasper S (2022) Serotonin-Theorie der Depression in Umbrella-Review nicht bestätigt? Psychopharmakotherap, 29: 187-189
• Kasper S (2022) Suizidalität: Von einer psychiatrischen zu einer juristischen Sichtweise? Jatros Neurologie & Psychiatrie , : 24-25
• Kasper S. (2022) Suizidalität: Von einer psychiatrischen zu einer juristischen Sichtweise? Journal für Neurologie, Neurochirurgie und Psychiatrie, 23: 5-6
• Kasper S, Erfurth A, Sachs G, Aichhorn W, Bartova L, Bengesser S, Buchmayer F, Deisenhammer E, Di Pauli J, Dold M, Falkai P, Frey R, Glück K, Hofer A, Holsboer-Trachsler E, Kautzky A, Konstantinidis A, Kraus C, Lehofer M, Marksteiner J, Mitschek M, Mörkl S, Oberlerchner H, Plener P, Psota G, Rados C, Rainer M, Schosser A, Seifritz E, Silberbauer C, Winkler D, Wunsch C, Zwanzger P (2022) Treatment-resistant Depression: Diagnosis and Treatment, Konsensus-Statement Jatros Neurologie & Psychiatrie , : 1-31
• Fugger G, Bartova L, Dold M, Kasper S (2022) Die therapieresistente Depression (TRD) – Herausforderungen und praktisches Management. psychopraxis. neuropraxis, : 49 – 54
  | Weblink |
• Kasper S (2022) Is treatment-resistant depression really resistant? Eur Neuropsychopharmacol, : 44–46
  | Weblink |
• Volz HP, Stirnweiß J, Kasper S, Möller HJ, Seifritz E (2022) Subthreshold depression – concept, operationalization and epidemiological data. A scoping review. Int J Psychiatry Clin Pract, 27: 92-106
  | Weblink |

• Mitschek M, Vanicek T, Unterholzner J, Kraus C, Weidenauer A, Naderi-Heiden A, Frey R, Silberbauer L, Gryglewski G, Papageorgiou K, Winkler D, Dold M, Kasper S, Praschak-Rieder N, Bartova L (2021) How to prevent and manage hyperammonemic encephalopathies in valproate therapy J Affect Disord, 5: 100186
  | Weblink |
• Möller H, Falkai P, Kasper S (2021) Obituary – Prof. Dr. Hanns Hippius Int. J. Neuropsychopharmacol., 24: 856-857
  | Weblink |
• Winkler D, Grohmann R, Friedrich ME, Toto S, Bleich S, Seifert J, Anastasios Konstantinidis A, Shariat SF, Kasper S, Pjrek E (2021) Urological adverse drug reactions of psychotropic medication in psychiatric inpatients – A drug surveillance report of German-speaking countries J Psychiatr Res, 144: 412–420
  | Weblink |
• Bartova L, Kasper S (2021) Chronobiologie der Depression Psychiatr Danub., 33: 446-453
  | Weblink |
• Sauerzopf U, Weidenauer A, Dajic I, Bauer M, Bartova L, Meyer B, Nics L, Philippe C, Pfaff S, Pichler V, Mitterhauser M, Wadsak W, Hacker M, Kasper S, Lanzenberger R, Pezawas L, Praschak-Rieder N, Willeit M (2021) Disrupted relationship between blood glucose and brain dopamine D2/3 receptor binding in patients with first-episode schizophrenia Neuroimage Clin, 32: 102813
  | Weblink |
• Gryglewski G, Lanzenberger R, Silberbauer LR, Pacher D, Kasper S, Rupprecht R, Frey R, Baldinger-Melich P (2021) Meta-analysis of brain structural changes after electroconvulsive therapy in depression Brain Stimul, 14: 927-937
  | Weblink |
• Kasper S, Bonelli A, Cattaneo A, Comandini A, Di Dato G, Heiman F, Pegoraro V, Palao D, Roca M, Volz HP (2021) Predictors of sick leave days in patients affected by major depressive disorder receiving antidepressant treatment in general practice setting in Germany Int J Psychiatry Clin Pract, 24: 393-402
• Kasper S, Young AH, Vieta E, Goodwin G, Meyer-Lindenberg A (2021) Letter to BJPsych in response to Horowitz and Moncrieff (electronic response to Horowitz MA and Moncrieff J) Are we repeating mistakes of the past? A review of the evidence for esketamine. Br J Psychiatry, 219: 619-620
  | Weblink |
• Seifritz E, Möller HJ, Volz HP, Müller WE, Hopyan T, Wacker A, Schläfke S, Kasper S (2021) No abuse potential of Silexan in healthy recreational drug users: a randomised controlled trial Int. J. Neuropsychopharmacol., 24: 171-180
• Dold M, Bartova L, Fugger G, Mitschek MMM, Fabbri C, Serretti A, Mendlewicz J, Souery D, Zohar J, Montgomery S, Kasper S (2021) Pregabalin augmentation of antidepressants in major depression – results from a European multicenter study J Affect Disord, 296: 485-492
  | Weblink |
• Volz H, Saliger J, Kasper S, Möller H, Seifritz E (2021) Subsyndromal generalised anxiety disorder: operationalisation and epidemiology – a systematic literature survey Int J Psychiatry Clin Pract,
  | Weblink |
• Bartova L, Dold M, Fugger G, Kautzky A, Mitschek M, Weidenauer A, Hienert M, Frey R, Mandelli L, Zohar J, Mendlewicz J, Souery D, Montgomery S, Fabbri C, Serretti A, Kasper S (2021) Sex‐related effects in major depressive disorder: Results of the European Group for the Study of Resistant Depression Depress Anxiety,
  | Weblink |
• Rischka L, Godbersen G, Pichler V, Michenthaler P, Klug S, Klöbl M, Ritter V, Wadsak W, Hacker M, Kasper S, Lanzenberger R, Hahn A (2021) Reliability of task-specific neuronal activation assessed with functional PET, ASL and BOLD imaging Cereb Blood Flow Metab, : 0271678X2110205
  | Weblink |
• Ludwig B, Carlberg L, Kienesberger K, Swoboda P, Mitschek M, Bernegger A, Koller R, Inaner M, Senft B, Meisner L, Fischer-Hansal D, Affenzeller A, Huber J, Schoenthaler S, Kapusta N, Haslacher H, Aigner M, Weinhaeusel A, Kasper S, Schosser A (2021) Monoamino Oxidase a Gene Single-Nucleotide Polymorphisms and Methylation Status and the Risk of Violent Suicide Attempts in Affective Disorder Patients Front Psychiatry, 12
  | Weblink |
• Bartova L, Fugger G, Dold M, Swoboda M, Zohar J, Mendlewicz J, Souery D, Montgomery S, Fabbri C, Serretti A, Kasper S (2021) Combining psychopharmacotherapy and psychotherapy is not associated with better treatment outcome in major depressive disorder - evidence from the European Group for the Study of Resistant Depression J Psychiatr Res, 141: 167-175
  | Weblink |
• Milenkovic I, Bartova L, Papageorgiou K, Kasper S, Traub-Weidinger T, Winkler D (2021) Case Report: Bupropion Reduces the [123I]FP-CIT Binding to Striatal Dopamine Transporter Front Psychiatry, 12: 631357
  | Weblink |
• Höflich A, Kraus C, Pfeiffer R, Seiger R, Rujescu D, Zarate C, Kasper S, Winkler D, Lanzenberger R (2021) Translating the immediate effects of S-Ketamine using hippocampal subfield analysis in healthy subjects-results of a randomized controlled trial Transl Psychiat, 11 (1): 200
  | Weblink |
• Dold M, Bartova L, Fugger G, Kautzky A, Mitschek M, Fabbri C, Montgomery S, Zohar J, Souery D, Mendlewicz J, Serretti A, Kasper S (2021) Melancholic features in major depression – a European multicenter study Prog Neuropsychopharmacol Biol Psychiatry, 110: 110285
  | Weblink |
• McIntyre R, Rosenblat J, Nemeroff C, Sanacora G, Murrough J, Berk M, Brietzke E, Dodd S, Gorwood P, Ho R, Iosifescu D, Lopez Jaramillo C, Kasper S, Kratiuk K, Lee J, Lee Y, Lui L, Mansur R, Papakostas G, Subramaniapillai M, Thase M, Vieta E, Young A, Zarate C, Stahl S (2021) Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation Am J Psychiatry, 178 (5): 383-399
  | Weblink |
• von Känel R, Kasper S, Bondolfi G, Holsboer‐Trachsler E, Hättenschwiler J, Hatzinger M, Imboden C, Heitlinger E, Seifritz E (2021) Therapeutic effects of Silexan on somatic symptoms and physical health in patients with anxiety disorders: A meta‐analysis Brain and Behavior, 11 (4): e01997
  | Weblink |
• Bartova L, Dold M, Fugger G, Kautzky A, Mitschek M, Weidenauer A, Handschuh P, Frey R, Mandelli L, Zohar J, Mendlewicz J, Souery D, Montgomery S, Fabbri C, Serretti A, Kasper S (2021) The Role of Relationship Status in Major Depressive Disorder Results of the European Group for the Study of Resistant Depression J Affect Disord, 286: 149-157
  | Weblink |
• Seiger R, Gryglewski G, Klöbl M, Kautzky A, Godbersen G, Rischka L, Vanicek T, Hienert M, Unterholzner J, Silberbauer L, Michenthaler P, Handschuh P, Hahn A, Kasper S, Lanzenberger R (2021) The influence of acute SSRI administration on white matter microstructure in patients suffering from major depressive disorder and healthy controls Int J Neuropsychopharmacol, 24 (7): 542-550
  | Weblink |
• Sarris J, Marx W, Ashton M, Ng C, Galvao-Coelho N, Ayati Z, Zhang Z, Kasper S, Ravindran A, Harvey B, Lopresti A, Mischoulon D, Amsterdam J, Yatham L, Berk M (2021) Plant-based Medicines (Phytoceuticals) in the Treatment of Psychiatric Disorders: A Meta-review of Meta-analyses of Randomized Controlled Trials: Les médicaments à base de plantes (phytoceutiques) dans le traitement des troubles psychiatriques: une méta-revue des méta-analyses d’essais randomisés contrôlés Can J Psychiatry, 6: 849-862
  | Weblink |
• McAllister-Williams R, Arango C, Blier P, Demyttenaere K, Falkai P, Gorwood P, Hopwood M, Javed A, Kasper S, Malhi G, Soares J, Vieta E, Young A, Papadopoulos A, Rush A (2021) Reconceptualising treatment-resistant depression as difficult-to-treat depression Lancet Psychiatry, 8 (1): 14-15
  | Weblink |
• Fabbri C, Kasper S, Zohar J, Souery D, Montgomery S, Albani D, Forloni G, Ferentinos P, Rujescu D, Mendlewicz J, Serretti A, Lewis C (2021) Cost-effectiveness of genetic and clinical predictors for choosing combined psychotherapy and pharmacotherapy in major depression J Affect Disord, 279: 722-729
  | Weblink |
• Fabbri C, Kasper S, Zohar J, Souery D, Montgomery S, Albani D, Forloni G, Ferentinos P, Rujescu D, Mendlewicz J, De Ronchi D, Riva M, Lewis C, Serretti A (2021) Drug repositioning for treatment-resistant depression: Hypotheses from a pharmacogenomic study Prog Neuropsychopharmacol Biol Psychiatry, 104: 110050
  | Weblink |
• Fanelli G, Benedetti F, Kasper S, Zohar J, Souery D, Montgomery S, Albani D, Forloni G, Ferentinos P, Rujescu D, Mendlewicz J, Serretti A, Fabbri C (2021) Higher polygenic risk scores for schizophrenia may be suggestive of treatment non-response in major depressive disorder Prog Neuropsychopharmacol Biol Psychiatry, : 110170
  | Weblink |
• Ionescu DF, Fu DJ, Qiu X, Lane R, Lim P, Kasper S, Hough D, Drevets WC, Manji H, Canuso CM (2021) Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II) Int J Neuropsychopharmacol, 24(1): 22-31
  | Weblink |
• Kautzky A, Möller H, Dold M, Bartova L, Seemüller F, Laux G, Riedel M, Gaebel W, Kasper S (2021) Combining machine learning algorithms for prediction of antidepressant treatment response Acta Psychiatr Scand, 143 (1): 36-49
  | Weblink |
• Möller H, Volz H, Seifritz E, Müller H, Kenntner-Mabiala R, Kaussner Y, Schoch S, Kasper S (2021) Silexan does not affect driving performance after single and multiple dose applications: Results from a double-blind, placebo and reference-controlled study in healthy volunteers J Psychiatr Res, 136: 543-551
  | Weblink |

• Cinquina V, Weidenauer A, Kasper S, Harkany T (2021) Cannabinoids in the brain: their mechanism of action in relation to neuropsychiatric disorders Jatros Neurologie & Psychiatrie , 6: 35-38
• Kasper S, Erfurth A, Sachs G, Aichhorn W, Bartova L, Bengesser S, Buchmayer F, Deisenhammer E, Di Pauli J, Dold M, Falkai P, Frey R, Glück K, Hofer A, Holsboer-Trachsler E, Kautzky A, Konstantinidis A, Kraus C, Lehofer M, Marksteiner J, Mitschek M, Mörkl S, Oberlerchner H, Plener P, Psota G, Rados C, Rainer M, Schosser A, Seifritz E, Silberbauer C, Winkler D, Wunsch C, Zwanzger P (2021) Therapieresistente Depression: Diagnose und Behandlung, Konsensus-Statement Jatros Neurologie & Psychiatrie , Sonderheft 03/2021: 1-32
• Calabrò M, Fabbri C, Kasper S, Zohar J, Souery D, Montgomery S, Albani D, Forloni G, Ferentinos P, Rujescu D, Mendlewicz J, Colombo R, De Ronchi D, Serretti A, Crisafulli C (2021) Research Domain Criteria (RDoC): A Perspective to Probe the Biological Background behind Treatment Efficacy in Depression Curr Med Chem, 28 (22): 4296-4320
  | Weblink |
• Dodd S, Bauer M, Carvalho A, Eyre H, Fava M, Kasper S, Kennedy S, Khoo J, Lopez Jaramillo C, Malhi G, McIntyre R, Mitchell P, Castro A, Ratheesh A, Severus E, Suppes T, Trivedi M, Thase M, Yatham L, Young A, Berk M (2021) A clinical approach to treatment resistance in depressed patients: What to do when the usual treatments don’t work well enough? World J Biol Psychiatry, 22 (7): 483-494
  | Weblink |
• Kasper S, Cubała W, Fagiolini A, Ramos-Quiroga J, Souery D, Young A (2021) Practical recommendations for the management of treatment-resistant depression with esketamine nasal spray therapy: Basic science, evidence-based knowledge and expert guidance World J Biol Psychiatry,
  | Weblink |

• Sachs G, Kasper S, Anditsch M, Erfurth A, Lehofer M, Marksteiner J, Rados C, Rujescu D, Sperner-Unterweger B (2021) Was in der Praxis zählt. Diagnostik und Therapie der generalisierten Angststörung. In: , Jatros Neurologie & Psychiatrie Universimed: 2-6
• Graf I, Willeit M, Kasper S, Praschak-Rieder (2021) The Impact of Genetic Polymorphisms on Neuroreceptor Binding: Results from PET and SPECT Neuroreceptor Imaging Studies. In: Dierckx RAJO, Otte A, de Vries EFJ, van Waarde A, Lammertsma AA (Hrsg.) PET and SPECT of Neurobiological Systems. . In: , Springer Nature Springer: 153-190
• Dajić I, Praschak-Rieder N, Lanzenberger R, Spindelegger C, Kasper S, Willeit M (2021) Neuroimaging in Seasons and Winter Depression. In: Rudi A.J.O. Dierckx, Andreas Otte, Erik F. J. de Vries, Aren van Waarde, Iris E. Sommer, PET and SPECT in Psychiatry, Vol.2 Springer International Publishing: 245-259
  | Weblink |

• Beiersdorf J, Hevesi Z, Calvigioni D, Pyszkowski J, Romanov RA, Szodorai E, Lubec G, Shirran S, Botting CH, Kasper S, Guy GW, Gray R, Di Marzo V, Harkany T, Keimpema E (2020) Adverse effects of tetrahydrocannabinol on neuronal bioenergetics during postnatal brain development. JCI Insight, 5: e135418
  | Weblink |
• Calabrò M, Porcelli S, Crisafulli C, Albani D, Kasper S, Zohar J, Souery D, Montgomery S, Mantovani V, Mendlewicz J, Bonassi S, Vieta E, Frustaci A, Ducci G, Landi S, Boccia S, Bellomo A, Di Nicola M, Janiri L, Colombo R, Mandelli L, Fabbri C, Serretti A (2020) Genetic variants associated with psychotic symptoms across disorders psychotic symptoms. Neurosci Lett, 720: 134754
  | Weblink |
• Spurny B, Seiger R, Moser P, Vanicek T, Reed M, Heckova E, Michenthaler P, Basaran A, Gryglewski G, Klöbl M, Trattnig S, Kasper S, Bogner W, Lanzenberger R (2020) Hippocampal GABA levels correlate with retrieval performance in an associative learning paradigm Neuroimage, 204: 116244
  | Weblink |
• Friedrich ME, Winkler D, Konstantinidis A, Huf W, Engel RR, Toto S, Grohmann R, Kasper S (2020) Cardiovascular adverse reactions during antipsychotic treatment: Results of AMSP- A drug surveillance program between 1993 and 2013. Int. J. Neuropsychopharmacol., 23: 67-75
• Gryglewski G, Seiger R, Baldinger-Melich P, Unterholzner J, Spurny B, Vanicek T, Hahn, Kasper S, Frey R, Lanzenberger R (2020) Changes in white matter microstructure after electroconvulsive therapy in treatment resistant depression Int J Neuropsychopharmacol, 23: 20-25
  | Weblink |
• Seifritz E, Möller H, Volz H, Müller W, Hopyan T, Wacker A, Schläfke S, Kasper S (2020) No Abuse Potential of Silexan in Healthy Recreational Drug Users: A Randomized Controlled Trial Int J Neuropsychopharmacol, 24 (3): 171-180
  | Weblink |
• Kraus C, Kadriu B, Lanzenberger R, Zarate C, Kasper S (2020) Prognosis and Improved Outcomes in Major Depression: A Review Focus, 18 (2): 220-235
  | Weblink |
• Kraus C, Hahn A, Sigurdardottir H, Spurny B, Wadsak W, Mitterhauser M, Hacker M, Kasper S, Lanzenberger R (2020) Brain glucose uptake during transcranial direct current stimulation measured with functional [18F]FDG-PET Brain Imaging Behav, 14 (2): 477-484
  | Weblink |
• Pjrek E, Friedrich M, Cambioli L, Dold M, Jäger F, Komorowski A, Lanzenberger R, Kasper S, Winkler D (2020) The Efficacy of Light Therapy in the Treatment of Seasonal Affective Disorder: A Meta-Analysis of Randomized Controlled Trials Psychother Psychosom, 89 (1): 17-24
  | Weblink |
• Kasper S, Möller H, Engberg G, Eriksson E, Hökfelt T (2020) Torgny Svensson, a superb mind and an inspiring colleague Int J Neuropsychopharmacol, 23 (8): 543-544
  | Weblink |
• Komorowski A, Weidenauer A, Murgaš M, Sauerzopf U, Wadsak W, Mitterhauser M, Bauer M, Hacker M, Praschak-Rieder N, Kasper S, Lanzenberger R, Willeit M (2020) Association of dopamine D2/3 receptor binding potential measured using PET and [11C]-(+)-PHNO with post-mortem DRD2/3 gene expression in the human brain Neuroimage, 223: 117270
  | Weblink |
• Dold M, Bartova L, Kasper S (2020) Treatment Response of Add-On Esketamine Nasal Spray in Resistant Major Depression in Relation to Add-On Second-Generation Antipsychotic Treatment Int J Neuropsychopharmacol, 23 (7): 440-445
  | Weblink |
• Fugger G, Dold M, Bartova L, Mitschek M, Souery D, Mendlewicz J, Serretti A, Zohar J, Montgomery S, Fabbri C, Frey R, Kasper S (2020) Clinical Correlates and Outcome of Major Depressive Disorder and Comorbid Migraine: A Report of the European Group for the Study of Resistant Depression Int J Neuropsychopharmacol, 23 (9): 571-577
  | Weblink |
• Unterholzner J, Gryglewski G, Philippe C, Seiger R, Pichler V, Godbersen G, Berroterán-Infante N, Murgaš M, Hahn A, Wadsak W, Mitterhauser M, Kasper S, Lanzenberger R (2020) Topologically Guided Prioritization of Candidate Gene Transcripts Coexpressed with the 5-HT1A Receptor by Combining In Vivo PET and Allen Human Brain Atlas Data Cereb. Cortex, 30 (6): 3771-3780
  | Weblink |
• Kautzky A, Vanicek T, Philippe C, Kranz G, Wadsak W, Mitterhauser M, Hartmann A, Hahn A, Hacker M, Rujescu D, Kasper S, Lanzenberger R (2020) Machine learning classification of ADHD and HC by multimodal serotonergic data Transl Psychiat, 10: 104
  | Weblink |
• Silberbauer L, Bartova L, Papageorgiou K, Lanzenberger R, Kasper S, Winkler D (2020) Oral Ketamine as a Treatment Option in Patients With Treatment Resistant Depression and Comorbid Arterial Hypertension J Clin Psychopharmacol, 40 (4): 418-420
• Hahn A, Breakspear M, Rischka L, Wadsak W, Godbersen G, Pichler V, Michenthaler P, Vanicek T, Hacker M, Kasper S, Lanzenberger R, Cocchi L (2020) Reconfiguration of functional brain networks and metabolic cost converge during task performance eLife, 9: e52443
  | Weblink |
• Calabrò M, Porcelli S, Crisafulli C, Albani D, Kasper S, Zohar J, Souery D, Montgomery S, Mantovani V, Mendlewicz J, Bonassi S, Vieta E, Frustaci A, Ducci G, Landi S, Boccia S, Bellomo A, Di Nicola M, Janiri L, Colombo R, Benedetti F, Mandelli L, Fabbri C, Serretti A (2020) Genetic variants associated with psychotic symptoms across psychiatric disorders Neurosci Lett, 720: 134754
  | Weblink |
• Spurny B, Seiger R, Moser P, Vanicek T, Reed M, Heckova E, Michenthaler P, Basaran A, Gryglewski G, Klöbl M, Trattnig S, Kasper S, Bogner W, Lanzenberger R (2020) Hippocampal GABA levels correlate with retrieval performance in an associative learning paradigm Neuroimage, 204: 116244
  | Weblink |
• Cinquina V, Calvigioni D, Farlik M, Halbritter F, Gernedl V, Shirran SL, Fuszard MA, Botting CH, Poullet P, Piscitelli F, Máté Z, Szabó G, Yanagawa Y, Kasper S, Di Marzo V, Mackie K, McBain CJ, Bock C, Keimpema E, Harkany T (2020) Life-long epigenetic programming of cortical architecture by maternal ‘Western’ diet during pregnancy Mol Psychiatry, 25 (1): 22-36
  | Weblink |
• Porcelli S, Kasper S, Zohar J, Souery D, Montgomery S, Ferentinos P, Rujescu D, Mendlewicz J, Merlo Pich E, Pollentier S, Penninx B, Serretti A (2020) Social dysfunction in mood disorders and schizophrenia: Clinical modulators in four independent samples Prog Neuropsychopharmacol Biol Psychiatry, 99: 109835
  | Weblink |
• Fagiolini A, Albert U, Ferrando L, Herman E, Muntean C, Pálová E, Cattaneo A, Comandini A, Di Dato G, Di Loreto G, Olivieri L, Salvatori E, Tongiani S, Kasper S (2020) A randomized, double-blind study comparing the efficacy and safety of trazodone once-a-day and venlafaxine extended-release for the treatment of patients with major depressive disorder Int Clin Psychopharmacol, 35 (3): 137-146
  | Weblink |
• Dold M, Bartova L, Fugger G, Mitschek M, Kautzky A, Frey R, Montgomery S, Zohar J, Mendlewicz J, Souery D, Fabbri C, Serretti A, Kasper S (2020) Add-on benzodiazepine treatment in patients with major depressive disorder – results from a European cross-sectional multicenter study Eur Neuropsychopharmacol, 41: 70-80
  | Weblink |
• Klöbl M, Gryglewski G, Rischka L, Godbersen G, Unterholzner J, Reed M, Michenthaler P, Vanicek T, Winkler-Pjrek E, Hahn A, Kasper S, Lanzenberger R (2020) Predicting Antidepressant Citalopram Treatment Response via Changes in Brain Functional Connectivity After Acute Intravenous Challenge Front Comput Neurosci, 14: 554186
  | Weblink |
• Wajs E, Aluisio L, Holder R, Daly E, Lane R, Lim P, George J, Morrison R, Sanacora G, Young A, Kasper S, Sulaiman A, Li C, Paik J, Manji H, Hough D, Grunfeld J, Jeon H, Wilkinson S, Drevets W, Singh J (2020) Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression J Clin Psychiatry, 81 (3): 19m12891
  | Weblink |
• Weidenauer A, Bauer M, Sauerzopf U, Bartova L, Nics L, Pfaff S, Philippe C, Berroterán-Infante N, Pichler V, Meyer B, Rabl U, Sezen P, Cumming P, Stimpfl T, Sitte H, Lanzenberger R, Mossaheb N, Zimprich A, Rusjan P, Dorffner G, Mitterhauser M, Hacker M, Pezawas L, Kasper S, Wadsak W, Praschak-Rieder N, Willeit M (2020) On the relationship of first-episode psychosis to the amphetamine-sensitized state: a dopamine D2/3 receptor agonist radioligand study Transl Psychiat, 10 (2): 2
  | Weblink |
• Fabbri C, Kasper S, Kautzky A, Zohar J, Souery D, Montgomery S, Albani D, Forloni G, Ferentinos P, Rujescu D, Mendlewicz J, Uher R, Lewis C, Serretti A (2020) A polygenic predictor of treatment-resistant depression using whole exome sequencing and genome-wide genotyping Transl Psychiat, 10 (1): 50
  | Weblink |
• Mörkl S, Seltenreich D, Letmaier M, Bengesser S, Wurm W, Grohmann R, Bleich S, Toto S, Stübner S, Butler MI, Kasper S (2020) Extrapyramidal reactions following treatment with antidepressants: Results of the AMSP multinational drug surveillance program World J Biol Psychiatry, 21 (4): 308-316
  | Weblink |
• Baldinger-Melich P, Urquijo Castro M, Seiger R, Ruef A, Dwyer D, Kranz G, Klöbl M, Kambeitz J, Kaufmann U, Windischberger C, Kasper S, Falkai P, Lanzenberger R, Koutsouleris N (2020) Sex Matters: A Multivariate Pattern Analysis of Sex- and Gender-Related Neuroanatomical Differences in Cis- and Transgender Individuals Using Structural Magnetic Resonance Imaging Cereb. Cortex, 30 (3): 1345-1356
  | Weblink |

• Fountoulakis KN, Young A, Yatham L, Grunze H, Vieta E, Tohen M, Blier P, Moeller HJ, Kasper S (2020) The CINP guidelines on the definition and the evidence-based interventions for treatment-resistant Bipolar disorder. Invited Review. Int. J. Neuropsychopharmacol., 23: 230-256
  | Weblink |
• Bartova L, Mitschek MMM, Kasper S (2020) Das aktuelle Verständnis der sogenannten behandlungsresistenten Depression Jatros Neurologie & Psychiatrie , 06/2020: 44-49
• Dold M, Kasper S (2020) Dose‐response relationship of selective serotonin reuptake inhibitors Acta Psychiatr Scand, 142 (6): 427-429
  | Weblink |
• McAllister-Williams R, Arango C, Blier P, Demyttenaere K, Falkai P, Gorwood P, Hopwood M, Javed A, Kasper S, Malhi G, Soares J, Vieta E, Young A, Papadopoulos A, Rush A (2020) The identification, assessment and management of difficult-to-treat depression: An international consensus statement J Affect Disord, 267: 264-282
  | Weblink |
• Kasper S, Bancher C, Eckert A, Förstl H, Frölich L, Hort J, Korczyn A, Kressig R, Levin O, Palomo M (2020) Management of mild cognitive impairment (MCI): The need for national and international guidelines World J Biol Psychiatry, 21 (8): 579-594
  | Weblink |
• Fountoulakis K, Moeller H, Kasper S, Tamminga C, Yamawaki S, Kahn R, Tandon R, Correll C, Javed A (2020) The report of the joint WPA/CINP workgroup on the use and usefulness of antipsychotic medication in the treatment of schizophrenia CNS Spectr,
  | Weblink |

• Silberbauer L, James G, Spies M, Michenthaler P, Kranz GS, Kasper S, Lanzenberger R (2020) Molecular neuroimaging of the serotonergic system with PET. In: , Handbook of the Behavioral Neurobiology of Serotonin Elsevier: 175-194

• Moeller HJ, Volz HP, Dienel A, Schlaefke S, Kasper S (2019) Efficacy of Silexan in subthreshold anxiety: meta‑analysis of randomised, placebo‑controlled trials Eur Arch Psychiatry Clin Neurosci,
• Möller HJ, Volz HP, Dienel A, Schläfke S, Kasper S (2019) Efficacy of Silexan in subthreshold anxiety: meta‑analysis of randomised, placebo‑controlled trials. Eur Arch Psychiatry Clin Neurosci, 269: 183-193
• Möller HJ, Volz HP, Dienel A, Schläfke S, Kasper S (2019) Efficacy of Silexan in subthreshold anxiety: meta‑analysis of randomised, placebo‑controlled trials. Eur Arch Psychiatry Clin Neurosci, 269: 183-193
  | Weblink |
• Möller HJ, Volz HP, Dienel A, Schläfke S, Kasper S (2019) Efficacy of Silexan in subthreshold anxiety: meta‑analysis of randomised, placebo‑controlled trials. Eur Arch Psychiatry Clin Neurosci, 269: 183-193
  | Weblink |
• Möller HJ, Volz HP, Dienel A, Schläfke S, Kasper S (2019) Efficacy of Silexan in subthreshold anxiety: meta‑analysis of randomised, placebo‑controlled trials. Eur Arch Psychiatry Clin Neurosci, 260: 183-193
  | Weblink |
• Möller HJ, Volz HP, Dienel A, Schläfke S, Kasper S (2019) Efficacy of Silexan in subthreshold anxiety: meta‑analysis of randomised, placebo‑controlled trials. Eur Arch Psychiatry Clin Neurosci, 260: 183-193
  | Weblink |
• Möller HJ, Volz HP, Dienel A, Schläfke S, Kasper S (2019) Efficacy of Silexan in subthreshold anxiety: meta‑analysis of randomised, placebo‑controlled trials. Eur Arch Psychiatry Clin Neurosci, 269: 183-193
  | Weblink |
• Möller HJ, Volz HP, Dienel A, Schläfke S, Kasper S (2019) Efficacy of Silexan in subthreshold anxiety: meta‑analysis of randomised, placebo‑controlled trials. European Archives of Psychiatry and Clinical Neuroscience , 269: 183-193
  | Weblink |
• Möller HJ, Volz HP, Dienel A, Schläfke S, Kasper S (2019) Efficacy of Silexan in subthreshold anxiety: meta‑analysis of randomised, placebo‑controlled trials. European Archives of Psychiatry and Clinical Neuroscience , 269: 183-193
  | Weblink |
• Möller HJ, Volz HP, Dienel A, Schläfke S, Kasper S (2019) Efficacy of Silexan in subthreshold anxiety: meta‑analysis of randomised, placebo‑controlled trials. European Archives of Psychiatry and Clinical Neuroscience , 269: 183-180
  | Weblink |
• Möller HJ, Volz HP, Dienel A, Schläfke S, Kasper S (2019) Efficacy of Silexan in subthreshold anxiety: meta‑analysis of randomised, placebo‑controlled trials. Eur Arch Psychiatry Clin Neurosci, 269: 183-180
  | Weblink |
• Müller WE, Eckert A, Eckert G, Fink H, Friedland K, Gauthier S, Hoerr R, Ihl R, Kasper S, Möller HJ (2019) Therapeutic efficacy of the Ginkgo special extract EGb761® within the framework of the mitochondrial cascade hypothesis of Alzheimer’s disease. World J Biol Psychiatry, 20: 173-189
  | Weblink |
• Rischka L, Gryglewski G, Berroterán-Infante N, Rausch I, James G, Klöbl M, Sigurdardottir H, Hartenbach M, Hahn A, Wadsak W, Mitterhauser M, Beyer T, Kasper S, Prayer D, Hacker M, Lanzenberger R (2019) Attenuation Correction Approaches for Serotonin Transporter Quantification With PET/MRI Front Physiol, 10: 1422
  | Weblink |
• Maron E, Baldwin D, Balõtšev R, Fabbri C, Gaur V, Hidalgo-Mazzei D, Hood S, Juhola M, Kampman O, Kasper S, Kärkkäinen H, Látalová K, Lähteenvuo M, Mastellos N, McTigue J, Metsallik J, Metspalu A, Nutt D, Nykänen P, Olisa N, Pogarell O, Popovic D, Antoni Ramos-Quiroga J, Ross P, Serretti A, Spies M, Thibaut F, Tiainen K, Tiihonen J, Vieta E, Võhma �, Van Westrhenen R, Zubanovic B, Eberhard J (2019) Manifesto for an international digital mental health network Digital Psychiatry, 2 (1): 14-24
  | Weblink |
• Gryglewski G, Seiger R, Baldinger-Melich P, Unterholzner J, Spurny B, Vanicek T, Hahn A, Kasper S, Frey R, Lanzenberger R (2019) Changes in White Matter Microstructure After Electroconvulsive Therapy for Treatment-Resistant Depression Int J Neuropsychopharmacol, 23 (1): 20-25
  | Weblink |
• Fountoulakis K, Dragioti E, Theofilidis A, Wikilund T, Atmatzidis X, Nimatoudis I, Thys E, Wampers M, Hranov L, Hristova T, Aptalidis D, Milev R, Iftene F, Spaniel F, Knytl P, Furstova P, From T, Karlsson H, Walta M, Salokangas R, Azorin J, Bouniard J, Montant J, Juckel G, Haussleiter I, Douzenis A, Michopoulos I, Ferentinos P, Smyrnis N, Mantonakis L, Nemes Z, Gonda X, Vajda D, Juhasz A, Shrivastava A, Waddington J, Pompili M, Comparelli A, Corigliano V, Rancans E, Navickas A, Hilbig J, Bukelskis L, Injac Stevovic L, Vodopic S, Esan O, Oladele O, Osunbote C, Rybakowski J, Wojciak P, Domowicz K, Figueira M, Linhares L, Crawford J, Panfil A, Smirnova D, Izmailova O, Lecic-Tosevski D, Temmingh H, Howells F, Bobes J, Garcia-Portilla M, García-Alvarez L, Erzin G, Karadağ H, De Sousa A, Bendre (2019) Staging of Schizophrenia With the Use of PANSS: An International Multi-Center Study Int J Neuropsychopharmacol, 22 (11): 681-697
  | Weblink |
• Spies M, Klöbl M, Höflich A, Hummer A, Vanicek T, Michenthaler P, Kranz G, Hahn A, Winkler D, Windischberger C, Kasper S, Lanzenberger R (2019) Association between dynamic resting-state functional connectivity and ketamine plasma levels in visual processing networks Sci Rep, 9 (1): 11484
  | Weblink |
• Pjrek E, Silberbauer L, Kasper S, Winkler D (2019) Alcohol consumption in Austrian physicians Ann Gen Psychiatry, 18 (1): 22
  | Weblink |
• Sigurdardottir H, Kranz G, Rami-Mark C, James G, Vanicek T, Gryglewski G, Berroterán-Infante N, Kautzky A, Hienert M, Traub-Weidinger T, Mitterhauser M, Wadsak W, Hartmann A, Hacker M, Rujescu D, Kasper S, Lanzenberger R (2019) Association of norepinephrine transporter methylation with in vivo NET expression and hyperactivity–impulsivity symptoms in ADHD measured with PET Mol Psychiatry,
  | Weblink |
• Ludwig B, Mitschek M, Carlberg L, Kienesberger K, Swoboda P, Bernegger A, Inaner M, Senft B, Kapusta N, Haslacher H, Aigner M, Kasper S, Schosser A (2019) Parasuicidal behavior and neuroinflammation: A genetics and gene expression approach Eur Neuropsychopharmacol, 29: S580-S581
  | Weblink |
• Ludwig B, Carlberg L, Kienesberger K, Swoboda P, Mitschek M, Bernegger A, Inaner M, Senft B, Kapusta N, Haslacher H, Aigner M, Kasper S, Schosser A (2019) P.1.14 Oxytocin receptor gene methylation as a molecular marker for severity of depressive symptoms in mood disorder patients Eur Neuropsychopharmacol, 29: S643-S644
  | Weblink |
• Friedrich M, Winkler D, Konstantindis A, Huf W, Engel R, Toto S, Grohmann R, Kasper S (2019) Cardiovascular adverse reactions during antipsychotic treatment: Results of AMSP- A drug surveillance program between 1993 and 2013 Int J Neuropsychopharmacol, 23 (2): 67-75
  | Weblink |
• Mori A, Klöbl M, Okada G, Reed M, Takamura M, Michenthaler P, Takagaki K, Handschuh P, Yokoyama S, Murgas M, Ichikawa N, Gryglewski G, Shibasaki C, Spies M, Yoshino A, Hahn A, Okamoto Y, Lanzenberger R, Yamawaki S, Kasper S (2019) Predicting Ventral Striatal Activation During Reward Anticipation From Functional Connectivity at Rest Front Hum Neurosci, 13: 289
  | Weblink |
• Kraus C, Seiger R, Pfabigan D, Sladky R, Tik M, Paul K, Woletz M, Gryglewski G, Vanicek T, Komorowski A, Kasper S, Lamm C, Windischberger C, Lanzenberger R (2019) Hippocampal Subfields in Acute and Remitted Depression—an Ultra-High Field Magnetic Resonance Imaging Study Int J Neuropsychopharmacol, 22 (8): 513-522
  | Weblink |
• Halbreich U, Schulze T, Botbol M, Javed A, Kallivayalil R, Ghuloum S, Baron D, Moreira Almeida A, Musalek M, Fung W, Sharma A, Tasman A, Christodoulou N, Kasper S, Ivbijaro G (2019) Partnerships for interdisciplinary collaborative global well-being Asia-Pac Psychiat, 11 (2): e12366
  | Weblink |
• Corponi F, Fabbri C, Bitter I, Montgomery S, Vieta E, Kasper S, Pallanti S, Serretti A (2019) Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone Eur Neuropsychopharmacol, 29 (9): 971-985
  | Weblink |
• Toto S, Grohmann R, Bleich S, Frieling H, Maier H, Greil W, Cordes J, Schmidt-Kraepelin C, Kasper S, Stübner S, Degner D, Druschky K, Zindler T, Neyazi A (2019) Psychopharmacological Treatment of Schizophrenia over time in 30,908 inpatients – Data from the AMSP study Int J Neuropsychopharmacol, 22 (9): 560-573
  | Weblink |
• Winkler D, Kaltenboeck A, Frey R, Kasper S, Pjrek E (2019) Changes over time of the diagnostic and therapeutic characteristics of patients of a psychiatric intensive care unit in Austria Compr Psychiatry, 93: 20-26
  | Weblink |
• Bartova L, Dold M, Kautzky A, Fabbri C, Spies M, Serretti A, Souery D, Mendlewicz J, Zohar J, Montgomery S, Schosser A, Kasper S (2019) Results of the European Group for the Study of Resistant Depression (GSRD) — basis for further research and clinical practice World J Biol Psychiatry, 20 (6): 427-448
  | Weblink |
• Silberbauer L, Gryglewski G, Berroterán-Infante N, Rischka L, Vanicek T, Pichler V, Hienert M, Kautzky A, Philippe C, Godbersen G, Vraka C, James G, Wadsak W, Mitterhauser M, Hacker M, Kasper S, Hahn A, Lanzenberger R (2019) Serotonin Transporter Binding in the Human Brain After Pharmacological Challenge Measured Using PET and PET/MR Front Mol Neurosci, 12: 172
  | Weblink |
• Vanicek T, Kranz G, Vyssoki B, Komorowski A, Fugger G, Höflich A, Micskei Z, Milovic S, Lanzenberger R, Eckert A, Kasper S, Frey R (2019) Repetitive Enhancement of Serum BDNF Subsequent to Continuation ECT Acta Psychiatr Scand, 140 (5): 426-434
  | Weblink |
• Kasper S (2019) A thank-you note from the Chief-Editor World J Biol Psychiatry, 20 (4): 254-257
  | Weblink |
• Fugger G, Dold M, Bartova L, Kautzky A, Souery D, Mendlewicz J, Serretti A, Zohar J, Montgomery S, Frey R, Kasper S (2019) Major depression and comorbid diabetes - Findings from the European Group for the Study of Resistant Depression Prog Neuropsychopharmacol Biol Psychiatry, 94: 109638
  | Weblink |
• Gryglewski G, Klöbl M, Berroterán-Infante N, Rischka L, Balber T, Vanicek T, Pichler V, Kautzky A, Klebermass E, Reed M, Vraka C, Hienert M, James G, Silberbauer L, Godbersen G, Unterholzner J, Michenthaler P, Hartenbach M, Winkler-Pjrek E, Wadsak W, Mitterhauser M, Hahn A, Hacker M, Kasper S, Lanzenberger R (2019) Modeling the acute pharmacological response to selective serotonin reuptake inhibitors in human brain using simultaneous PET/MR imaging Eur Neuropsychopharmacol, 29 (6): 711-719
  | Weblink |
• Olgiati P, Serretti A, Souery D, Kasper S, Kraus C, Montgomery S, Zohar J, Mendlewicz J (2019) Attrition in treatment-resistant depression Int Clin Psychopharmacol, 34 (4): 161-169
  | Weblink |
• Kranz G, Kasper S (2019) On the suitability of medical analogies, from hypertension to broken leg World J Biol Psychiatry, 20 (3): 171-172
  | Weblink |
• Pazan F, , Weiss C, Wehling M (2019) The FORTA (Fit fOR The Aged) List 2018: Third Version of a Validated Clinical Tool for Improved Drug Treatment in Older People Drugs Aging, 36 (5): 481-484
  | Weblink |
• Vanicek T, Kranz G, Vyssoki B, Fugger G, Komorowski A, Höflich A, Saumer G, Milovic S, Lanzenberger R, Eckert A, Kasper S, Frey R (2019) Acute and subsequent continuation electroconvulsive therapy elevates serum BDNF levels in patients with major depression Brain Stimul, 12 (4): 1041-1050
  | Weblink |
• Balestri M, Porcelli S, Souery D, Kasper S, Dikeos D, Ferentinos P, Papadimitriou G, Rujescu D, Martinotti G, Nicola M, Janiri L, Caletti E, Mandolini G, Pigoni A, Paoli R, Lazzaretti M, Brambilla P, Sala M, Abbiati V, Bellani M, Perlini C, Rossetti M, Piccin S, Bonivento C, Fabbro D, Damante G, Ferrari C, Rossi R, Pedrini L, Benedetti F, Montgomery S, Zohar J, Mendlewicz J, Serretti A (2019) Temperament and character influence on depression treatment outcome J Affect Disord, 252: 464-474
  | Weblink |
• Fugger G, Dold M, Bartova L, Kautzky A, Souery D, Mendlewicz J, Serretti A, Zohar J, Montgomery S, Frey R, Kasper S (2019) Comorbid hypertension in patients with major depressive disorder – Results from a European multicenter study Eur Neuropsychopharmacol, 29 (6): 777-785
  | Weblink |
• Fountoulakis K, Gonda X, Siamouli M, Panagiotidis P, Moutou K, Nimatoudis I, Kasper S (2019) A case-control study of paternal and maternal age as risk factors in mood disorders Int J Psychiatry Clin Pract, 23 (2): 90-98
  | Weblink |
• Winkler D, Reichardt B, Kranz G, Bartova L, Kasper S, Pjrek E (2019) Seasonality of antidepressant prescriptions and sick leaves J Psychiatr Res, 111: 128-133
  | Weblink |
• Kasper S, Frazer A (2019) Editorial for Treatment-Resistant Depression (TRD) Int J Neuropsychopharmacol, 22 (2): 83-84
  | Weblink |
• Baldinger-Melich P, Gryglewski G, Philippe C, James G, Vraka C, Silberbauer L, Balber T, Vanicek T, Pichler V, Unterholzner J, Kranz G, Hahn A, Winkler D, Mitterhauser M, Wadsak W, Hacker M, Kasper S, Frey R, Lanzenberger R (2019) The effect of electroconvulsive therapy on cerebral monoamine oxidase A expression in treatment-resistant depression investigated using positron emission tomography Brain Stimul, 12 (3): 714-723
  | Weblink |
• Kautzky A, James G, Philippe C, Baldinger-Melich P, Kraus C, Kranz G, Vanicek T, Gryglewski G, Hartmann A, Wadsak W, Mitterhauser M, Rujescu D, Kasper S, Lanzenberger R (2019) Epistasis of HTR1A and BDNF risk genes alters cortical 5-HT1A receptor binding: PET results link genotype to molecular phenotype in depression Transl Psychiat, 9 (1): 5
  | Weblink |
• Dold M, Bartova L, Kautzky A, Porcelli S, Montgomery S, Zohar J, Mendlewicz J, Souery D, Serretti A, Kasper S (2019) Psychotic Features in Patients With Major Depressive Disorder J Clin Psychiatry, 80 (1): 17m12090
  | Weblink |
• Mandelli L, Serretti A, Souery D, Mendlewicz J, Kasper S, Montgomery S, Zohar J (2019) High occupational level is associated with poor response to the treatment of depression: A replication study Eur Neuropsychopharmacol, 29 (3): 349-355
  | Weblink |
• Kasper S (2019) Choosing among second-generation antidepressant treatments for depressed patients with cardiac diseases Int J Psychiatry Clin Pract, 23 (2): 134-148
  | Weblink |
• Hidalgo-Mazzei D, Berk M, Cipriani A, Cleare A, Di Florio A, Dietch D, Geddes J, Goodwin GM, Grunze H, Hayes JF, Jones I, Kasper S, Macritchie K, McAllister-Williams H, Morriss R, Nayrouz S, Pappa S, Soares JC, Smith DJ, Suppes T, Talbot P, Vieta E, Watson S, Yatham LN, Young AH, Stokes PRA (2019) Treatment-resistant and multi-therapy-resistant criteria for bipolar depression: consensus definition Br J Psychiatry, 214 (1): 27-35
  | Weblink |
• Hasan A, Bandelow B, Yatham L, Berk M, Falkai P, Möller H, Kasper S, (2019) WFSBP guidelines on how to grade treatment evidence for clinical guideline development World J Biol Psychiatry, 20 (1): 2-16
  | Weblink |
• Hahn A, Lanzenberger R, Kasper S (2019) Making Sense of Connectivity Int J Neuropsychopharmacol, 22 (3): 194-207
  | Weblink |
• Greil W, Zhang X, Stassen H, Grohmann R, Bridler R, Hasler G, Toto S, Bleich S, Kasper S (2019) Cutaneous adverse drug reactions to psychotropic drugs and their risk factors – a case-control study Eur Neuropsychopharmacol, 29: 111-121
  | Weblink |
• Ng C, Kato T, Han C, Wang G, Trivedi M, Ramesh V, Shao D, Gala S, Narayanan S, Tan W, Feng Y, Kasper S (2019) Definition of treatment-resistant depression – Asia Pacific perspectives J Affect Disord, 245: 626-636
  | Weblink |
• Gryglewski G, Baldinger-Melich P, Seiger R, Godbersen G, Michenthaler P, Klöbl M, Spurny B, Kautzky A, Vanicek T, Kasper S, Frey R, Lanzenberger R (2019) Structural changes in amygdala nuclei, hippocampal subfields and cortical thickness following electroconvulsive therapy in treatment-resistant depression: longitudinal analysis Br J Psychiatry, 214: 159-167
  | Weblink |
• Kooij J, Bijlenga D, Salerno L, Jaeschke R, Bitter I, Balázs J, Thome J, Dom G, Kasper S, Nunes Filipe C, Stes S, Mohr P, Leppämäki S, Casas Brugué M, Bobes J, Mccarthy J, Richarte V, Kjems Philipsen A, Pehlivanidis A, Niemela A, Styr B, Semerci B, Bolea-Alamanac B, Edvinsson D, Baeyens D, Wynchank D, Sobanski E, Philipsen A, McNicholas F, Caci H, Mihailescu I, Manor I, Dobrescu I, Krause J, Fayyad J, Ramos-Quiroga J, Foeken K, Rad F, Adamou M, Ohlmeier M, Fitzgerald M, Gill M, Lensing M, Motavalli Mukaddes N, Brudkiewicz P, Gustafsson P, Tani P, Oswald P, Carpentier P, De Rossi P, Delorme R, Markovska Simoska S, Pallanti S, Young S, Bejerot S, Lehtonen T, Kustow J, Müller-Sedgwick U, Hirvikoski T, Pironti V, Ginsberg Y, Félegeházy Z, Garcia-Portilla M, Asherson P (2019) Updated European Consensus Statement on diagnosis and treatment of adult ADHD Eur Psychiatry, 56: 14-34
  | Weblink |
• Fabbri C, Kasper S, Kautzky A, Bartova L, Dold M, Zohar J, Souery D, Montgomery S, Albani D, Raimondi I, Dikeos D, Rujescu D, Uher R, Lewis C, Mendlewicz J, Serretti A (2019) Genome-wide association study of treatment-resistance in depression and meta-analysis of three independent samples Br J Psychiatry, 214 (1): 36-41
  | Weblink |
• James G, Gryglewski G, Vanicek T, Berroterán-Infante N, Philippe C, Kautzky A, Nics L, Vraka C, Godbersen G, Unterholzner J, Sigurdardottir H, Spies M, Seiger R, Kranz G, Hahn A, Mitterhauser M, Wadsak W, Bauer A, Hacker M, Kasper S, Lanzenberger R (2019) Parcellation of the Human Cerebral Cortex Based on Molecular Targets in the Serotonin System Quantified by Positron Emission Tomography In vivo Cereb. Cortex, 29: 372-382
  | Weblink |
• Kautzky A, Dold M, Bartova L, Spies M, Kranz G, Souery D, Montgomery S, Mendlewicz J, Zohar J, Fabbri C, Serretti A, Lanzenberger R, Dikeos D, Rujescu D, Kasper S (2019) Clinical factors predicting treatment resistant depression: affirmative results from the European multicenter study Acta Psychiatr Scand, 139 (1): 78-88
  | Weblink |
• Mandelli L, Serretti A, Porcelli S, Souery D, Mendlewicz J, Kasper S, Montgomery S, Zohar J (2019) Opinion paper: poor response to treatment of depression in people in high occupational levels Psychol Med, 49 (01): 49-54
  | Weblink |
• Fountoulakis K, Karavelas V, Moysidou S, Mavridis D, Pastiadis K, Petalidou N, Nimatoudis I, Kasper S (2019) Efficacy of Add-on Pregabalin in the Treatment of Patients with Generalized Anxiety Disorder and Unipolar Major Depression With an Early Nonresponse to Escitalopram: A Double-Blind Placebo-Controlled Study Pharmacopsychiatry, 52 (04): 193-202
  | Weblink |
• Höflich A, Michenthaler P, Kasper S, Lanzenberger R (2019) Circuit mechanisms of reward, anhedonia and depression Int J Neuropsychopharmacol, 22 (2): 105-118
  | Weblink |
• Fabbri C, Corponi F, Souery D, Kasper S, Montgomery S, Zohar J, Rujescu D, Mendlewicz J, Serretti A (2019) The Genetics of Treatment-Resistant Depression: A Critical Review and Future Perspectives Int J Neuropsychopharmacol, 22 (2): 93-104
  | Weblink |

• Fountoulakis K, Yatham L, Grunze H, Vieta E, Young A, Blier P, Tohen M, Kasper S, Moeller H (2019) The CINP Guidelines on the Definition and Evidence-Based Interventions for Treatment-Resistant Bipolar Disorder Int J Neuropsychopharmacol, 23 (4): 230-256
  | Weblink |
• Spies M, Frey R, Friedrich M, Kasper S, Baldinger-Melich P (2019) Delir – ein evidenzbasierter Überblick Wien Klin Wochenschr Educ , 14 (1-4): 1-17
  | Weblink |
• Hienert M, Ritter P, Bauer M, Lanzenberger R, Kasper S (2019) Die klinische Anwendung von Milnacipran in Österreich und Deutschland Nervenheilkunde, 38 (04): 178-183
  | Weblink |
• Komorowski A, Kautzky A, Vanicek T, Lanzenberger R, Kasper S (2019) Hirnbildgebung im forensischen Kontext – Möglichkeiten und Grenzen Journal für Neurologie, Neurochirurgie und Psychiatrie, 20: 25-33
• Fountoulakis KN, Moeller HJ, Kasper S (2019) Personalised and precision psychiatry: What do the CINP bipolar guidelines suggest? Int J Psychiatry Clin Pract, 23 (1): 80-81
  | Weblink |

• Kautzky A, Lanzenberger R, Kasper S (2019) Big Data Guided Interventions: Predicting Treatment Response. In: Passos IC, Mwangi B, Kapczinski F, Personalized Psychiatry - Big Data Analytics in Mental Health Springer International Publishing: 53-76
  | Weblink |
• Kraus C, Lanzenberger R, Kasper S (2019) Neurobiologische Erklärungsmodelle. . In: Bundesministerium für Arbeit, Soziales, Gesundheit und Konsumentenschutz., Depressionsbericht Österreich. Eine interdisziplinäre und multiperspektivische Bestandsaufnahme. Bundesministerium für Arbeit, Soziales, Gesundheit und Konsumentenschutz.: 64-69
• Löffler-Stastka H, Kasper S (2019) Verlauf und Prognose. . In: Bundesministerium für Arbeit, Soziales, Gesundheit und Konsumentenschutz., Depressionsbericht Österreich. Eine interdisziplinäre und multiperspektivische Bestandsaufnahme. Bundesministerium für Arbeit, Soziales, Gesundheit und Konsumentenschutz.: 52-55
• Kasper S, Bartova L, Dold M (2019) Psychopharmakotherapie der unipolaren Depression. . In: Bundesministerium für Arbeit, Soziales, Gesundheit und Konsumentenschutz., Depressionsbericht Österreich. Eine interdisziplinäre und multiperspektivische Bestandsaufnahme. Bundesministerium für Arbeit, Soziales, Gesundheit und Konsumentenschutz.: 170-182

• Kasper S, Sachs GM (2018) Österreichische Konsensus-Dokumente – Psychopharmakologie. Sammelband der ÖGPB 2005–2018 CliniCum neuropsy, Sonderausgabe 2018
• Gil E, Garcia- Alonso F, Boldeanu A, Baleeiro Teixeira T (2018) Safety and efficacy of self-administered inhaled loxapine (ADASUVE) in agitated patients outside the hospital setting: protocol for a phase IV, single-arm, open-label trial BMJ Open, 8 (10): e020242
  | Weblink |
• Fugger G, Gleiss A, Aigner M, Kasper S, Frey R (2018) Emotionen psychiatrischer Patienten während der Fixierung. (Emotions in psychiatric patients under mechanical restraint) Journal für Neurologie, Neurochirurgie und Psychiatrie, 19 (1): 20-26
  | Weblink |
• Kasper S (2018) Nachbericht des Vortrags von Prof. Kasper bei Buchpräsentation „Forensische Psychodiagnostik und Psychotherapie im Strafvollzug” Einführung in die Konfrontationsanalyse ethischer Defizite, : 65-67
• Kraus C, Klöbl M, Tik M, Auer B, Vanicek T, Geissberger N, Pfabigan D, Hahn A, Woletz M, Paul K, Komorowski A, Kasper S, Windischberger C, Lamm C, Lanzenberger R (2018) The pulvinar nucleus and antidepressant treatment: dynamic modeling of antidepressant response and remission with ultra-high field functional MRI Mol Psychiatry, 24 (5): 746-756
  | Weblink |
• Fugger G, Dold M, Bartova L, Kautzky A, Souery D, Mendlewicz J, Serretti A, Zohar J, Montgomery S, Frey R, Kasper S (2018) Comorbid thyroid disease in patients with major depressive disorder - results from the European Group for the Study of Resistant Depression (GSRD) Eur Neuropsychopharmacol, 28 (6): 752-760
  | Weblink |
• Kautzky A, Seiger R, Hahn A, Fischer P, Krampla W, Kasper S, Kovacs G, Lanzenberger R (2018) Prediction of Autopsy Verified Neuropathological Change of Alzheimer’s Disease Using Machine Learning and MRI Front Aging Neurosci, 10: 406
  | Weblink |
• Nussbaumer-Streit B, Pjrek E, Kien C, Gartlehner G, Bartova L, Friedrich M, Kasper S, Winkler D (2018) Implementing prevention of seasonal affective disorder from patients’ and physicians’ perspectives – a qualitative study BMC Psychiatry, 18 (1): 372
  | Weblink |
• Gryglewski G, Seiger R, James G, Godbersen G, Komorowski A, Unterholzner J, Michenthaler P, Hahn A, Wadsak W, Mitterhauser M, Kasper S, Lanzenberger R (2018) Corrigendum to “Spatial analysis and high resolution mapping of the human whole-brain transcriptome for integrative analysis in neuroimaging” Neuroimage,
  | Weblink |
• Calabrò M, Fabbri C, Crisafulli C, Albani D, Forloni G, Kasper S, Sidoti A, Velardi E, Zohar J, Juven-Wetzler A, Souery D, Montgomery S, Mendlewicz J, Serretti A (2018) The serotonin transporter and the activity regulated cytoskeleton-associated protein genes in antidepressant response and resistance: 5-HTTLPR and other variants Hum Psychopharm Clin, 33 (6): e2682
  | Weblink |
• Dold M, Bartova L, Kautzky A, Serretti A, Porcelli S, Souery D, Mendlewicz J, Montgomery S, Zohar J, Kasper S (2018) Clinical factors associated with augmentation treatment with second-generation antipsychotics and lithium in major depression – Results from a European multicenter study Eur Neuropsychopharmacol, 28 (12): 1305-1313
  | Weblink |
• Spies M, James G, Vraka C, Philippe C, Hienert M, Gryglewski G, Komorowski A, Kautzky A, Silberbauer L, Pichler V, Kranz G, Nics L, Balber T, Baldinger-Melich P, Vanicek T, Spurny B, Winkler-Pjrek E, Wadsak W, Mitterhauser M, Hacker M, Kasper S, Lanzenberger R, Winkler D (2018) Brain monoamine oxidase A in seasonal affective disorder and treatment with bright light therapy Transl Psychiat, 8 (1): 198
  | Weblink |
• Benedetti F, Avery D, Bauer M, Bunney W, Çaliyurt O, Camardese G, Colombo C, Dallaspezia S, Henriksen T, Kasper S, Kuriyama K, Lam R, Martiny K, Meesters Y, Mishima K, Schulte R, Suzuki M, Święcicki �, Uchiyama M, Veale D, Winkler D, Wu J, Kupeli N, Yoshiike T, Yu X (2018) Evidence for the Efficacy of Bright Light Therapy for Bipolar Depression Am J Psychiatry, 175 (9): 905-906
  | Weblink |
• Bartova L, Papageorgiou K, Milenkovic I, Dold M, Weidenauer A, Willeit M, Winkler D, Kasper S (2018) Rapid antidepressant effect of S-ketamine in schizophrenia Eur Neuropsychopharmacol, 28 (8): 980-982
  | Weblink |
• Hienert M, Gryglewski G, Stamenkovic M, Kasper S, Lanzenberger R (2018) Striatal dopaminergic alterations in Tourette’s syndrome: a meta-analysis based on 16 PET and SPECT neuroimaging studies Transl Psychiat, 8 (1): 143
  | Weblink |
• Stübner S, Grohmann R, Greil W, Zhang X, Müller-Oerlinghausen B, Bleich S, Rüther E, Möller H, Engel R, Falkai P, Toto S, Kasper S, Neyazi A (2018) Suicidal Ideation and Suicidal Behavior as Rare Adverse Events of Antidepressant Medication: Current Report from the AMSP Multicenter Drug Safety Surveillance Project Int J Neuropsychopharmacol, 21 (9): 814-821
  | Weblink |
• Rischka L, Gryglewski G, Pfaff S, Vanicek T, Hienert M, Klöbl M, Hartenbach M, Haug A, Wadsak W, Mitterhauser M, Hacker M, Kasper S, Lanzenberger R, Hahn A (2018) Reduced task durations in functional PET imaging with [ 18 F]FDG approaching that of functional MRI Neuroimage, 181: 323-330
  | Weblink |
• Pazan F, , Weiss C, Wehling M (FORTA-List: Burkhardt H, Schwarz S, Wedding U, Johnell K, Eriksson T, Ruths S, Husebø BS, Huupponen R, Ranhoff AH, Onder G, Incalzi RA, Marcucci M, Cherubini A, Volpato S, Ruggiero C, Mugelli A, Laville M, Annweiler C, Mouchoux C, Robert P, Rhalimi M, Jaurrieta JJS, Mañas LR, Núñez JFM, Jentoft AJC, Rexach JAS, Agustí A, Mateos R, Laporte AS, Gladman J, Crome P, Hughes C, O'Mahony D, Byrne S, Ekpo E, Ashton C, Witham MD, Soiza RL, Wieczorowska-Tobis K, Kostka T, Sławek J, Klich-Rączka A, Grodzicki T, Bień B, Broncel M, Mierzejewski P, Jansen RWMM, van den Bemt PMLA, van der Cammen TJM, Bauer J, Berthold HK, Denkinger M, Dovjak P, Frohnhofen H, Frühwald T, Gisinger C, Gogol M, Gosch M, Gutzmann H, Heuser I, Hüll M, Iglseder B, Kasper S, Kwetkat A, von Renteln (2018) The EURO-FORTA (Fit fOR The Aged) List: International Consensus Validation of a Clinical Tool for Improved Drug Treatment in Older People Drugs Aging, 35 (1): 61-71
  | Weblink |
• Szodorai E, Bampali K, Romanov R, Kasper S, Hökfelt T, Ernst M, Lubec G, Harkany T (2018) Diversity matters: combinatorial information coding by GABA A receptor subunits during spatial learning and its allosteric modulation Cell Signal, 50: 142-159
  | Weblink |
• Ludwig B, Kienesberger K, Carlberg L, Swoboda P, Bernegger A, Koller R, Wang Q, Inaner M, Zotter M, Kapusta N, Haslacher H, Aigner M, Kasper S, Schosser A (2018) Influence of CRHR1 Polymorphisms and Childhood Abuse on Suicide Attempts in Affective Disorders: A GxE Approach Front Psychiatry, 26(9): 165
  | Weblink |
• Winkler D, Spies M, Al-Resheg Y, Wu J, Bunney W, Bunney B, Kasper S, Pjrek E (2018) Usage of Therapeutic Sleep Deprivation: A Survey in Psychiatric Hospitals in Austria, Germany, and Switzerland Behav Sleep Med, 17 (6): 713-720
  | Weblink |
• Dold M, Bartova L, Fugger G, Kautzky A, Souery D, Mendlewicz J, Papadimitriou G, Dikeos D, Ferentinos P, Porcelli S, Serretti A, Zohar J, Montgomery S, Kasper S (2018) Major Depression and the Degree of Suicidality: Results of the European Group for the Study of Resistant Depression (GSRD) Int J Neuropsychopharmacol, 21 (6): 539-549
  | Weblink |
• Caraci F, Calabrese F, Molteni R, Bartova L, Dold M, Leggio G, Fabbri C, Mendlewicz J, Racagni G, Kasper S, Riva M, Drago F (2018) International Union of Basic and Clinical Pharmacology CIV: The Neurobiology of Treatment-resistant Depression: From Antidepressant Classifications to Novel Pharmacological Targets Pharmacol Rev, 70 (3): 475-504
  | Weblink |
• Fugger G, Dold M, Bartova L, Kautzky A, Souery D, Mendlewicz J, Serretti A, Zohar J, Montgomery S, Frey R, Kasper S (2018) Comorbid thyroid disease in patients with major depressive disorder - results from the European Group for the Study of Resistant Depression (GSRD) Eur Neuropsychopharmacol, 28 (6): 752-760
  | Weblink |
• Gryglewski G, Seiger R, James G, Godbersen G, Komorowski A, Unterholzner J, Michenthaler P, Hahn A, Wadsak W, Mitterhauser M, Kasper S, Lanzenberger R (2018) Spatial analysis and high resolution mapping of the human whole-brain transcriptome for integrative analysis in neuroimaging Neuroimage, 176: 259-267
  | Weblink |
• Kraus C, Vanicek T, Weidenauer A, Khanaqa T, Stamenkovic M, Lanzenberger R, Willeit M, Kasper S (2018) DiGeorge syndrome Wien. Klin. Wochenschr., 130 (7-8): 283-287
  | Weblink |
• Satyanarayanan S, Shih Y, Chien Y, Huang S, Gałecki P, Kasper S, Chang J, Su K (2018) Anti-Oxidative Effects of Melatonin Receptor Agonist and Omega-3 Polyunsaturated Fatty Acids in Neuronal SH-SY5Y Cells: Deciphering Synergic Effects on Anti-Depressant Mechanisms Mol Neurobiol, 55 (9): 7271-7284
  | Weblink |
• Dold M, Bartova L, Mendlewicz J, Souery D, Serretti A, Porcelli S, Zohar J, Montgomery S, Kasper S (2018) Clinical correlates of augmentation/combination treatment strategies in major depressive disorder Acta Psychiatr Scand, 137 (5): 401-412
  | Weblink |
• Bernegger A, Kienesberger K, Carlberg L, Swoboda P, Ludwig B, Koller R, Inaner M, Zotter M, Kapusta N, Aigner M, Haslacher H, Kasper S, Schosser A (2018) The Impact of COMT and Childhood Maltreatment on Suicidal Behaviour in Affective Disorders Sci Rep, 12;8 (1): 692
  | Weblink |
• Kautzky A, Dold M, Bartova L, Spies M, Vanicek T, Souery D, Montgomery S, Mendlewicz J, Zohar J, Fabbri C, Serretti A, Lanzenberger R, Kasper S (2018) Refining Prediction in Treatment-Resistant Depression J Clin Psychiatry, 79 (1): 16m11385
  | Weblink |
• Olgiati P, Serretti A, Souery D, Dold M, Kasper S, Montgomery S, Zohar J, Mendlewicz J (2018) Early improvement and response to antidepressant medications in adults with major depressive disorder. Meta-analysis and study of a sample with treatment-resistant depression J Affect Disord, 227: 777-786
  | Weblink |
• Kranz G, Hahn A, Kraus C, Spies M, Pichler V, Jungwirth J, Mitterhauser M, Wadsak W, Windischberger C, Kasper S, Lanzenberger R (2018) Probing the association between serotonin-1A autoreceptor binding and amygdala reactivity in healthy volunteers Neuroimage, 171: 1-5
  | Weblink |
• Grunze H, Vieta E, Goodwin G, Bowden C, Licht R, Azorin J, Yatham L, Mosolov S, Möller H, Kasper S, (2018) The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Acute and long-term treatment of mixed states in bipolar disorder World J Biol Psychiatry, 19 (1): 2-58
  | Weblink |
• Fabbri C, Corponi F, Albani D, Raimondi I, Forloni G, Schruers K, Kasper S, Kautzky A, Zohar J, Souery D, Montgomery S, Cristalli C, Mantovani V, Mendlewicz J, Serretti A (2018) Pleiotropic genes in psychiatry: Calcium channels and the stress-related FKBP5 gene in antidepressant resistance Prog Neuropsychopharmacol Biol Psychiatry, 81: 203-210
  | Weblink |
• Spies M, James G, Berroterán-Infante N, Ibeschitz H, Kranz G, Unterholzner J, Godbersen M, Gryglewski G, Hienert M, Jungwirth J, Pichler V, Reiter B, Silberbauer L, Winkler D, Mitterhauser M, Stimpfl T, Hacker M, Kasper S, Lanzenberger R (2018) Assessment of Ketamine Binding of the Serotonin Transporter in Humans with Positron Emission Tomography Int J Neuropsychopharmacol, 21 (2): 145-153
  | Weblink |
• Fountoulakis K, Gonda X, Siamouli M, Panagiotidis P, Moutou K, Nimatoudis I, Kasper S (2018) Paternal and maternal age as risk factors for schizophrenia: a case–control study Int J Psychiatry Clin Pract, 22 (3): 170-176
  | Weblink |
• Kranz G, Hahn A, Kaufmann U, Tik M, Ganger S, Seiger R, Hummer A, Windischberger C, Kasper S, Lanzenberger R (2018) Effects of testosterone treatment on hypothalamic neuroplasticity in female-to-male transgender individuals Brain Struct Funct, 223 (1): 321-328
  | Weblink |
• Kasper S, Müller W, Volz H, Möller H, Koch E, Dienel A (2018) Silexan in anxiety disorders: clinical data and pharmacological background World J Biol Psychiatry, 19(6): 412-420
  | Weblink |
• Letmaier M, Grohmann R, Kren C, Toto S, Bleich S, Engel R, Gary T, Papageorgiou K, Konstantinidis A, Holl A, Painold A, Kasper S (2018) Venous thromboembolism during treatment with antipsychotics - results of a drug surveillance program World J Biol Psychiatry, 19(3): 175-186
  | Weblink |

• Weidenauer A, Sauerzopf U, Bartova L, Bauer M, Praschak-Rieder N, Kasper S, Willeit M (2018) Sensibilisierung auf Amphetamine: Bedeutung für die Schizophrenie- und Suchtforschung Journal für Neurologie, Neurochirurgie und Psychiatrie, 19 (2): 66-der 71
  | Weblink |
• Sauerzopf U, Weidenauer A Praschak-Rieder N, Kasper S Sitte H, Willeit M (2018) Reprogrammierte Zellen: Zukunft der psychiatrischen Forschung? Journal für Neurologie, Neurochirurgie und Psychiatrie, 19 (2): 60-63
  | Weblink |
• Anghelescu I, Edwards D, Seifritz E, Kasper S (2018) Stress management and the role of Rhodiola rosea: a review Int J Psychiatry Clin Pract, 22 (4): 242-252
  | Weblink |
• Dodd S, Mitchell P, Bauer M, Yatham L, Young A, Kennedy S, Williams L, Suppes T, Lopez Jaramillo C, Trivedi M, Fava M, Rush A, McIntyre R, Thase M, Lam R, Severus E, Kasper S, Berk M (2018) Monitoring for antidepressant-associated adverse events in the treatment of patients with major depressive disorder: An international consensus statement World J Biol Psychiatry, 19 (5): 330-348
  | Weblink |

• Hahn A, Gryglewski G, Nics L, Rischka L, Ganger S, Sigurdardottir H, Vraka C, Silberbauer L, Vanicek T, Kautzky A, Wadsak W, Mitterhauser M, Hartenbach M, Hacker M, Kasper S, Lanzenberger R (2017) Task-relevant brain networks identified with simultaneous PET/MR imaging of metabolism and connectivity Brain Struct Funct, 223: 1369-1378
  | Weblink |
• Grünberger J, Rainer M, Ücelehan S, Mulaoglu A, Reigbert K, Otzelberger B, Grünberger M, Stöhr H, Kasper S (2017) Pupillometrische Diagnostik dementieller Erkrankunge Journal für Neurologie, Neurochirurgie und Psychiatrie, 18 (3): 99-102
• Möller H, Volz H, Dienel A, Schläfke S, Kasper S (2017) Efficacy of Silexan in subthreshold anxiety: meta-analysis of randomised, placebo-controlled trials Eur Arch Psychiatry Clin Neurosci, 269 (2): 183-193
  | Weblink |
• Dold M, Bartova L, Souery D, Mendlewicz J, Porcelli S, Serretti A, Zohar J, Montgomery S, Kasper S (2017) Low comorbid obsessive-compulsive disorder in patients with major depressive disorder – Findings from a European multicenter study J Affect Disord, 227: 254-259
  | Weblink |
• Schosser A, Carlberg L, Calati R, Serretti A, Massat I, Spindelegger C, Linotte S, Mendlewicz J, Souery D, Zohar J, Montgomery S, Kasper S (2017) The Impact of BDNF Polymorphisms on Suicidality in Treatment-Resistant Major Depressive Disorder: A European Multicenter Study Int J Neuropsychopharmacol, 20 (10): 782-787
  | Weblink |
• Dold M, Bartova L, Rupprecht R, Kasper S (2017) Dose Escalation of Antidepressants in Unipolar Depression: A Meta-Analysis of Double-Blind, Randomized Controlled Trials Psychother Psychosom, : 283-291
  | Weblink |
• Nussbaumer-Streit B, Winkler D, Spies M, Kasper S, Pjrek E (2017) Prevention of seasonal affective disorder in daily clinical practice: results of a survey in German-speaking countries BMC Psychiatry, 17 (1): 247:1-9
  | Weblink |
• Dold M, Bartova L, Kautzky A, Souery D, Mendlewicz J, Serretti A, Porcelli S, Zohar J, Montgomery S, Kasper S (2017) The impact of comorbid post-traumatic stress disorder in patients with major depressive disorder on clinical features, pharmacological treatment strategies, and treatment outcomes – Results from a cross-sectional European multicenter study Eur Neuropsychopharmacol, 27 (7): 625-632
  | Weblink |
• Kautzky A, James G, Philippe C, Baldinger-Melich P, Kraus C, Kranz G, Vanicek T, Gryglewski G, Wadsak W, Mitterhauser M, Rujescu D, Kasper S, Lanzenberger R (2017) The influence of the rs6295 gene polymorphism on serotonin-1A receptor distribution investigated with PET in patients with major depression applying machine learning Transl Psychiat, 7 (6): e1150
  | Weblink |
• Winkler-Pjrek E, Spies M, Baldinger-Melich P, Perkmann L, Kasper S, Winkler D (2017) Use of Light Therapy by Office-Based Physicians Neuropsychobiology, 74(4): 182-187
  | Weblink |
• Bartova L, Weidenauer A, Dold M, Naderi-Heiden A, Kasper S, Willeit M, Praschak-Rieder N (2017) Robust Antidepressant Effect Following Alternating Intravenous Racemic Ketamine and Electroconvulsive Therapy in Treatment-Resistant Depression J ECT, 33: e31-e32
  | Weblink |
• Kasper S, Dienel A (2017) Multicenter, open-label, exploratory clinical trial with Rhodiola rosea extract in patients suffering from burnout symptoms Neuropsychiatr Dis Treat, Volume 13: 889-898
  | Weblink |
• Kasper S, Möller H, Volz H, Schläfke S, Dienel A (2017) Silexan in generalized anxiety disorder Int Clin Psychopharmacol, 32 (4): 195-204
  | Weblink |
• Fabbri C, Crisafulli C, Calati R, Albani D, Forloni G, Calabrò M, Martines R, Kasper S, Zohar J, Juven-Wetzler A, Souery D, Montgomery S, Mendlewicz J, Serretti A (2017) Neuroplasticity and second messenger pathways in antidepressant efficacy: pharmacogenetic results from a prospective trial investigating treatment resistance Eur Arch Psychiatry Clin Neurosci, 267: 723-735
  | Weblink |
• Dold M, Bartova L, Souery D, Mendlewicz J, Serretti A, Porcelli S, Zohar J, Montgomery S, Kasper S (2017) Clinical characteristics and treatment outcomes of patients with major depressive disorder and comorbid anxiety disorders - results from a European multicenter study J Psychiatr Res, 91: 1-13
  | Weblink |
• Gastpar M, Müller W, Volz H, Möller H, Schläfke S, Dienel A, Kasper S (2017) Silexan does not cause withdrawal symptoms even when abruptly discontinued Int J Psychiatry Clin Pract, 21 (3): 177-180
  | Weblink |
• Kraus C, Castrén E, Kasper S, Lanzenberger R (2017) Serotonin and Neuroplasticity – Links between molecular, functional and structural pathophysiology in depression Neurosci Biobehav R, 77: 317-326
  | Weblink |
• Kranz G, Seiger R, Kaufmann U, Hummer A, Hahn A, Ganger S, Tik M, Windischberger C, Kasper S, Lanzenberger R (2017) Effects of sex hormone treatment on white matter microstructure in individuals with gender dysphoria Neuroimage, 150: 60-67
  | Weblink |
• James G, Baldinger-Melich P, Philippe C, Kranz G, Vanicek T, Hahn A, Gryglewski G, Hienert M, Spies M, Traub-Weidinger T, Mitterhauser M, Wadsak W, Hacker M, Kasper S, Lanzenberger R (2017) Effects of Selective Serotonin Reuptake Inhibitors on Interregional Relation of Serotonin Transporter Availability in Major Depression Front Hum Neurosci, 11: 48
  | Weblink |
• Litvan Z, Bauer M, Kasper S, Frey R (2017) Electroconvulsive therapy with S-ketamine anesthesia for catatonia in coexisting depression and dementia Int Psychogeriatr, 29 (07): 1223-1225
  | Weblink |
• Kautzky A, Baldinger-Melich P, Kranz G, Vanicek T, Souery D, Montgomery S, Mendlewicz J, Zohar J, Serretti A, Lanzenberger R, Kasper S (2017) A New Prediction Model for Evaluating Treatment-Resistant Depression J Clin Psychiatry, 78: 215-222
  | Weblink |
• Kraus C, Rabl U, Vanicek T, Carlberg L, Popovic A, Spies M, Bartova L, Gryglewski G, Papageorgiou K, Lanzenberger R, Willeit M, Winkler D, Rybakowski J, Kasper S (2017) Administration of ketamine for unipolar and bipolar depression Int J Psychiatry Clin Pract, 21: 2-12
  | Weblink |
• Spies M, Kraus C, Geissberger N, Auer B, Klöbl M, Tik M, Stürkat I, Hahn A, Woletz M, Pfabigan D, Kasper S, Lamm C, Windischberger C, Lanzenberger R (2017) Default mode network deactivation during emotion processing predicts early antidepressant response Transl Psychiatry, 7 (1): e1008
  | Weblink |
• Gryglewski G, Rischka L, Philippe C, Hahn A, James G, Klebermass E, Hienert M, Silberbauer L, Vanicek T, Kautzky A, Berroterán-Infante N, Nics L, Traub-Weidinger T, Mitterhauser M, Wadsak W, Hacker M, Kasper S, Lanzenberger R (2017) Simple and rapid quantification of serotonin transporter binding using [11C]DASB bolus plus constant infusion Neuroimage, 149: 23-32
  | Weblink |
• Fountoulakis K, Gonda X, Siamouli M, Moutou K, Nitsa Z, Leonard B, Kasper S (2017) Higher than recommended dosages of antipsychotics in male patients with schizophrenia are associated with increased depression but no major neurocognitive side effects: Results of a cross-sectional pilot naturalistic study Prog Neuropsychopharmacol Biol Psychiatry, 75: 113-119
  | Weblink |
• Fountoulakis K, Grunze H, Vieta E, Young A, Yatham L, Blier P, Kasper S, Moeller H (2017) The International College of Neuro-Psychopharmacology (CINP) treatment guidelines for Bipolar disorder in adults (CINP-BD-2017), part 3: The clinical guidelines. Int J Neuropsychopharmacol, 20: 180-195
  | Weblink |
• Höflich A, Ganger S, Tik M, Hahn A, Kranz G, Vanicek T, Spies M, Kraus C, Windischberger C, Kasper S, Winkler D, Lanzenberger R (2017) Imaging the neuroplastic effects of ketamine with VBM and the necessity of placebo control Neuroimage, 147: 198-203
  | Weblink |
• Soyka M, Kranzler H, Hesselbrock V, Kasper S, Mutschler J, Möller H, (2017) Guidelines for biological treatment of substance use and related disorders, part 1: Alcoholism, first revision World J Biol Psychiat, 18: 86-119
  | Weblink |
• Fountoulakis KN, Young A, Yatham L, Grunze H, Vieta E, Blier P, Moeller HJ, Kasper S (2017) The International College of Neuropsychopharmacology (CINP) treatment guidelines for bipolar disorder in adults, part 1: background and methods of the development of guidelines Int. J. Neuropsychopharmacol., 20: 98-120
  | Weblink |
• Fountoulakis K, Yatham L, Grunze H, Vieta E, Young A, Blier P, Kasper S, Moeller H (2017) The International College of Neuro-Psychopharmacology (CINP) treatment guidelines for Bipolar disorder in adults (CINP-BD-2017), part 2: Review, grading of the evidence and a precise algorithm Int J Neuropsychopharmacol, 20: 121-179
  | Weblink |
• Komorowski A, James GM, Philippe C, Gryglewski G, Bauer A, Hienert M, Spies M, Kautzky A, Vanicek T, Hahn A, Traub-Weidinger T, Winkler D, Wadsak W, Mitterhauser M, Hacker M, Kasper S, Lanzenberger (2017) Association of protein distribution and gene expression revealed by PET and post-mortem quantification in the serotonergic system of the human brain Cereb. Cortex, 27: 117-130
  | Weblink |
• Fountoulakis K, Vieta E, Young A, Yatham L, Grunze H, Blier P, Moeller H, Kasper S (2017) The International College of Neuropsychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 4: Unmet Needs in the Treatment of Bipolar Disorder and Recommendations for Future Research Int J Neuropsychopharmacol, 20: 196-205
  | Weblink |
• Winkler D, Pjrek E, Spies M, Willeit M, Dorffner G, Lanzenberger R, Kasper S (2017) Has the existence of seasonal affective disorder been disproven? J Affect Disord, 208: 54-55
  | Weblink |
• Baldinger-Melich P, Weidenauer A, Linder C, Hienert M, Kasper S, Stamenkovic M, Willeit M (2017) Case Report: ECT in a patient with primary Parkinsonian syndrome and schizophrenia J ECT, 33 (1): e2-e3
  | Weblink |
• Vanicek T, Kutzelnigg A, Philippe C, Sigurdardottir H, James G, Hahn A, Kranz G, Höflich A, Kautzky A, Traub-Weidinger T, Hacker M, Wadsak W, Mitterhauser M, Kasper S, Lanzenberger R (2017) Altered interregional molecular associations of the serotonin transporter in attention deficit/hyperactivity disorder assessed with PET Human Brain Mapping, 38 (2): 792-802
  | Weblink |
• Generoso M, Trevizol A, Kasper S, Cho H, Cordeiro Q, Shiozawa P (2017) Pregabalin for generalized anxiety disorder: An updated systematic review and meta-analysis Int Clin Psychopharmacol, 32 (1): 49-55
  | Weblink |
• Baumann P, Spies M, Möller H, Kasper S, Bitter I, Laux G (2017) A proposal for a psychopharmacology–pharmacotherapy catalogue of learning objectives and a curriculum in Europe World J Biol Psychiat, 18: 29-38
  | Weblink |
• Höflich A, Hahn A, Küblböck M, Kranz G, Vanicek T, Ganger S, Spies M, Windischberger C, Kasper S, Winkler D, Lanzenberger R (2017) Ketamine-dependent neuronal activation in healthy volunteers Brain Struct Funct, 222 (3): 1533-1542
  | Weblink |

• Kasper S (2017) Phythotherapeutika bei Depression und Angst. Hilfe aus dem Pflanzenreich. Interview Jatros Neurologie & Psychiatrie , 06/2017: 39-40
• Bauer M, Severus E, Möller H, Young A, (2017) Pharmacological treatment of unipolar depressive disorders: summary of WFSBP guidelines Int J Psychiatry Clin Pract, 21 (3): 166-176
  | Weblink |
• Kraus C, Lanzenberger R, Kasper S (2017) Ketamine for the Treatment of Depression JAMA Psychiatry, 74 (9): 970
  | Weblink |
• Caraci F, Enna S, Zohar J, Racagni G, Zalsman G, van den Brink W, Kasper S, Koob G, Pariante C, Piazza P, Yamada K, Spedding M, Drago F, (2017) A New Nomenclature for Classifying Psychotropic Drugs Brit J Clin Pharmaco, 83 (8): 1614-1616
  | Weblink |
• Weidenauer A, Bauer M, Sauerzopf U, Bartova L, Praschak-Rieder N, Sitte H, Kasper S, Willeit M (2017) Making Sense of: Sensitization in Schizophrenia Int J Neuropsychopharmacol, 20 (1): 1-10
  | Weblink |

• Kasper S (2017) Vorwort. In: , Forensische Psychodiagnostik und Psychotherapie im Strafvollzug Facultas Verlag
• Volz HP, Kasper S, Möller HJ (2017) Psychopharmakotherapie - klinisch-empirische Grundlagen. In: Möller HJ, Laux G, Kapfhammer HP (Hrsg.), Psychiatrie, Psychosomatik und Psychotherapie. 5. Auflage Springer-Verlag Berlin Heidelberg: 795-842
  | Weblink |
• Kreuzer P, Jooyandeh S, Langguth B, Kranz G, Padberg F, Kasper S, Baghai T (2017) Elektrokonvulsionstherapie, Hirnstimulationsverfahren. In: Möller HJ, Laux G, Kapfhammer HP (Hrsg.), Psychiatrie, Psychosomatik und Psychotherapie. 5. Auflage Springer-Verlag Berlin Heidelberg: 843-887
  | Weblink |
• Kasper S (2017) Lichttherapie. In: Möller HJ, Laux G, Kapfhammer HP (Hrsg.), Psychiatrie, Psychosomatik und Psychotherapie. 5. Auflage Springer-Verlag Berlin Heidelberg: 895-901
  | Weblink |
• Kasper S (2017) Schlafentzugsbehandlung. In: Möller HJ, Laux G, Kapfhammer HP (Hrsg.), Psychiatrie, Psychosomatik und Psychotherapie. 5. Auflage Springer-Verlag Berlin Heidelberg: 889-894
  | Weblink |
• Kasper S, Dold M (2017) Mental disorders in primary care: A guide to their evaluation and management. In: Carvalho AF, McIntyre RS, Anxiety disorders in primary care Oxford University Press, Oxford: 90-98

• Kasper S (2016) Wie Männer mit psychischen Belastungen umgehen. Buchbesprechung. „Möller-Leimkühler AM: Vom Dauerstress zur Depression“ CliniCum neuropsy, 4: 58
• Kasper S (2016) Trends und Perspektiven in der Psychiatrie: Erkennen österreichische Gerichte psychiatrische Erkrankungen als medizinische Erkrankungen an? Journal für Neurologie, Neurochirurgie und Psychiatrie, 17: 125-126
• Hienert M, Weidenauer A, Kraus C, Willeit M, Kasper S, Stamenkovic M (2016) Pregabalin in Tourette’s Syndrome: A Case Series Am J Psychiatry, 173 (12): 1242-1243
  | Weblink |
• Dold M, Kautzky A, Bartova L, Rabl U, Souery D, Mendlewicz J, Porcelli S, Serretti A, Zohar J, Montgomery S, Kasper S (2016) Pharmacological treatment strategies in unipolar depression in European tertiary psychiatric treatment centers – A pharmacoepidemiological cross-sectional multicenter study Eur Neuropsychopharmacol, 26 (12): 1960-1971
  | Weblink |
• Dold M, Kasper S (2016) Evidence-based pharmacotherapy of treatment-resistant unipolar depression Int J Psychiatry Clin Pract, 21: 13-23
  | Weblink |
• Hienert M, Weidenauer A, Kraus C, Willeit M, Kasper S, Stamenkovic M (2016) (2016) Pregabalin in Tourette syndrome Am J Psychiatry, 173: 1242-1243
• Seiger R, Hahn A, Hummer A, Kranz G, Ganger S, Woletz M, Kraus C, Sladky R, Kautzky A, Kasper S, Windischberger C, Lanzenberger R (2016) Subcortical gray matter changes in transgender subjects after long-term cross-sex hormone administration Psychoneuroendocrinology, 74: 371-379
  | Weblink |
• Zohar J, Kasper S (2016) Neuroscience-based Nomenclature (NbN): A call for action World J Biol Psychiat, 17 (5): 318-320
  | Weblink |
• Hahn A, Gryglewski G, Nics L, Hienert M, Rischka L, Vraka C, Sigurdardottir H, Vanicek T, James G, Seiger R, Kautzky A, Silberbauer L, Wadsak W, Mitterhauser M, Hacker M, Kasper S, Lanzenberger R (2016) Quantification of task-specific glucose metabolism with constant infusion of 18F-FDG J Nucl Med, 57 (12): 1933-1940
  | Weblink |
• Möller H, Bandelow B, Volz H, Barnikol U, Seifritz E, Kasper S (2016) The relevance of ‘mixed anxiety and depression’ as a diagnostic category in clinical practice Eur Arch Psychiatry Clin Neurosci, 266: 725-736
  | Weblink |
• Schmitt A, Rujescu D, Gawlik M, Hasan A, Hashimoto K, Iceta S, Jarema M, Kambeitz J, Kasper S, Keeser D, Kornhuber J, Koutsouleris N, Lanzenberger R, Malchow B, Saoud M, Spies M, Stöber G, Thibaut F, Riederer P, Falkai P (2016) Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia part II: Cognition, neuroimaging and genetics World J Biol Psychiat, 17 (6): 406-428
  | Weblink |
• Pazan F, Weiss C, Wehling M (Bauer J, Berthold HK, Burkhardt H, Denkinger M, Dovjak P, Frohnhofen H, Frühwald T, Gisinger C, Gogol M, Gosch M, Gutzmann H, Heuser I, Hüll M, Iglseder B, Kasper S, Kwetkat A, Von Renteln-Kruse W, Schindler C, Schuler M, Schulz RJ, Schwarz S, Sommeregger U, Wedding U, Zeyfang A)Drugs (2016) The FORTA (Fit fOR The Aged) List 2015: Update of a Validated Clinical Tool for Improved Pharmacotherapy in the Elderly Drugs Aging, 33 (6): 447-449
• Kasper S (2016) Silexan: gelassener in die Zukunft blicken Pharmakon, 4: 365-372
• Yatham L, Vieta E, Goodwin G, Bourin M, de Bodinat C, Laredo J, Calabrese J (2016) Agomelatine or placebo as adjunctive therapy to a mood stabiliser in bipolar I depression: randomised double-blind placebo-controlled trial Br J Psychiatry, 208 (1): 78-86
  | Weblink |
• Mandelli L, Serretti A, Souery D, Mendlewicz J, Kasper S, Montgomery S, Zohar J (2016) High occupational level is associated with poor response to treatment of depression Eur Neuropsychopharmacol, 26 (8): 1320-1326
  | Weblink |
• Kranz GS, Lanzenberger R, Kasper S (2016) Hat Testosteron einen stimmungsaufhellenden Effekt? Ärzte Woche, 1-2:18
• Mandelli L, Souery D, Bartova L, Kasper S, Montgomery S, Zohar J, Mendlewicz J, Serretti A (2016) Bipolar II disorder as a risk factor for postpartum depression J Affect Disord, 204: 54-58
  | Weblink |
• Müller WE, Eckert A, Eckert GP, Fink H, Friedland K, Hörr R, Ihl R, Kasper S, Möller HJ (2016) Ginkgo-Spezialextrakt 761® (Tebonin®): Ein präklinisches und klinisches Update im Wandel klinischer und ätiopathogenetischer Konzepte der Alzheimer-Demenz Psychopharmakotherap, 23: 102-117
• Kasper S, Volz H, Dienel A, Schläfke S (2016) Efficacy of Silexan in mixed anxiety–depression – A randomized, placebo-controlled trial Eur Neuropsychopharmacol, 26 (2): 331-340
  | Weblink |
• Garriga M, Pacchiarotti I, Kasper S, Zeller S, Allen M, Vázquez G, Baldaçara L, San L, McAllister-Williams R, Fountoulakis K, Courtet P, Naber D, Chan E, Fagiolini A, Möller H, Grunze H, Llorca P, Jaffe R, Yatham L, Hidalgo-Mazzei D, Passamar M, Messer T, Bernardo M, Vieta E (2016) Assessment and management of agitation in psychiatry: Expert consensus World J Biol Psychiat, 17 (2): 86-128
  | Weblink |
• Pjrek E, Baldinger-Melich P, Spies M, Papageorgiou K, Kasper S, Winkler D (2016) Epidemiology and socioeconomic impact of seasonal affective disorder in Austria Eur Psychiatry, 32: 28-33
  | Weblink |
• Baldinger-Melich P, Kraus C, Hahn A, Lanzenberger R, Kasper S (2016) Zerebrale Bildgebung bei affektiven Störungen und Angsterkrankungen Journal für Neurologie, Neurochirurgie und Psychiatrie, 17 (1): 16-20
• Kaltenboeck A, Winkler D, Kasper S (2016) Bipolar and related disorders in DSM-5 and ICD-10 CNS Spectr, 21 : 318-323
  | Weblink |
• Dold M, Tardy M, Samara M, Li C, Kasper S, Leucht S (2016) Are all first-generation antipsychotics equally effective in treating schizophrenia? A meta-analysis of randomised, haloperidol-controlled trials World J Biol Psychiat, 17 (3): 210-220
  | Weblink |
• Klein M, Schmoeger M, Kasper S, Schosser A (2016) Meta-analysis of the COMT Val158Met polymorphism in major depressive disorder: the role of gender World J Biol Psychiat, 17 (2): 147-158
  | Weblink |
• Baldinger-Melich P, Fugger G, Kraus C, Lanzenberger R, Popp W, Kasper S, Frey R (2016) Treatment-resistant Catatonia - A Case Report Clinical Neuropsychiatry, 13: 24-27
• Friedrich ME, Akimova E, Huf W, Konstantinidis A, Papageorgiou K, Winkler D, Toto S, Greil W, Grohmann R, Kasper S (2016) Drug-Induced Liver Injury during Antidepressant Treatment: Results of AMSP, a Drug Surveillance Program Int. J. Neuropsychopharmacol., 19: 1-9
  | Weblink |
• Spies M, Hahn A, Kranz G, Sladky R, Kaufmann U, Hummer A, Ganger S, Kraus C, Winkler D, Seiger R, Comasco E, Windischberger C, Kasper S, Lanzenberger R (2016) Gender transition affects neural correlates of empathy: A resting state functional connectivity study with ultra high-field 7T MR imaging Neuroimage, 138: 257-265
  | Weblink |
• Hahn A, Kranz G, Sladky R, Kaufmann U, Ganger S, Hummer A, Seiger R, Spies M, Vanicek T, Winkler D, Kasper S, Windischberger C, Swaab D, Lanzenberger R (2016) Testosterone affects language areas of the adult human brain Human Brain Mapping, 37 (5): 1738-1748
  | Weblink |
• Sigurdardottir H, Kranz G, Rami-Mark C, James G, Vanicek T, Gryglewski G, Kautzky A, Hienert M, Traub-Weidinger T, Mitterhauser M, Wadsak W, Hacker M, Rujescu D, Kasper S, Lanzenberger R (2016) Effects of norepinephrine transporter gene variants on NET binding in ADHD and healthy controls investigated by PET Human Brain Mapping, 37 (3): 884-895
  | Weblink |
• Balestri M, Calati R, Souery D, Kautzky A, Kasper S, Montgomery S, Zohar J, Mendlewicz J, Serretti A (2016) Socio-demographic and clinical predictors of treatment resistant depression: A prospective European multicenter study J Affect Disord, 189: 224-232
  | Weblink |
• Fugger G, Gleiss A, Baldinger P, Strnad A, Kasper S, Frey R (2016) Psychiatric patients' perception of physical restraint Acta Psychiatr Scand, 133 (3): 221-231
  | Weblink |
• Höfer P, Schosser A, Calati R, Serretti A, Massat I, Kocabas N, Konstantinidis A, Mendlewicz J, Souery D, Zohar J, Juven-Wetzler A, Montgomery S, Kasper S (2016) The impact of serotonin receptor 1A and 2A gene polymorphisms and interactions on suicide attempt and suicide risk in depressed patients with insufficient response to treatment – a European multicentre study Int Clin Psychopharmacol, 31 (1): 1-7
  | Weblink |
• Meyer B, Huemer J, Rabl U, Boubela R, Kalcher K, Berger A, Banaschewski T, Barker G, Bokde A, Büchel C, Conrod P, Desrivières S, Flor H, Frouin V, Gallinat J, Garavan H, Heinz A, Ittermann B, Jia T, Lathrop M, Martinot J, Nees F, Rietschel M, Smolka M, Bartova L, Popovic A, Scharinger C, Sitte H, Steiner H, Friedrich M, Kasper S, Perkmann T, Praschak-Rieder N, Haslacher H, Esterbauer H, Moser E, Schumann G, Pezawas L (2016) Oppositional COMT Val158Met effects on resting state functional connectivity in adolescents and adults Brain Struct Funct, 221 (1): 103-114
  | Weblink |

• Huf P, Kasper S (2016) Geschlechterspezifische Aspekte psychiatrischer Erkrankungen. In: Hornberg C, Pauli A, Wrede B, Medizin - Gesundheit - Geschlecht: Eine gesundheitswissenschaftliche Perspektive Springer Fachmedien Wiesbaden: pp. 157-176

• Kasper S, Bancher C, Hörr R, Ihl R, Jagsch C, Marksteiner J, Mayer S, Rados C, Rainer M, Röper C (2016) Expertenmeeting: Ginkgo biloba EGb 761® (Cerebokan). Fixer Stellenwert in der Demenz-Therapie. , Medizin Medien Austria GmbH

• Phillips A, Hongaard-Andersen P, Moscicki R, Sahakian B, Quirion R, Krishnan K, Race T (2015) Proceedings of the 2013 CINP Summit: Innovative Partnerships to Accelerate CNS Drug Discovery for Improved Patient Care Int J Neuropsychopharmacol, 18 (3): pyu100
• Bartova L, Dold M, Praschak-Rieder N, Naderi-Heiden A, Kasper S (2015) Ultra-High-Dose Long-Acting Injectable Aripiprazole in Chronic Refractory Schizophrenia: A Case Report J Clin Toxicol, 05 (05)
• Willeit M, Vyssoki B, Kapusta N, Dorffner G, Kasper S, Praschak-Rieder N (2015) Sunshine Influences Suicide Rates Independent of Season Eur Psychiatry, 30: 28
• Bernegger A, Kienesberger K, Carlberg L, Swoboda P, Ludwig B, Koller R, Kapusta N, Aigner M, Haslacher H, Schmöger M, Kasper S, Schosser A (2015) Influence of Sex on Suicidal Phenotypes in Affective Disorder Patients with Traumatic Childhood Experiences PLoS One, 10 (9): e0137763
• Kasper S, Anghelescu I, Dienel A (2015) Efficacy of orally administered Silexan in patients with anxiety-related restlessness and disturbed sleep – A randomized, placebo-controlled trial Eur Neuropsychopharmacol, 25: 2183-2184
• Bartova L, Vogl S, Stamenkovic M, Praschak-Rieder N, Naderi-Heiden A, Kasper S, Willeit M (2015) Combination of intravenous S-ketamine and oral tranylcypromine in treatment-resistant depression: A report of two cases Eur Neuropsychopharmacol, 25: 2183-2184
• Zaninotto L, Souery D, Calati R, Di Nicola M, Montgomery S, Kasper S, Zohar J, Mendlewicz J, Cloninger RC, Serretti A, Janiri L (2015) Temperament and character profiles in bipolar I, bipolar II and major depressive disorder: Impact over illness course, comorbidity pattern and psychopathological features of depression J Affect Disord, 184: 51-59
• Ganger S, Hahn A, Küblböck M, Kranz G, Spies M, Vanicek T, Seiger R, Sladky R, Windischberger C, Kasper S, Lanzenberger R (2015) Comparison of continuously acquired resting state and extracted analogues from active tasks Human Brain Mapping, 36 (10): 4053-4063
• Dold M, Fugger G, Aigner M, Lanzenberger R, Kasper S (2015) Dose escalation of antipsychotic drugs in schizophrenia: A meta-analysis of randomized controlled trials Schizophr Res, 166 (1-3): 187-193
• Zaninotto L, Souery D, Calati R, Camardese G, Janiri L, Montgomery S, Kasper S, Zohar J, De Ronchi D, Mendlewicz J, Serretti A. (2015) Dimensions of Delusions in Major Depression: Socio-demographic and Clinical Correlates in an Unipolar-Bipolar Sample Clin Psychopharmacol Neurosci, 13: 48-52
• Fabbri C, Crisafulli C, Gurwitz D, Stingl J, Calati R, Albani D, Forloni G, Calabrò M, Martines R, Kasper S, Zohar J, Juven-Wetzler A, Souery D, Montgomery S, Mendlewicz J, Girolamo G, Serretti A (2015) Neuronal cell adhesion genes and antidepressant response in three independent samples Pharmacogenomics J, 15: 538-548
• Bridler R, Häberle A, Müller S, Cattapan K, Grohmann R, Toto S, Kasper S, Greil W (2015) Psychopharmacological treatment of 2195 in-patients with borderline personality disorder: A comparison with other psychiatric disorders Eur Neuropsychopharmacol, 25 (6): 763-772
• Dold M, Aigner M, Lanzenberger R, Kasper S (2015) Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: an update meta-analysis of double-blind, randomized, placebo-controlled trials Int J Neuropsychopharmacol,
• Hoflich A, Hahn A, Kublbock M, Kranz G, Vanicek T, Windischberger C, Saria A, Kasper S, Winkler D, Lanzenberger R (2015) Ketamine-induced modulation of the thalamo-cortical network in healthy volunteers as a model for schizophrenia Int J Neuropsychopharmacol,
• Bartova L, Meyer B, Diers K, Rabl U, Scharinger C, Popovic A, Pail G, Kalcher K, Boubela R, Huemer J, Mandorfer D, Windischberger C, Sitte H, Kasper S, Praschak-Rieder N, Moser E, Brocke B, Pezawas L (2015) Reduced Default Mode Network Suppression during a Working Memory Task in Remitted Major Depression J Psychiatr Res, 64: 9-18
• Seiger R, Hahn A, Hummer A, Kranz GS, Ganger S, Küblböck M, Kraus C, Sladky R, Kasper S, Windischberger C, Lanzenberger R (2015) Voxel-based morphometry at ultra-high fields. A comparison of 7 T and 3 T MRI data Neuroimage, 113: 207-216
• Kautzky A, Baldinger P, Souery D, Montgomery S, Mendlewicz J, Zohar J, Serretti A, Lanzenberger R, Kasper S (2015) The combined effect of genetic polymorphisms and clinical parameters on treatment outcome in treatment-resistant depression Eur Neuropsychopharmacol, 25 (4): 441-453
• Dold M, Aigner M, Klabunde M, Treasure J, Kasper S (2015) Second-Generation Antipsychotic Drugs in Anorexia Nervosa: A Meta-Analysis of Randomized Controlled Trials Psychother Psychosom, 84: 110-116
• Baldinger P, Kraus C, Rami-Mark C, Gryglewski G, Kranz G, Haeusler D, Hahn A, Spies M, Wadsak W, Mitterhauser M, Rujescu D, Kasper S, Lanzenberger R (2015) Interaction between 5-HTTLPR and 5-HT1B genotype status enhances cerebral 5-HT1A receptor binding Neuroimage, 111: 505-512
• Souery D, Calati R, Papageorgiou K, Juven-Wetzler A, Gailledreau J, Modavi D, Sentissi O, Pitchot W, Papadimitriou G, Dikeos D, Montgomery S, Kasper S, Zohar J, Serretti A, Mendlewicz J (2015) What to expect from a third step in treatment resistant depression: A prospective open study on escitalopram World J Biol Psychiatry, 6: 472-482
• Sladky R, Spies M, Hoffmann A, Kranz G, Hummer A, Gryglewski G, Lanzenberger R, Windischberger C, Kasper S (2015) (S)-citalopram influences amygdala modulation in healthy subjects: a randomized placebo-controlled double-blind fMRI study using dynamic causal modeling Neuroimage, 113: 207-216
• Hahn A, Kranz G, Sladky R, Ganger S, Windischberger C, Kasper S, Lanzenberger R (2015) Individual diversity of functional brain network economy Brain Connect, 5 (3): 156-165
• Kasper S, Montagnani G, Trespi G, Di Fiorino M (2015) Treatment of depressive symptoms in patients with schizophrenia Int Clin Psychopharmacol, 30 (1): 14-22
• Holl A, Grohmann R, Letmaier M, Painold A, Mörkl S, Toto S, Kasper S (2015) Pharmacotherapy of anxiety disorders in German-speaking countries: current status and changes between 1994 and 2011 Eur Arch Psychiatry Clin Neurosci, 265 (3): 199-208
• Carlberg L, Schosser A, Calati R, Serretti A, Massat I, Papageorgiou K, Kocabas N, Mendlewicz J, Zohar J, Montgomery S, Souery D, Kasper S (2015) Association study of CREB1 polymorphisms and suicidality in MDD: results from a European multicenter study on treatment resistant depression Int J Neurosci, 125 (5): 336-343

• Popovic A, Sauerzopf U, Kasper S, Willeit M (2015) Neuroimaging des Dopaminsystems bei Schizophrenie Jatros Neurologie & Psychiatrie ,
• Kasper S, Dold M (2015) Factors contributing to the increasing placebo response in antidepressant trials World Psychiatry, 14 (3): 304-306
• Spies M, Knudsen G, Lanzenberger R, Kasper S (2015) The serotonin transporter in psychiatric disorders: insights from PET imaging Lancet Psychiatry, 2 (8): 743-755
• Bauer M, Severus E, Köhler S, Whybrow P, Angst J, Möller H on behalf of the WFSBP Task Force on Treatment Guidelines for Unipolar Depressive Disorders (Adli M, Anderson I, Ayuso-Gutierrez JL, Baldwin D, Bauer M, Bech P, Berk M, Bitter I, Bschor T, Burrows G, Cassano G, Cetkovich-Bakmas M, Cookson JC, da Costa D, Gheorghe MD, Grunze H, Hasler G, Heinze G, Higuchi T, Hirschfeld RMA, Höschl C, Holsboer-Trachsler E, Kang RH, Kasper S, Katona C, Keller MB, Kirli S, Köhler S, Kostukova E, Kulhara P, Kupfer DJ, Lee MS, Leonard B, Licht RW, Lim SW, Lingjaerde O, Liu CY, Lublin H, Mendlewicz J, Mitchell P, Möller HJ, Paik JW, Park YC, Paykel ES, Pfennig A, Puzynski S, Rush AJ, Rybakowski JK, Tadic A, Tylee A, Unützer J, Vestergaard P, Vieta E, Whybrow PC, Yamada K, Yazici A) (2015) World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders. Part 2: Maintenance Treatment of Major Depressive Disorder-Update 2015 World J Biol Psychiatry, 16 (2): 76-95
• Dold M, Kasper S (2015) Increasing placebo response in antipsychotic trials: a clinical perspective Evid Based Ment Health, 18 (3): 77-79
• Kasper S (2015) Phytopharmaceutical treatment of anxiety, depression, and dementia in the elderly: evidence from randomized, controlled clinical trials Wien Med Wochenschr, 165 (11-12): 217-228
• Volz HP, Kasper S, Möller HJ (2015) Somatoforme Störungen und Möglichkeiten der Veränderungsmessung somatischer Symptome im Rahmen dieser Störungen Psychopharmakotherap, 22: 197-204
• Kasper S, Müller WE, Gastpar M, Volz HP, Seifritz E, Möller H (2015) Silexan bei Angststörungen und verwandten Erkrankungen: Eine evidenzbasierte Übersicht. Psychopharmakotherap, 22: 15-24
• Müller WE, Schuwald A, Nöldner M, Kasper S, Friedwald K (2015) Pharmakologische Grundlagen der therapeutischen Anwendung von Silexan (Lasea) Psychopharmakotherap, 22: 3-14
• Ihl R, Bunevicius R, Frölich L, Winblad B, Schneider L, Dubois B, Burns A, Thibaut F, Kasper S, Möller H (2015) World Federation of Societies of Biological Psychiatry guidelines for the pharmacological treatment of dementias in primary care Int J Psychiatry Clin Pract, 19 (1): 2-7

• Carlberg L, Scheibelreiter J, Hassler M, Schloegelhofer M, Schmoeger M, Ludwig B, Kasper S, Aschauer H, Egger G, Schosser A (2014) Brain-derived neurotrophic factor (BDNF)—Epigenetic regulation in unipolar and bipolar affective disorder J Affect Disord, 168: 399-406
• Carlberg L, Scheibelreiter J, Hassler M, Schloegelhofer M, Schmoeger M, Ludwig B, Kasper S, Aschauer H, Egger G, Schosser A (2014) Brain-derived neurotrophic factor (BDNF)—Epigenetic regulation in unipolar and bipolar affective disorder J Affect Disord, 168: 399-406
• Carlberg L, Scheibelreiter J, Hassler M, Schloegelhofer M, Schmoeger M, Ludwig B, Kasper S, Aschauer H, Egger G, Schosser A (2014) Brain-derived neurotrophic factor (BDNF)—Epigenetic regulation in unipolar and bipolar affective disorder J Affect Disord, 168: 399-406
• Spindelegger C, Papageorgiou K, Grohmann R, Engel RR, Greil W, Konstantinidis A, Agelink MW, Bleich S, Rüther E, Toto S, Kasper S (2014) Cardiovascular adverse reactions during antidepressant treatment. A drug surveillance report of German speaking countries between 1993-2010 Int J Neuropsychopharmacol,
• Baldinger P, Höflich AS, Mitterhauser M, Hahn A, Rami-Mark C, Spies M, Wadsak W, Lanzenberger R, Kasper S (2014) Effects of Silexan on the serotonin-1A receptor and microstructure of the human brain: a randomized, placebo-controlled, double-blind, cross-over study with molecular and structural neuroimaging. Int. J. Neuropsychopharmacol.,
• Kranz G, Wadsak W, Kaufmann U, Savli M, Baldinger P, Gryglewski G, Haeusler D, Spies M, Mitterhauser M, Kasper S, Lanzenberger R (2014) High-Dose Testosterone Treatment Increases Serotonin Transporter Binding in Transgender People Biol Psychiatry,
• Kranz G, Hahn A, Kaufmann U, Kublbock M, Hummer A, Ganger S, Seiger R, Winkler D, Swaab D, Windischberger C, Kasper S, Lanzenberger R (2014) White Matter Microstructure in Transsexuals and Controls Investigated by Diffusion Tensor Imaging J Neurosci, 34 (46): 15466-15475
• Kutzelnigg A, Kopeinig M, Chen C, Fábián A, Pujol-Luna M, Shin Y, Treuer T, D’yachkova Y, Deix C, Kasper S, Doby D (2014) Compliance as a stable function in the treatment course of bipolar disorder in patients stabilized on olanzapine: results from a 24-month observational study International Journal of Bipolar Disorders, 2 (1): 13
• Vanicek T, Spies M, Rami-Mark C, Savli M, Höflich A, Kranz G, Hahn A, Kutzelnigg A, Traub-Weidinger T, Mitterhauser M, Wadsak W, Hacker M, Volkow N, Kasper S, Lanzenberger R (2014) The Norepinephrine Transporter in Attention-Deficit/Hyperactivity Disorder Investigated With Positron Emission Tomography JAMA Psychiatry, 71 (12): 1340-1349
• Meyer BM, Huemer J, Rabl U, Boubela RN, Kalcher K, Berger A, Banaschewski T, Barker G, Bokde A, Büchel C, Conrod P, Desrivières S, Flor H, Frouin V, Gallinat J, Garavan H, Heinz A, Ittermann B, Jia T, Lathrop M, Martinot JL, Nees F, Rietschel M, Smolka MN, Bartova L, Popovic A, Scharinger C, Sitte HH, Steiner H, Friedrich MH, Kasper S, Perkmann T, Praschak-Rieder N, Haslacher H, Esterbauer H, Moser E, Schumann G, Pezawas L (2014) Oppositional COMT Val158Met effects on resting state functional connectivity in adolescents and adults Brain Struct Funct, 221(1): 103-114
• Kasper S (2014) Treatment-resistant depression: a challenge for future research Acta Neuropsychiatr, 26 (03): 131-133
• Hahn A, Kranz G, Küblböck M, Kaufmann U, Ganger S, Hummer A, Seiger R, Spies M, Winkler D, Kasper S, Windischberger C, Swaab D, Lanzenberger R (2014) Structural Connectivity Networks of Transgender People Cereb. Cortex,
• Zaninotto L, Souery D, Calati R, Scudellari P, Janiri L, Montgomery S, Kasper S, Zohar J, Mendlewicz J, Serretti A (2014) Mixed, melancholic, and anxious features in depression: A cross-sectional study of sociodemographic and clinical correlates Ann Clin Psychiatry, 26: 243-253
• Kraus C, Baldinger P, Rami-Mark C, Gryglewski G, Kranz G, Haeusler D, Hahn A, Wadsak W, Mitterhauser M, Rujescu D, Kasper S, Lanzenberger R (2014) Exploring the Impact of BDNF Val66Met Genotype on Serotonin Transporter and Serotonin-1A Receptor Binding PLoS One, 9 (9): e106810
• Rabl U, Meyer B, Diers K, Bartova L, Berger A, Mandorfer D, Popovic A, Scharinger C, Huemer J, Kalcher K, Pail G, Haslacher H, Perkmann T, Windischberger C, Brocke B, Sitte H, Pollak D, Dreher J, Kasper S, Praschak-Rieder N, Moser E, Esterbauer H, Pezawas (2014) Additive Gene-Environment Effects on Hippocampal Structure in Healthy Humans J Neurosci, 34 (30): 9917-9926
  | Article (PDF) || Weblink |
• Riedel Monika, Röehrling Gerald, Czypionka Thomas, Kasper Siegfried (2014) A gap analysis for future supply of and demand for psychiatrists in Austria. J Ment Health Policy Econ, 1: 9-18
• Serretti A, Chiesa A, Calati R, Sentissi O, Akimova E, Kasper S, Zohar J, De Ronchi D, Mendlewicz J, Amital D, Montgomery S, Souery D (2014) Family history of major depression and residual symptoms in responder and non-responder depressed patients Compr Psychiatry, 55 (1): 51-55
• Kasper S, Brasser M, Schweizer E, Lyndon G, Prieto R (2014) How well do randomized controlled trial data generalize to ‘real-world’ clinical practice settings? A comparison of two generalized anxiety disorder studies Eur Neuropsychopharmacol, 24 (1): 125-132
• Kasper S, Iglesias-García C, Schweizer E, Wilson J, DuBrava S, Prieto R, Pitman V, Knapp L (2014) Pregabalin long-term treatment and assessment of discontinuation in patients with generalized anxiety disorder Int J Neuropsychopharmacol, 17 (05): 685-695
• Kasper S, Gastpar M, Müller W, Volz H, Möller H, Schläfke S, Dienel A (2014) Lavender oil preparation Silexan is effective in generalized anxiety disorder – a randomized, double-blind comparison to placebo and paroxetine Int J Neuropsychopharmacol, 17 (06): 859-869
• Di Fiorino M, Montagnani G, Trespi G, Kasper S (2014) Extended-release quetiapine fumarate (quetiapine XR) versus risperidone in the treatment of depressive symptoms in patients with schizoaffective disorder or schizophrenia Int Clin Psychopharmacol, 29 (3): 166-176
• Saller R, Kasper S, Dimpfel W, Savaskan E, Pfister T, Rostock M, Witt C, Thuile C, Das O, Unger M (2014) Phytotherapie in der Geriatrie und Gerontologie Forsch Komplementmed, 21 (s1): 2-18
• Michl J, Scharinger C, Zauner M, Kasper S, Freissmuth M, Sitte H, Ecker G, Pezawas L (2014) A multivariate approach linking reported side effects of clinical antidepressant and antipsychotic trials to in vitro binding affinities Eur Neuropsychopharmacol, 24 (9): 1463-1474
  | Weblink |
• Carlberg L, Scheibelreiter J, Hassler M, Schloegelhofer M, Schmoeger M, Ludwig B, Kasper S, Aschauer H, Egger G, Schosser A (2014) Brain-derived neurotrophic factor (BDNF)—Epigenetic regulation in unipolar and bipolar affective disorder J Affect Disord, 168: 399-406
• Kranz G, Hahn A, Baldinger P, Haeusler D, Philippe C, Kaufmann U, Wadsak W, Savli M, Hoeflich A, Kraus C, Vanicek T, Mitterhauser M, Kasper S, Lanzenberger R (2014) Cerebral serotonin transporter asymmetry in females, males and male-to-female transsexuals measured by PET in vivo Brain Struct Funct, 219 (1): 171-183
• Kraus C, Ganger S, Losak J, Hahn A, Savli M, Kranz G, Baldinger P, Windischberger C, Kasper S, Lanzenberger R (2014) Gray matter and intrinsic network changes in the posterior cingulate cortex after selective serotonin reuptake inhibitor intake Neuroimage, 84: 236-244
• Baldinger P, Kranz G, Haeusler D, Savli M, Spies M, Philippe C, Hahn A, Höflich A, Wadsak W, Mitterhauser M, Lanzenberger R, Kasper S (2014) Regional differences in SERT occupancy after acute and prolonged SSRI intake investigated by brain PET Neuroimage, 88: 252-262
• Hahn A, Haeusler D, Kraus C, Höflich A, Kranz G, Baldinger P, Savli M, Mitterhauser M, Wadsak W, Karanikas G, Kasper S, Lanzenberger R (2014) Attenuated serotonin transporter association between dorsal raphe and ventral striatum in major depression Human Brain Mapping, 35 (8): 3857-3866
• Scharinger C, Rabl U, Kasess C, Meyer B, Hofmaier T, Diers K, Bartova L, Pail G, Huf W, Uzelac Z, Hartinger B, Kalcher K, Perkmann T, Haslacher H, Meyer-Lindenberg A, Kasper S, Freissmuth M, Windischberger C, Willeit M, Lanzenberger R, Esterbauer H ,Brocke B, Moser E, Sitte H, Pezawas L (2014) Platelet Serotonin Transporter Function Predicts Default-Mode Network Activity PLoS One, 9 (3): e92543
• Fabbri C, Marsano A, Albani D, Chierchia A, Calati R, Drago A, Crisafulli C, Calabrò M, Kasper S, Lanzenberger R, Zohar J, Juven-Wetzler A, Souery D, Montgomery S, Mendlewicz J, Serretti A (2014) PPP3CC gene: a putative modulator of antidepressant response through the B-cell receptor signaling pathway Pharmacogenomics J, 14 (5): 463-472
• Baldinger P, Lotan A, Frey R, Kasper S, Lerer B, Lanzenberger R (2014) Neurotransmitters and Electroconvulsive Therapy J ECT, 30 (2): 116-121
• Kranz G, Rami-Mark C, Kaufmann U, Baldinger P, Hahn A, Höflich A, Savli M, Stein P, Wadsak W, Mitterhauser M, Winkler D, Lanzenberger R, Kasper S (2014) Effects of hormone replacement therapy on cerebral serotonin-1A receptor binding in postmenopausal women examined with [carbonyl-11C]WAY-100635 Psychoneuroendocrinology, 45: 1-10
• Stein P, Baldinger P, Kaufmann U, Christina R, Hahn A, Höflich A, Kranz G, Savli M, Wadsak W, Mitterhauser M, Winkler D, Kasper S, Lanzenberger R (2014) Relation of progesterone and DHEAS serum levels to 5-HT1A receptor binding potential in pre- and postmenopausal women Psychoneuroendocrinology, 46: 52-63
• Winkler D, Pjrek E, Lanzenberger R, Baldinger P, Eitel D, Kasper S, Frey R (2014) Actigraphy in patients with treatment-resistant depression undergoing electroconvulsive therapy J Psychiatr Res, 57: 96-100
• Kasper S, Kranz G, Lanzenberger R (2014) Testosterone, Neural Circuits, and Male Depression Biol Psychiatry, 76 (4): 272-273

• Riedmann LT, Kasper S (2014) Bipolare Erkrankungen: Behandlungsrichtlinien Jatros Neurologie & Psychiatrie , 03/2014: 32-34
• Kasper S, Gryglewski G, Lanzenberger R (2014) Imaging brain circuits in anxiety disorders Lancet Psychiatry, 1 (4): 251-252
• Fountoulakis K, Gonda X, Baghai T, Baldwin D, Bauer M, Blier P, Gattaz W, Hasler G, Möller H, Tandon R, Vieta E, Kasper S (2014) Report of the WPA section of pharmacopsychiatry on the relationship of antiepileptic drugs with suicidality in epilepsy Int J Psychiatry Clin Pract, : 1-29
• Slyepchenko A, Carvalho AF, Cha DS, Kasper S, McIntrye RS (2014) Gut emotions - mechanisms of action of probiotics as novel therapeutic targets for depression and anxiety disorders CNS Neurol Disord Drug Targets, 13: 1770-1786

• Spindelegger C, Willeit M, Praschak-Rieder N, Lanzenberger R, Kasper S (2014) Neuroimaging in seasons and winter depression. In: Dierckx RAJO, Otte A, de Vries EFJ, van Waarde A, den Boer JA (eds.), PET and SPECT in Psychiatry. Vol. 1. Berlin-Heidelberg-New York: Springer Verlag: pp. 209-222
• Willeit M, Kasper S, Praschak-Rieder N (2014) The impact of genetic polymorphisms on neuroreceptor imaging. In: den Boer JA, Dierckx RAJO, Otte A, de Vries EFJ, van Waarde A (eds.), PET and SPECT of Neurobiological Systems. Vol. 3. Berlin-Heidelberg-New York: Springer Verlag: pp. 149-178
• Kasper S (2014) Lichttherapie. In: Kasper S, Volz HP (Hrsg.), Psychiatrie und Psychotherapie compact. 3. Auflage. Stuttgart: Thieme Verlag: pp. 392-399
• Kasper S (2014) Schlafentzugsbehandlung. In: Kasper S, Volz HP (Hrsg.), Psychiatrie und Psychotherapie compact. 3. Auflage. Stuttgart: Thieme Verlag: pp. 380-384
• Kasper S (2014) Phasenprophylaktika. In: Kasper S, Volz HP (Hrsg.), Psychiatrie und Psychotherapie compact. 3. Auflage. Stuttgart: Thieme Verlag: pp. 361-370
• Kasper S (2014) Antidementiva. In: Kasper S, Volz HP (Hrsg.), Psychiatrie und Psychotherapie compact. 3. Auflage. Stuttgart: Thieme Verlag: pp. 342-348
• Kasper S (2014) Antipsychotika/Neuroleptika. In: Kasper S, Volz HP (Hrsg.), Psychiatrie und Psychotherapie compact. 3. Auflage. Stuttgart: Thieme Verlag: pp. 331-341
• Kasper S (2014) Neurotische Störungen, Belastungsstörungen und somatoforme Störungen (ICD-10: F40-F49). In: Kasper S, Volz HP (Hrsg.), Psychiatrie und Psychotherapie compact. 3. Auflage. Stuttgart: Thieme Verlag: pp. 158-194

• Kasper S, Konstantinidis A (2014) Sammelband 10 Jahre ÖAMSP. , CliniCum neuropsy Sonderausgabe Jänner 2014
• Kasper S, Volz HP (2014) Psychiatrie und Psychotherapie compact. 3 Auflage. , Stuttgart: Thieme Verlag

• Carlberg L, Scheibelreiter J, Hassler M, Schloeglhofer M, Schmoeger M, Ludwig B, Kasper S, Aschauer H, Egger G, Schosser A (2013) P.1.a.010 DNA methylation of the BDNF gene in schizophrenia Eur Neuropsychopharmacol, 23: S165
• Zaninotto L, Souery D, Calati R, Sentissi O, Kasper S, Akimova E, Zohar J, Montgomery S, Mendlewicz J, Serretti A (2013) Treatment resistance in severe unipolar depression: no association with psychotic or melancholic features Ann Clin Psychiatry, 2: 97-106
• Bandelow B, Boerner RJ, Kasper S, Linden M, Wittchen HU, Möller HJ (2013) In reply Deutsches Ärzteblatt, 37: 610-611
• Linden M, Bandelow B, Boerner R, Brasser M, Kasper S, Möller H, Pyrkosch L, Volz H, Wittchen H (2013) The best next drug in the course of generalized anxiety disorders: the “PN-GAD-algorithm” Int J Psychiatry Clin Pract, 17 (2): 78-89
• Kasper S, Corruble E, Hale A, Lemoine P, Montgomery S, Quera-Salva M (2013) Antidepressant efficacy of agomelatine versus SSRI/SNRI Int Clin Psychopharmacol, 28 (1): 12-19
• Höfer P, Schosser A, Calati R, Serretti A, Massat I, Kocabas N, Konstantinidis A, Linotte S, Mendlewicz J, Souery D, Zohar J, Juven-Wetzler A, Montgomery S, Kasper S (2013) The impact of Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes on suicide attempt and suicide risk—a European multicentre study on treatment-resistant major depressive disorder Eur Arch Psychiatry Clin Neurosci, 263 (5): 385-391
• Amital D, Fostick L, Silberman A, Calati R, Spindelegger C, Serretti A, Juven-Wetzler A, Souery D, Mendlewicz J, Montgomery S, Kasper S, Zohar J (2013) Physical co-morbidity among treatment resistant vs. treatment responsive patients with major depressive disorder Eur Neuropsychopharmacol, 23 (8): 895-901
• Serretti A, Souery D, Antypa N, Calati R, Sentissi O, Amital D, Moser U, Kasper S, Zohar J, Mendlewicz J (2013) The Impact of Adverse Life Events on Clinical Features and Interaction with Gene Variants in Mood Disorder Patients Psychopathology, 46 (6): 384-389
• Demyttenaere K, Corruble E, Hale A, Quera-Salva M, Picarel-Blanchot F, Kasper S (2013) A pooled analysis of six month comparative efficacy and tolerability in four randomized clinical trials: agomelatine versus escitalopram, fluoxetine, and sertraline CNS Spectr, 18 (03): 163-170
• Grunze H, Vieta E, Goodwin G, Bowden C, Licht R, Möller H, Kasper S (2013) The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2012 on the long-term treatment of bipolar disorder World J Biol Psychiatry, 14 (3): 154-219
• Calati R, Crisafulli C, Balestri M, Serretti A, Spina E, Calabrò M, Sidoti A, Albani D, Massat I, Höfer P, Amital D, Juven-Wetzler A, Kasper S, Zohar J, Souery D, Montgomery S, Mendlewicz J (2013) Evaluation of the role of MAPK1 and CREB1 polymorphisms on treatment resistance, response and remission in mood disorder patients Prog Neuropsychopharmacol Biol Psychiatry, 44: 271-278
• Antypa N, Calati R, Souery D, Pellegrini S, Sentissi O, Amital D, Moser U, Montgomery S, Kasper S, Zohar J, De Ronchi D, Mendlewicz J, Serretti A (2013) Variation in the HTR1A and HTR2A genes and social adjustment in depressed patients J Affect Disord, 150 (2): 649-652
• Fountoulakis K, Hoschl C, Kasper S, Lopez-Ibor J, Möller H (2013) The media and intellectuals' response to medical publications: the anti-depressants' case Ann Gen Psychiatry, 12 (1): 11
• Kasper S (2013) International Journal of Psychiatry in Clinical Practice Int J Psychiatry Clin Pract, 17 (2): 77-77
• Serretti A, Chiesa A, Souery D, Calati R, Sentissi O, Kasper S, Akimova E, Marsano A, Balestri M, Alberti S, Zohar J, Amital D, Montgomery S, Mendlewicz J (2013) Social adjustment among treatment responder patients with mood disorders J Affect Disord, 150 (3): 961-966
• Bauer M, Dell'Osso L, Kasper S, Pitchot W, Dencker Vansvik E, Köhler J, Jørgensen L, Montgomery S (2013) Extended-release quetiapine fumarate (quetiapine XR) monotherapy and quetiapine XR or lithium as add-on to antidepressants in patients with treatment-resistant major depressive disorder J Affect Disord, 151 (1): 209-219
• Kasper S, Hajak G (2013) The efficacy of agomelatine in previously-treated depressed patients Eur Neuropsychopharmacol, 23 (8): 814-821
• Pacchiarotti I, Bond D, Baldessarini R, Nolen W, Grunze H, Licht R, Post R, Berk M, Goodwin G, Sachs G, Tondo L, Findling R, Youngstrom E, Tohen M, Undurraga J, González-Pinto A, Goldberg J, Yildiz A, Altshuler L, Calabrese J, Mitchell P, Thase M, Koukopo (2013) The International Society for Bipolar Disorders (ISBD) Task Force Report on Antidepressant Use in Bipolar Disorders Am J Psychiatry, 170 (11): 1249
• Lanzenberger R, Baldinger P, Hahn A, Ungersboeck J, Mitterhauser M, Winkler D, Micskei Z, Stein P, Karanikas G, Wadsak W, Kasper S, Frey R (2013) Global decrease of serotonin-1A receptor binding after electroconvulsive therapy in major depression measured by PET Mol Psychiatry, 18 (1): 93-100
• Lanzenberger R, Baldinger P, Hahn A, Ungersboeck J, Mitterhauser M, Winkler D, Micskei Z, Stein P, Karanikas G, Wadsak W, Kasper S, Frey R (2013) Impact of electroconvulsive therapy on 5-HT1A receptor binding in major depression Mol Psychiatry, 18 (1): 1-1
• Kalcher K, Boubela R, Huf W, Biswal B, Baldinger P, Sailer U, Filzmoser P, Kasper S, Lamm C, Lanzenberger R, Moser E, Windischberger C (2013) RESCALE: Voxel-specific task-fMRI scaling using resting state fluctuation amplitude Neuroimage, 70: 80-88
• Hahn A, Nics L, Baldinger P, Wadsak W, Savli M, Kraus C, Birkfellner W, Ungersboeck J, Haeusler D, Mitterhauser M, Karanikas G, Kasper S, Frey R, Lanzenberger R (2013) Application of image-derived and venous input functions in major depression using [carbonyl-11C]WAY-100635 Nucl Med Biol, 40 (3): 371-377
• Höflich A, Savli M, Comasco E, Moser U, Novak K, Kasper S, Lanzenberger R (2013) Neuropsychiatric deep brain stimulation for translational neuroimaging Neuroimage, 79: 30-41
• Baldinger P, Hahn A, Mitterhauser M, Kranz G, Friedl M, Wadsak W, Kraus C, Ungersböck J, Hartmann A, Giegling I, Rujescu D, Kasper S, Lanzenberger R (2013) Impact of COMT genotype on serotonin-1A receptor binding investigated with PET Brain Struct Funct, 219 (6): 2017-2028

• Bandelow B, Boerner J R, Kasper S, Linden M, Wittchen HU, Möller HJ (2013) The diagnosis and treatment of generalized anxiety disorder. Deutsches Ärzteblatt, 17: 300-309
• Kasper S (2013) An orally administered lavandula oil preparation (Silexan) for anxiety disorder and related conditions: an evidence based review Int J Psychiatry Clin Pract, 17 (S1): 15-22
• Baldinger P, Kranz G, Höflich A, Savli M, Stein P, Lanzenberger R, Kasper S (2013) Hormonersatztherapie und deren Wirkung auf Psyche und Gehirn Nervenarzt, 84 (1): 14-19
• Höfer P, Lanzenberger R, Kasper S (2013) Testosterone in the brain: Neuroimaging findings and the potential role for neuropsychopharmacology Eur Neuropsychopharmacol, 23 (2): 79-88
• Dold M, Aigner M, Lanzenberger R, Kasper S (2013) Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials Int. J. Neuropsychopharmacol., 16 (3): 557-574

• Kasper S (2013) Fachärztlicher Beitrag über Depressionen der Universitätsklinik für Psychiatrie und Psychotherapie, Medizinische Universität Wien. In: Wildner A, Wege aus der Depression ins Leben. Bielefeld: tao.de Verlag: pp.178-183
• Kasper S, Akimova E (2013) The role of atypical antipsychotics in inadequate-response and treatment-resistant depression. In: Kasper S, Montgomery S (eds.), Treatment-resistant depression. Chichester: Wiley-Blackwell: pp. 107-128
• Kasper S (2013) The multifunctional challenge in understanding and treatment of depression. In: Trazodone, a worldwide appreciated drug for managing major depressive disorder and associated symptoms. An international case collection. Rome: Content Ed Net: pp. 40-43

• Kasper S, Sachs GM (2013) Österreichische Konsensus-Dokumente – Psychopharmakologie. Sammelband der ÖGPB 2005-2013. , CliniCum neuropsy
• Kasper S, Montgomery S (2013) Treatment-resistant depression. , Chichester: Wiley-Blackwell

• Baldinger P, Hahn A, Friedl M, Kranz GS, Ungersböck J, Höflich A, Mitterhauser M, Rujescu D, Wadsak W, Lanzenberger R, Kasper S (2012) Einfluss der HTR1A-Polymorphismus rs878567 auf das Serotonin-1A-Bindungspotenzial in vivo Journal für Neurologie, Neurochirurgie und Psychiatrie, 13(1): 36-38
• Serretti A, Chiesa A, Crisafulli C, Massat I, Linotte S, Calati R, Kasper S, Bailer U, Lecrubier Y, Fink M, Antonijevic I, Forray C, Snyder L, Bollen J, Zohar J, De Ronchi D, Souery D, Mendlewicz J (2012) Failure to Replicate Influence of GRIK4 and GNB3 Polymorphisms on Treatment Outcome in Major Depression Neuropsychobiology, 65 (2): 70-75
• Pjrek E, Frey R, Naderi-Heiden A, Strnad A, Kowarik A, Kasper S, Winkler D (2012) Actigraphic Measurements in Opioid Detoxification With Methadone or Buprenorphine J Clin Psychopharmacol, 32 (1): 75-82
• Möller H, Bitter I, Bobes J, Fountoulakis K, Höschl C, Kasper S (2012) Position statement of the European Psychiatric Association (EPA) on the value of antidepressants in the treatment of unipolar depression Eur Psychiatry, 27 (2): 114-128
• Schosser A, Calati R, Serretti A, Massat I, A. Kocabas N, Papageorgiou K, Linotte S, Mendlewicz J, Souery D, Zohar J, Juven-Wetzler A, Montgomery S, Kasper S (2012) The impact of COMT gene polymorphisms on suicidality in treatment resistant major depressive disorder — A European Multicenter Study Eur Neuropsychopharmacol, 22 (4): 259-266
• Naderi-Heiden A, Gleiss A, Bäcker C, Bieber D, Nassan-Agha H, Kasper S, Frey R (2012) Mortality and employment after in-patient opiate detoxification Eur Psychiatry, 27 (4): 294-300
• Vyssoki B, Praschak-Rieder N, Sonneck G, Blüml V, Willeit M, Kasper S, Kapusta N (2012) Effects of sunshine on suicide rates Compr Psychiatry, 53 (5): 535-539
• Boubela R, Huf W, Kalcher K, Sladky R, Filzmoser P, Pezawas L, Kasper S, Windischberger C, Moser E (2012) A highly parallelized framework for computationally intensive MR data analysis MAGMA, 25 (4): 313-320
• Fischer R, Kasper S, Pjrek E, Winkler D (2012) On the application of light therapy in German-speaking countries Eur Arch Psychiatry Clin Neurosci, 262 (6): 501-505
• Schlaepfer T, Agren H, Monteleone P, Gasto C, Pitchot W, Rouillon F, Nutt D, Kasper S (2012) The hidden third: improving outcome in treatment-resistant depression J Psychopharmacol, 26 (5): 587-602
• Schosser A, Serretti A, Souery D, Mendlewicz J, Zohar J, Montgomery S, Kasper S (2012) European Group for the Study of Resistant Depression (GSRD) — Where have we gone so far: Review of clinical and genetic findings Eur Neuropsychopharmacol, 22 (7): 453-468
• Mendlewicz J, Crisafulli C, Calati R, Kocabas N, Massat I, Linotte S, Kasper S, Fink M, Sidoti A, Scantamburlo G, Ansseau M, Antonijevic I, Forray C, Snyder L, Bollen J, Montgomery S, Zohar J, Souery D, Serretti A (2012) Influence of COX-2 and OXTR polymorphisms on treatment outcome in treatment resistant depression Neurosci Lett, 516 (1): 85-88
• Bandelow B, Sher L, Bunevicius R, Hollander E, Kasper S, Zohar J, Möller H (2012) Guidelines for the pharmacological treatment of anxiety disorders, obsessive–compulsive disorder and posttraumatic stress disorder in primary care Int J Psychiatry Clin Pract, 16 (2): 77-84
• Serretti A, Chiesa A, Calati R, Linotte S, Sentissi O, Papageorgiou K, Kasper S, Zohar J, Ronchi D, Mendlewicz J, Amital D, Montgomery S, Souery D (2012) Influence of family history of major depression, bipolar disorder, and suicide on clinical features in patients with major depression and bipolar disorder Eur Arch Psychiatry Clin Neurosci, 263 (2): 93-103
• Fountoulakis K, Kasper S, Andreassen O, Blier P, Okasha A, Severus E, Versiani M, Tandon R, Möller H, Vieta E (2012) Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry Eur Arch Psychiatry Clin Neurosci, 262 (S1): 1-48
• Kasper S (2012) Clinical data in early intervention Int Psychogeriatr, 24 (S1): S41-S45
• Kalcher K, Huf W, Boubela R, Filzmoser P, Pezawas L, Biswal B, Kasper S, Moser E, Windischberger C (2012) Fully exploratory network independent component analysis of the 1000 functional connectomes database Front Hum Neurosci, 6: 301
• Fagiolini A, Comandini A, Dell’Osso M, Kasper S (2012) Rediscovering Trazodone for the Treatment of Major Depressive Disorder CNS Drugs, 26 (12): 1033-1049
• Spindelegger C, Stein P, Wadsak W, Fink M, Mitterhauser M, Moser U, Savli M, Mien L, Akimova E, Hahn A, Willeit M, Kletter K, Kasper S, Lanzenberger R (2012) Light-dependent alteration of serotonin-1A receptor binding in cortical and subcortical limbic regions in the human brain World J Biol Psychiat, 13 (6): 413-422
• Hahn A, Wadsak W, Windischberger C, Baldinger P, Hoflich A, Losak J, Nics L, Philippe C, Kranz G, Kraus C, Mitterhauser M, Karanikas G, Kasper S, Lanzenberger R (2012) Differential modulation of the default mode network via serotonin-1A receptors PNAS, 109 (7): 2619-2624
• Hahn A, Nics L, Baldinger P, Ungersböck J, Dolliner P, Frey R, Birkfellner W, Mitterhauser M, Wadsak W, Karanikas G, Kasper S, Lanzenberger R (2012) Combining image-derived and venous input functions enables quantification of serotonin-1A receptors with [carbonyl-11C]WAY-100635 independent of arterial sampling Neuroimage, 62 (1): 199-206
• Savli M, Bauer A, Mitterhauser M, Ding Y, Hahn A, Kroll T, Neumeister A, Haeusler D, Ungersboeck J, Henry S, Isfahani S, Rattay F, Wadsak W, Kasper S, Lanzenberger R (2012) Normative database of the serotonergic system in healthy subjects using multi-tracer PET Neuroimage, 63 (1): 447-459
• Lanzenberger R, Kranz G, Haeusler D, Akimova E, Savli M, Hahn A, Mitterhauser M, Spindelegger C, Philippe C, Fink M, Wadsak W, Karanikas G, Kasper S (2012) Prediction of SSRI treatment response in major depression based on serotonin transporter interplay between median raphe nucleus and projection areas Neuroimage, 63 (2): 874-881
• Kraus C, Hahn A, Savli M, Kranz G, Baldinger P, Höflich A, Spindelegger C, Ungersboeck J, Haeusler D, Mitterhauser M, Windischberger C, Wadsak W, Kasper S, Lanzenberger R (2012) Serotonin-1A receptor binding is positively associated with gray matter volume — A multimodal neuroimaging study combining PET and structural MRI Neuroimage, 63 (3): 1091-1098

• Stein P, Lanzenberger R, Kasper S, Aigner M (2012) Psychiatrische Manifestation einer milden Form der limbischen Encephalitis. Journal für Neurologie, Neurochirurgie und Psychiatrie, 13(1): 31-34
• Bauer M, Praschak-Rieder N, Kasper S, Willeit M. (2012) Is dopamine neurotransmission altered in prodromal schizophrenia? A review of the evidence Curr Pharm Des, 12: 1568-1579
• Höflich A, Baldinger P, Savli M, Lanzenberger R, Kasper S (2012) Imaging treatment effects in depression Rev Neurosci, 23 (3)

• Kindler J, Frey R, Kasper S (2012) Do antidepressants increase the risk of suicide?. In: Shrivastava A, Kimbrell M, Lester D (ed.), Suicide from a global perspective: vulnerable populations and controversies. Hauppauge: Nova Science Publishers: pp. 101-110
• Kasper S (2012) Geleitwort. In: Sachs G, Volz HP (Hrsg.), Neurokognition und Affektregulierung bei schizophrenen Psychosen. Stuttgart: Schattauer
• Kasper S (2012) Vorwort. In: Gregor S, D-Day 24 Stunden der Entscheidung – mein Kampf gegen die Depression. München: Scorpio Verlag: pp. 6-8

• Kocabas N, Antonijevic I, Faghel C, Forray C, Kasper S, Lecrubier Y, Linotte S, Massat I, Mendlewicz J, Noro M, Montgomery S, Oswald P, Snyder L, Zohar J, Souery D (2011) Brain-derived neurotrophic factor gene polymorphisms Int Clin Psychopharmacol, 26 (1): 1-10
• Huf W, Kalcher K, Kasper S (2011) Widespread Methodological Problems Limit Validity of Meta-Analytic Results Psychother Psychosom, 80 (4): 246-246
• Pail G, Huf W, Pjrek E, Winkler D, Willeit M, Praschak-Rieder N, Kasper S (2011) Bright-Light Therapy in the Treatment of Mood Disorders Neuropsychobiology, 64 (3): 152-162
• Olajossy-Hilkesberger L, Godlewska B, Schosser-Haupt A, Olajossy M, Wojcierowski J, Landowski J, Marmurowska-Michałowska H, Kasper S (2011) Polymorphisms of the 5-HT2A Receptor Gene and Clinical Response to Olanzapine in Paranoid Schizophrenia Neuropsychobiology, 64 (4): 202-210
• Kasper S, Meshkat D, Kutzelnigg A (2011) Improvement of the noradrenergic symptom cluster following treatment with milnacipran Neuropsychiatr Dis Treat, 7: 21-27
• Serretti A, Chiesa A, Calati R, Massat I, Linotte S, Kasper S, Lecrubier Y, Antonijevic I, Forray C, Snyder L (2011) A preliminary investigation of the influence of CREB1 gene on treatment resistance in major depression J Affect Disord, 128 (1-2): 56-63
• Bauer S, Steiner H, Feucht M, Stompe T, Karnik N, Kasper S, Plattner B (2011) Psychosocial background in incarcerated adolescents from Austria, Turkey and former Yugoslavia Psychiat Res, 185 (1-2): 193-199
• Konstantinidis A, Martiny K, Bech P, Kasper S (2011) A comparison of the Major Depression Inventory (MDI) and the Beck Depression Inventory (BDI) in severely depressed patients Int J Psychiatry Clin Pract, 15 (1): 56-61
• Huf W, Kalcher K, Pail G, Friedrich M, Filzmoser P, Kasper S (2011) Meta-analysis: Fact or fiction? How to interpret meta-analyses World J Biol Psychiatry, 12 (3): 188-200
• Soyka M, Kranzler H, van den Brink W, Krystal J, Möller H, Kasper S (2011) The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Substance Use and Related Disorders. Part 2: Opioid dependence World J Biol Psychiatry, 12 (3): 160-187
• Winkler D, Naderi-Heiden A, Strnad A, Pjrek E, Scharfetter J, Kasper S, Frey R (2011) Intensive care in psychiatry Eur Psychiatry, 26 (4): 260-264
• Serretti A, Chiesa A, Calati R, Massat I, Linotte S, Kasper S, Lecrubier Y, Fink M, Antonijevic I, Forray C, Snyder L, Bollen J, Zohar J, De Ronchi D, Souery D, Mendlewicz J (2011) No influence of PTGS2 polymorphisms on response and remission to antidepressants in major depression Psychiat Res, 188 (1): 166-169
• Massat I, Kocabas N, Crisafulli C, Chiesa A, Calati R, Linotte S, Kasper S, Fink M, Antonijevic I, Forray C, Snyder L, Bollen J, Zohar J, De Ronchi D, Souery D, Serretti A, Mendlewicz J (2011) COMT and age at onset in mood disorders: A replication and extension study Neurosci Lett, 498 (3): 218-221
• Souery D, Serretti A, Calati R, Oswald P, Massat I, Konstantinidis A, Linotte S, Kasper S, Montgomery S, Zohar J, Mendlewicz J (2011) Citalopram versus desipramine in treatment resistant depression: Effect of continuation or switching strategies. A randomized open study World J Biol Psychiatry, 12 (5): 364-375
• Souery D, Serretti A, Calati R, Oswald P, Massat I, Konstantinidis A, Linotte S, Bollen J, Demyttenaere K, Kasper S, Lecrubier Y, Montgomery S, Zohar J, Mendlewicz J (2011) Switching Antidepressant Class Does Not Improve Response or Remission in Treatment-Resistant Depression J Clin Psychopharmacol, 31 (4): 512-516
• Aigner M, Treasure J, Kaye W, Kasper S (2011) World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Eating Disorders World J Biol Psychiatry, 12 (6): 400-443
• Scharinger C, Rabl U, Pezawas L, Kasper S (2011) The genetic blueprint of major depressive disorder: Contributions of imaging genetics studies World J Biol Psychiatry, 12 (7): 474-488
• Baghai T, Blier P, Baldwin D, Bauer M, Goodwin G, Fountoulakis K, Kasper S, Leonard B, Malt U, Stein D, Versiani M, Möller H (2011) General and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders: a report by the WPA section of pharmacopsychiatry Eur Arch Psychiatry Clin Neurosci, 261 (S3): 207-245
• Souery D, Zaninotto L, Calati R, Linotte S, Sentissi O, Amital D, Moser U, Kasper S, Zohar J, Mendlewicz J, Serretti A (2011) Phenomenology of psychotic mood disorders: Lifetime and major depressive episode features J Affect Disord, 135 (1-3): 241-250
• Baghai T, Blier P, Baldwin D, Bauer M, Goodwin G, Fountoulakis K, Kasper S, Leonard B, Malt U, Stein D, Versiani M, Möller H (2011) Executive summary of the report by the WPA section on pharmacopsychiatry on general and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders Eur Arch Psychiatry Clin Neurosci, 262 (1): 13-22
• Konstantinidis A, Papageorgiou K, Grohmann R, Horvath A, Engel R, Kasper S (2011) Increase of antipsychotic medication in depressive inpatients from 2000 to 2007: results from the AMSP International Pharmacovigilance Program Int J Neuropsychopharmacol, 15 (04): 449-457
• Letmaier M, Painold A, Holl A, Vergin H, Engel R, Konstantinidis A, Kasper S, Grohmann R (2011) Hyponatraemia during psychopharmacological treatment: results of a drug surveillance programme Int J Neuropsychopharmacol, 15 (06): 739-748
• Kasper S, Ebert B, Larsen K, Tonnoir B (2011) Combining escitalopram with gaboxadol provides no additional benefit in the treatment of patients with severe major depressive disorder Int J Neuropsychopharmacol, 15 (06): 715-725
• Hahn A, Stein P, Windischberger C, Weissenbacher A, Spindelegger C, Moser E, Kasper S, Lanzenberger R (2011) Reduced resting-state functional connectivity between amygdala and orbitofrontal cortex in social anxiety disorder Neuroimage, 56 (3): 881-889
• Lanzenberger R, Mitterhauser M, Kranz G, Spindelegger C, Wadsak W, Stein P, Moser U, Savli M, Kletter K, Kasper S (2011) Progesterone Level Predicts Serotonin-1A Receptor Binding in the Male Human Brain Neuroendocrinology, 94 (1): 84-88

• Kasper S (2011) Trends & Perspektiven in der Psychiatrie. Die verschiedenen Facetten des Ansprechens auf einen antidepressive Therapie und deren praktische Bedeutung Journal für Neurologie, Neurochirurgie und Psychiatrie, 12(2): 116-117
• Spindelegger C, Konstantinidis A, Kasper S (2011) Stevens-Johnson-Syndrom unter Carbamazepin: Genetische Prädisposition asiatischer Patienten Journal für Neurologie, Neurochirurgie und Psychiatrie, 12(2): 176-178
• Fink M, Moser U, Akimova E, Savli M, Lanzenberger R, Kasper S (2011) ) Multimodale Bildgebung bei einer organischen depressiven Störung mittels fMRT und PET Journal für Neurologie, Neurochirurgie und Psychiatrie, 12(2): 180-182
• Volz HP, Gastpar M, Kasper S, Möller HJ, Müller WE (2011) Subsyndromale Angststörungen: Definition, Messparameter und Epidemiologie Journal für Neurologie, Neurochirurgie und Psychiatrie, 12(2): 162-167
• Dold M, Aigner M, Lanzenberger R, Kasper S (2011) Effektivität einer Augmentationstherapie mit Antipsychotika bei therapieresistenten Zwangsstörungen – eine Metaanalyse doppelblinder, randomisierter, placebokontrollierter Studien Fortschr Neurol Psychiatr, 79 (08): 453-466

• Stolba K, Kasper S, Pritz N (2011) Klinische Psychologie in der Psychiatrie. In: Lehrner J, Stolba K, Traun-Vogt G, Völkl-Kernstock S (Hrsg.), Klinische Psychologie im Krankenhaus. Wien: Springer Verlag: pp. 263-272
• Kasper S (2011) Kann man Gefühle sichtbar machen? Die Seele weint mit dem Gehirn. In: van Heyster P, Klammer B, Pycha R, Schwitzer J (Hrsg.), Die verborgene Kraft des Glaubens. Brixen: Provinz Verlag: pp. 27-31
• Kasper S, Baghai TC, Padberg F (2011) Sonstige biologische Therapieverfahren - Theoretische und empirische Grundlagen sowie klinische Anwendungsprinzipien. In: Möller HJ, Laux G, Kapfhammer HP (Hrsg.), Psychiatrie und Psychotherapie. 4. Auflage Heidelberg: Springer: pp. 767-805
• Kasper S, Möller HJ (2011) Psychopharmakotherapie: klinisch-empirische Grundlagen. In: Möller HJ, Laux G, Kapfhammer HP (Hrsg.), Psychiatrie und Psychotherapie. 4. Auflage Heidelberg: Springer: pp. 731-766

• Winkler D, Pjrek E, Kasper S (2010) Gen-Umwelt-Interaktionen und Gen-Umwelt-Korrelationen bei psychiatrischen Erkrankungen (Gene-environment interaction and gene-environment correlation in psychiatric disorders) Journal für Neurologie, Neurochirurgie und Psychiatrie, 11: 58-62
• Moser U, Kasper S, Winkler D (2010) Therapie der Alzheimer Demenz: Status quo und Zukunftsperspektiven Journal für Neurologie, Neurochirurgie und Psychiatrie, 11: 72-78
• Meshkat D, Kutzelnigg A, Kasper S, Winkler D (2010) Ärgerattacken bei Depressionen: Geschlechtsspezifische Aspekte Journal für Neurologie, Neurochirurgie und Psychiatrie, 3: 22-25
• Kasper S, Gastpar M, Möller H, Müller W, Volz H, Dienel A, Kieser M (2010) Better tolerability of St. Johnʼs wort extract WS 5570 compared to treatment with SSRIs: a reanalysis of data from controlled clinical trials in acute major depression Int Clin Psychopharmacol, 25 (4): 204-213
• Kasper S, Montgomery S, Möller H, van Oers H, Jan Schutte A, Vrijland P, van der Meulen E (2010) Longitudinal analysis of the suicidal behaviour risk in short-term placebo-controlled studies of mirtazapine in major depressive disorder World J Biol Psychiatry, 11 (1): 36-44
• Kasper S, Hajak G, Wulff K, Hoogendijk W, Montejo A, Smeraldi E, Rybakowski J, Quera-Salva M, Wirz-Justice A, Picarel-Blanchot F, Baylé F (2010) Efficacy of the Novel Antidepressant Agomelatine on the Circadian Rest-Activity Cycle and Depressive and Anxiety Symptoms in Patients With Major Depressive Disorder J Clin Psychiatry, 71 (02): 109-120
• Grunze H, Vieta E, Goodwin G, Bowden C, Licht R, Möller H, Kasper S (2010) The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression World J Biol Psychiatry, 11 (2): 81-109
• Naderi-Heiden A, Naderi A, Naderi M, Rahmani-Didar F, Salimi A, Gleiss A, Kasper S, Frey R (2010) Ultra-Rapid Opiate Detoxification Followed by Nine Months of Naltrexone Maintenance Therapy in Iran Pharmacopsychiatry, 43 (04): 130-137
• Noro M, Antonijevic I, Forray C, Kasper S, Kocabas N, Lecrubier Y, Linotte S, Mendlewicz J, Montgomery S, Snyder L, Souery D, Verbanck P, Zohar J, Massat I (2010) 5HT1A and 5HT2A receptor genes in treatment response phenotypes in major depressive disorder Int Clin Psychopharmacol, 25 (4): 228-231
• Kocabas N, Faghel C, Barreto M, Kasper S, Linotte S, Mendlewicz J, Noro M, Oswald P, Souery D, Zohar J, Massat I (2010) The impact of catechol-O-methyltransferase SNPs and haplotypes on treatment response phenotypes in major depressive disorder: a case–control association study Int Clin Psychopharmacol, 25 (4): 218-227
• Kasper S, Gastpar M, Müller W, Volz H, Möller H, Dienel A, Schläfke S (2010) Silexan, an orally administered Lavandula oil preparation, is effective in the treatment of ‘subsyndromal’ anxiety disorder: a randomized, double-blind, placebo controlled trial Int Clin Psychopharmacol, 25 (5): 277-287
• Mendlewicz J, Massat I, Linotte S, Kasper S, Konstantinidis A, Lecrubier Y, Montgomery S, Serretti A, Zohar J, Souery D (2010) Identification of clinical factors associated with resistance to antidepressants in bipolar depression: results from an European Multicentre Study Int Clin Psychopharmacol, 25 (5): 297-301
• Kasper S, Pail G (2010) Milnacipran: a unique antidepressant? Neuropsychiatr Dis Treat, : 23
• Kasper S, Caraci F, Forti B, Drago F, Aguglia E (2010) Efficacy and tolerability of Hypericum extract for the treatment of mild to moderate depression Eur Neuropsychopharmacol, 20 (11): 747-765
• Kocabas N, Antonijevic I, Faghel C, Forray C, Kasper S, Lecrubier Y, Linotte S, Massat I, Montgomery S, Noro M, Oswald P, Snyder L, Souery D, Zohar J, Mendlewicz J (2010) Dysbindin gene ( DTNBP1 ) in major depressive disorder (MDD) patients: Lack of association with clinical phenotypes World J Biol Psychiatry, 11 (8): 985-990
• Kasper S, Gastpar M, Müller W, Volz H, Möller H, Dienel A, Schläfke S (2010) Efficacy and safety of silexan, a new, orally administered lavender oil preparation, in subthreshold anxiety disorder – evidence from clinical trials Wien Med Wochenschr, 160 (21-22): 547-556
• Montgomery S, Hansen T, Kasper S (2010) Efficacy of escitalopram compared to citalopram: a meta-analysis Int J Neuropsychopharmacol, 14 (02): 261-268
• Witte A, Savli M, Holik A, Kasper S, Lanzenberger R (2010) Regional sex differences in grey matter volume are associated with sex hormones in the young adult human brain Neuroimage, 49 (2): 1205-1212
• Windischberger C, Lanzenberger R, Holik A, Spindelegger C, Stein P, Moser U, Gerstl F, Fink M, Moser E, Kasper S (2010) Area-specific modulation of neural activation comparing escitalopram and citalopram revealed by pharmaco-fMRI: A randomized cross-over study Neuroimage, 49 (2): 1161-1170
• Moser U, Wadsak W, Spindelegger C, Mitterhauser M, Mien L, Bieglmayer C, Kletter K, Kasper S, Lanzenberger R (2010) Hypothalamic serotonin-1A receptor binding measured by PET predicts the plasma level of dehydroepiandrosterone sulfate in healthy women Neurosci Lett, 476 (3): 161-165
• Lanzenberger R, Wadsak W, Spindelegger C, Mitterhauser M, Akimova E, Mien L, Fink M, Moser U, Savli M, Kranz G, Hahn A, Kletter K, Kasper S (2010) Cortisol plasma levels in social anxiety disorder patients correlate with serotonin-1A receptor binding in limbic brain regions Int J Neuropsychopharmacol, 13 (9): 1129-1143
• Hahn A, Lanzenberger R, Wadsak W, Spindelegger C, Moser U, Mien L, Mitterhauser M, Kasper S (2010) Escitalopram Enhances the Association of Serotonin-1A Autoreceptors to Heteroreceptors in Anxiety Disorders J Neurosci, 30 (43): 14482-14489

• Kasper S (2010) Trends & Perspektiven in der Psychiatrie. Begriffsverwirrung in der Psychopharmakologie Journal für Neurologie, Neurochirurgie und Psychiatrie, 11 : 4-5
• Moser U, Kasper S, Winkler D (2010) Therapie der Alzheimer-Demenz: Status quo und Zukunftsperspektiven Journal für Neurologie, Neurochirurgie und Psychiatrie, 11 : 72-78
• Winkler D, Pjrek E, Kasper S (2010) Gen-Umwelt-Interaktionen und Gen-Umwelt-Korrelationen bei psychiatrischenmeos Erkrankungen Journal für Neurologie, Neurochirurgie und Psychiatrie, 11 : 58-62
• Stein P, Lanzenberger R, Kasper S (2010) Veränderung der emtionalen Wahrnehmung Jatros Neurologie & Psychiatrie , 08/2010: 36-37
• Kranz G, Kasper S, Lanzenberger R (2010) Reward and the serotonergic system Neuroscience, 166 (4): 1023-1035

• Kasper S (2010) Social anxiety disorder. In: Stolerman I (ed.), Encyclopedia of Psychopharmacology. Heidelberg: Springer Verlag: pp. 1242-1244
• Akimova E, Kasper S (2010) Ethnopsychopharmakologie: Eine aktuelle klinische Perspektive. In: Stompe T, Ritter K (Hrsg.), Psychisch kranke Migranten - Die Versorgungssituation in Österreich. Wien: Facultas Verlag: pp.123-136
• Möller-Leimkühler AM, Kasper S (2010) Psychische und Verhaltensstörungen. In: Bardehle D, Stiehler M (Hrsg.), Erster Deutscher Männerbericht. Ein Pilotbericht. Germering/München: W. Zuckschwerdt Verlag: pp. 135-159

• Kasper S, Rosenthal N (2010) Lichttherapy. , Kneipp-Verlag
• Lehofer M, Pail G, Kasper S (2010) Chronopsychiatrie. , Wien: Update Europe

• Pjrek E, Konstantinidis A, Assem-Hilger E, Praschak-Rieder N, Willeit M, Kasper S, Winkler D (2009) Therapeutic effects of escitalopram and reboxetine in seasonal affective disorder: a pooled analysis. J Psychiatr Res, 43 (8): 792-797
• Winkler D, Scharfetter J, Kasper S, Frey R (2009) The Psychiatric Intensive Care Unit: Ethically and technically progressive care of somatically and psychiatrically critically ill patients Journal of Hospital Ethics, 3: 5-8
• Kasper S, Herman B, Nivoli G, Ameringen M, Petralia A, Mandel F, Baldinetti F, Bandelow B (2009) Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial Int Clin Psychopharmacol, 24 (2): 87-96
• Kasper S, Hamon M (2009) Beyond the monoaminergic hypothesis: Agomelatine, a new antidepressant with an innovative mechanism of action World J Biol Psychiatry, 10 (2): 117-126
• Grunze H, Vieta E, Goodwin G, Bowden C, Licht R, Möller H, Kasper S, WFSBP Task Force on Treatment Guide , Grunze H, Vieta E, Goodwin G, Bowden C, Licht R, Möller H, Kasper S, WFSBP Task Force on Treatment Guide (2009) The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2009 on the Treatment of Acute Mania World J Biol Psychiatry, 10 (2): 85-116
• Naderi-Heiden A, Shadnia S, Salimi A, Naderi A, Naderi M, Schmid D, Gleiss A, Kasper S, Frey R (2009) Self-poisonings with tricyclic antidepressants and selective serotonin reuptake inhibitors in Tehran, Iran World J Biol Psychiatry, 10 (4): 302-312
• Kasper S, Winkler D, Kutzelnigg A (2009) Stellenwert von Ginkgo-biloba -Extrakt bei Demenzerkrankungen. Wirksamkeit und Sicherheit belegt Pharm Unserer Zeit, 38 (5): 424-430
• Kasper S, Saya L, Tekin B, Loze J (2009) How to improve adherence to antipsychotic treatment: Outcomes of the IMproving PAtient outComes in psychiaTry (IMPACT) Berlin 2009 meeting workshop Int J Psychiatry Clin Pract, 13 (4): 245-252
• Künzel H, Ackl N, Hatzinger M, Held K, Holsboer-Trachsler E, Ising M, Kaschka W, Kasper S, Konstantinidis A, Sonntag A, Uhr M, Yassouridis A, Holsboer F, Steiger A (2009) Outcome in delusional depression comparing trimipramine monotherapy with a combination of amitriptyline and haloperidol – A double-blind multicenter trial J Psychiatr Res, 43 (7): 702-710
• Kasper S, Baldwin D, Larsson Lönn S, Boulenger J (2009) Superiority of escitalopram to paroxetine in the treatment of depression Eur Neuropsychopharmacol, 19 (4): 229-237
• Pjrek E, Konstantinidis A, Assem-Hilger E, Praschak-Rieder N, Willeit M, Kasper S, Winkler D (2009) Therapeutic effects of escitalopram and reboxetine in seasonal affective disorder: A pooled analysis J Psychiatr Res, 43 (8): 792-797
• Seyringer M, Kasper S (2009) Ranking antidepressants Landet, 373 (9677): 1760-1761
• Kasper S (2009) The psychiatrist confronted with a fibromyalgia patient Hum Psychopharmacol, 24 (S1): S25-S30
• Serretti A, Calati R, Massat I, Linotte S, Kasper S, Lecrubier Y, Sens-Espel R, Bollen J, Zohar J, Berlo J, Lienard P, De Ronchi D, Mendlewicz J, Souery D (2009) Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes are not associated with response and remission in a sample of depressive patients Int Clin Psychopharmacol, 24 (5): 250-256
• Kasper S, Schubert H (2009) Ginkgo-Spezialextrakt EGb 761® in der Behandlung der Demenz: Evidenz für Wirksamkeit und Verträglichkeit Fortschr Neurol Psychiatr, 77 (09): 494-506
• Feldmann R, Kranz G, Praschak-Rieder N, Kasper S (2009) Psycho-pharmacotherapy for anxiety and obsessive-compulsive disorder: the issue of prolonged barbiturate retention Curr Med Res Opin, 25 (9): 2281-2285
• Plattner B, Steiner H, The S, Kraemer H, Bauer S, Kindler J, Friedrich M, Kasper S, Feucht M (2009) Sex-specific predictors of criminal recidivism in a representative sample of incarcerated youth Compr Psychiatry, 50 (5): 400-407
• Schosser A, Kasper S (2009) The role of pharmacogenetics in the treatment of depression and anxiety disorders Int Clin Psychopharmacol, 24 (6): 277-288
• Kasper S, Möller H, Hale A (2009) The European Post-marketing Observational Sertindole Study: an investigation of the safety of antipsychotic drug treatment Eur Arch Psychiatry Clin Neurosci, 260 (1): 59-68
• Spindelegger C, Lanzenberger R, Wadsak W, Mien L, Stein P, Mitterhauser M, Moser U, Holik A, Pezawas L, Kletter K, Kasper S (2009) Influence of escitalopram treatment on 5-HT1A receptor binding in limbic regions in patients with anxiety disorders Mol Psychiatry, 14 (11): 1040-1050
• Witte A, Flöel A, Stein P, Savli M, Mien L, Wadsak W, Spindelegger C, Moser U, Fink M, Hahn A, Mitterhauser M, Kletter K, Kasper S, Lanzenberger R (2009) Aggression is related to frontal serotonin-1A receptor distribution as revealed by PET in healthy subjects Human Brain Mapping, 30 (8): 2558-2570
• Fink M, Wadsak W, Savli M, Stein P, Moser U, Hahn A, Mien L, Kletter K, Mitterhauser M, Kasper S, Lanzenberger R (2009) Lateralization of the serotonin-1A receptor distribution in language areas revealed by PET Neuroimage, 45 (2): 598-605

• Kasper S (2009) Trends & Perspektiven in der Psychiatrie. Und sie wirken doch! Neuere Antidepressiva auf dem Prüfstand Journal für Neurologie, Neurochirurgie und Psychiatrie, 10: 4-5
• Kasper S (2009) Trends & Perspektiven in der Psychiatrie. Wechselwirkungen zwischen seelischer Gesundheit und Körper meist unterschätzt Journal für Neurologie, Neurochirurgie und Psychiatrie, 10: 3-4
• Moser U, Kasper S, Lesch O, Frey R (2009) Schmerzen, Substanzabhängigkeit und Depression – Fallbericht und Diskussion Jatros Neurologie & Psychiatrie , 08/2009: 10-14
• Fink M, Akimova E, Spindelegger C, Hahn A, Lanzenberger R, Kasper S. (2009) Social anxiety disorder: epidemiology, biology and treatment. Psychiatr Danub., 21(4): 533-42
• Kasper S, Sacher J, Klein N, Mossaheb N, Attarbaschi-Steiner T, Lanzenberger R, Spindelegger C, Asenbaum S, Holik A, Dudczak R (2009) Differences in the dynamics of serotonin reuptake transporter occupancy may explain superior clinical efficacy of escitalopram versus citalopram Int Clin Psychopharmacol, 24 (3): 119-125
• Akimova E, Lanzenberger R, Kasper S (2009) The Serotonin-1A Receptor in Anxiety Disorders Biol Psychiatry, 66 (7): 627-635

• Winkler D, Pjrek E, Konstantinidis A, Kasper S (2009) Drug treatment of seasonal affective disorder. In: Partonen T, Pandi-Perumal SR (eds.), Seasonal Affective Disorder: Practice and Research. 2nd edition. Oxford: Oxford University Press: pp. 281-295
• Kasper S (2009) Specific actions, patient subgroups and stages of illness. In: Herrman H, Maj M, Sartorius N (eds.), Depressive Disorders. 3rd edition. London: John Wiley & Sons: pp. 88-91
• Kasper S (2009) Ursachen und Therapie der Depression. In: Kasper S, Möller-Leimkühler AM, Volkskrankheit Depression. E-Book. Wien: Picus Verlag: pp. 11-39
• Kasper S, Akimova E, Fink M, Lanzenberger R (2009) Maintenance pharmacotherapy in schizophrenia. In: Kasper S, Papadimitriou G (eds.), Schizophrenia: Biopsychosocial Approaches and Current Challenges. 2nd edition. London: Informa Healthcare: pp. 174-184

• Kasper S, Papadimitriou G (2009) Schizophrenia: Biopsychosocial Approaches and Current Challenges. 2nd edition. , London: Informa Healthcare
• Kasper S, Möller-Leimkühler AM (2009) Volkskrankheit Depression? E-Book. , Wien: Picus Verlag

• Chourbaji S, Brandwein C, Gau D, Depner M, Saam C, Johansson C, Schalling M, Partonen T, Kasper S, Adolfsson R, Urani A, Lemberger T, Schütz G, Schumann G, Gass P (2008) CREB-regulated diurnal activity patterns are not indicative for depression-like symptoms in mice and men Med Hypotheses, 70 (1): 117-121
• Willeit M, Sitte H, Thierry N, Michalek K, Praschak-Rieder N, Zill P, Winkler D, Brannath W, Fischer M, Bondy B, Kasper S, Singer E (2008) Enhanced Serotonin Transporter Function during Depression in Seasonal Affective Disorder Neuropsychopharmacology, 33 (7): 1503-1513
• Sacher J, Mossaheb N, Spindelegger C, Klein N, Geiss-Granadia T, Sauermann R, Lackner E, Joukhadar C, Müller M, Kasper S (2008) Effects of Olanzapine and Ziprasidone on Glucose Tolerance in Healthy Volunteers Neuropsychopharmacology, 33 (7): 1633-1641
• Bandelow B, Zohar J, Kasper S, Möller H (2008) How to grade categories of evidence World J Biol Psychiatry, 9 (4): 242-247
• Bandelow B, Zohar J, Hollander E, Kasper S, Möller H, WFSBP TASK FORCE ON TREATMENT GUIDE , Bandelow B, Zohar J, Hollander E, Kasper S, Möller H, WFSBP TASK FORCE ON TREATMENT GUIDE (2008) World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision World J Biol Psychiatry, 9 (4): 248-312
• Pjrek E, Willeit M, Praschak-Rieder N, Konstantinidis A, Semlitsch H, Kasper S, Winkler D (2008) Treatment of Seasonal Affective Disorder with Duloxetine: An Open-Label Study Pharmacopsychiatry, 41 (3): 100-105
• Grass F, Kasper S (2008) Humoral phototransduction: Light transportation in the blood, and possible biological effects Med Hypotheses, 71 (2): 314-317
• Kasper S (2008) Do we need another atypical antipsychotic? Eur Neuropsychopharmacol, 18: S146-S152
• Möller H, Baldwin D, Goodwin G, Kasper S, Okasha A, Stein D, Tandon R, Versiani M (2008) Do SSRIs or antidepressants in general increase suicidality? Eur Arch Psychiatry Clin Neurosci, 258 (S3): 3-23
• Kasper S, Volz H, Möller H, Dienel A, Kieser M (2008) Continuation and long-term maintenance treatment with Hypericum extract WS® 5570 after recovery from an acute episode of moderate depression — A double-blind, randomized, placebo controlled long-term trial Eur Neuropsychopharmacol, 18 (11): 803-813
• Stein P, Savli M, Wadsak W, Mitterhauser M, Fink M, Spindelegger C, Mien L, Moser U, Dudczak R, Kletter K, Kasper S, Lanzenberger R (2008) The serotonin-1A receptor distribution in healthy men and women measured by PET and [carbonyl-11C]WAY-100635 Eur J Nucl Med Mol Imaging, 35 (12): 2159-2168
• Gerstl F, Windischberger C, Mitterhauser M, Wadsak W, Holik A, Kletter K, Moser E, Kasper S, Lanzenberger R (2008) Multimodal imaging of human early visual cortex by combining functional and molecular measurements with fMRI and PET Neuroimage, 41 (2): 204-211

• Kasper S, Lentner S (2008) Generics in psychiatry - do they have the same therapeutic equivalence as the original? Neuropsychiatr, 22 (4): 221-222
• Kasper S, McEwen B (2008) Neurobiological and Clinical Effects of the Antidepressant Tianeptine. CNS Drugs, 22 (1): 15-26
• Papakostas G, Nelson J, Kasper S, Möller H (2008) A meta-analysis of clinical trials comparing reboxetine, a norepinephrine reuptake inhibitor, with selective serotonin reuptake inhibitors for the treatment of major depressive disorder Eur Neuropsychopharmacol, 18 (2): 122-127

• Kasper S (2008) Leidet die Seele nur psychisch?. In: van Heyster P, Hinterhuber H, Kasper S (Hrsg.), Das Prinzip Hoffnung. Von der Klage zur Hoffnung. Brixen: Provinz Verlag: pp 142-151

• Kasper S, Bauer A (2008) Schizophrenie: Symptome - Diagnose - Therapie. , Wien: Verlagshaus der Ärzte
• van Heyster P, Hinterhuber H, Kasper S (2008) Das Prinzip Hoffnung. Von der Klage zur Hoffnung. , Brixen: Provinz Verlag

• Robert PH, Michel E, Van Os J, Altamura AC, Bobes J, Gerlach J, Hellewell JS, Kasper S, Nabel D. (2007) 2-COM: presentation of an instrument facilitating communication between physicians and carers in daily practice Encephale, 33 (1): 60-64
• Souery D, Oswald P, Massat I, Bailer U, Bollen J, Demyttenaere K, Kasper S, Lecrubier Y, Montgomery S, Serretti A, Zohar J, Mendlewicz J (2007) Group for the Study of Resistant Depression. Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. J Clin Psychiatry, 68 (7): 1062-1070
• Kasper S, Anghelescu I, Szegedi A, Dienel A, Kieser M (2007) Placebo controlled continuation treatment with Hypericum extract WS® 5570 after recovery from a mild or moderate depressive episode Wien Med Wochenschr, 157 (13-14): 362-366
• Pjrek E, Winkler D, Stastny J, Praschak-Rieder N, Willeit M, Kasper S (2007) Escitalopram in Seasonal Affective Disorder: Results of an Open Trial Pharmacopsychiatry, 40 (1): 20-24
• Partonen T, Treutlein J, Alpman A, Frank J, Johansson C, Depner M, Aron L, Rietschel M, Wellek S, Soronen P, Paunio T, Koch A, Chen P, Lathrop M, Adolfsson R, Persson M, Kasper S, Schalling M, Peltonen L, Schumann G (2007) Three circadian clock genes Per2, Arntl, and Npas2 contribute to winter depression Ann Med, 39 (3): 229-238
• Attarbaschi T, Sacher J, Geiss-Granadia T, Klein N, Mossaheb N, Lanzenberger R, Asenbaum S, Dudczak R, Kasper S, Tauscher J (2007) Striatal D2 receptor occupancy in bipolar patients treated with olanzapine Eur Neuropsychopharmacol, 17 (2): 102-107
• Konstantinidis A, Hrubos W, Nirnberger G, Windhager E, Lehofer M, Aschauer H, Kasper S (2007) Quetiapine in combination with citalopram in patients with unipolar psychotic depression Prog Neuropsychopharmacol Biol Psychiatry, 31 (1): 242-247
• Klein N, Sacher J, Geiss-Granadia T, Mossaheb N, Attarbaschi T, Lanzenberger R, Spindelegger C, Holik A, Asenbaum S, Dudczak R, Tauscher J, Kasper S (2007) Higher serotonin transporter occupancy after multiple dose administration of escitalopram compared to citalopram: an [123I]ADAM SPECT study Psychopharmycol, 191 (2): 333-339
• Sacher J, Asenbaum S, Klein N, Geiss-Granadia T, Mossaheb N, Poetzi C, Attarbaschi T, Lanzenberger R, Spindelegger C, Rabas A, Heinze G, Dudczak R, Kasper S, Tauscher J (2007) Binding kinetics of 123I[ADAM] in healthy controls: a selective SERT radioligand Int J Neuropsychopharmacol, 10 (02): 211
• Grunze H, Adli M, Bauer M, Berger M, Bergmann A, Bräunig P, Bschor T, Falkai P, Gastpar M, Greil W, Kasper S, Krüger S, Laux G, Müller W, Naber D, Walden J (2007) Klinischer Stellenwert der Valproat-Therapie bei bipolaren Störungen Fortschr Neurol Psychiatr, 75 (4): 220-235
• KUDLA D, LAMBERT M, DOMIN S, KASPER S, NABER D (2007) Effectiveness, tolerability, and safety of ziprasidone in patients with schizophrenia or schizoaffective disorder: Results of a multi-centre observational trial Eur Psychiatry, 22 (3): 195-202
• Lanzenberger R, Mitterhauser M, Spindelegger C, Wadsak W, Klein N, Mien L, Holik A, Attarbaschi T, Mossaheb N, Sacher J, Geiss-Granadia T, Kletter K, Kasper S, Tauscher J (2007) Reduced Serotonin-1A Receptor Binding in Social Anxiety Disorder Biol Psychiatry, 61 (9): 1081-1089
• Winkler D, Pjrek E, Moser U, Kasper S (2007) Escitalopram in a working population: results from an observational study of 2378 outpatients in Austria Hum Psychopharmacol, 22 (4): 245-251
• Montgomery S, Kasper S (2007) Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine Int Clin Psychopharmacol, 22 (5): 283-291
• Pierre Olié J, Kasper S (2007) Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder Int J Neuropsychopharmacol, 10 (05)
• Pjrek E, Winkler D, Praschak-Rieder N, Willeit M, Stastny J, Konstantinidis A, Kasper S (2007) Season of birth in siblings of patients with seasonal affective disorder Eur Arch Psychiatry Clin Neurosci, 257 (7): 378-382
• Montgomery S, Baldwin D, Blier P, Fineberg N, Kasper S, Lader M, Lam R, Lépine J, Möller H, Nutt D, Rouillon F, Schatzberg A, Thase M (2007) Which antidepressants have demonstrated superior efficacy? A review of the evidence Int Clin Psychopharmacol, 22 (6): 323-329
• Peuskens J, Kasper S, Arango C, Bandinelli P, Gastpar M, Keks N, Mitchell S, Oral T, Timdahl K, Vieta E (2007) Management of acutely ill patients in the hospital setting: focus on quetiapine Int J Psychiatry Clin Pract, 11 (1): 61-72
• Oswald P, Souery D, Kasper S, Lecrubier Y, Montgomery S, Wyckaert S, Zohar J, Mendlewicz J (2007) Current issues in bipolar disorder: A critical review Eur Neuropsychopharmacol, 17 (11): 687-695
• Lanzenberger R, Mitterhauser M, Spindelegger C, Wadsak W, Klein N, Mien LK, Holik A, Attarbaschi T, Mossaheb N, Sacher J, Geiss-Granadia T, Kletter K, Kasper S, Tauscher J. (2007) Reduced Serotonin-1A Receptor Binding in Social Anxiety Disorder. Biol Psychiatry, 61(9): 1081-9

• Moser U, Pezawas L, Kasper S (2007) Die Neurobiologie der Depression – im Fokus: Imaging Genetics Journal für Neurologie, Neurochirurgie und Psychiatrie, 3: 34-41
• Bandelow B, Boerner RJ, Kasper S, Linden M, Volz HP, Wittchen HU, Möller HJ (2007) Die medikamentöse Behandlung der Generalisierten Angststörung - ein Konsensuspapier. Psychopharmakotherap, 14: 136-142
• Pezawas L, Moser U, Kasper S (2007) Die Neurobiologie der Depression - im Fokus: Imaging Genetics Journal für Neurologie, Neurochirurgie und Psychiatrie, 8 (1): 35-44

• Kasper S (2007) Prinzipien der Psychopharmakotherapie. In: Schölmerich J. (Hrsg.), Medizinische Therapie 2007/2008. 3. Auflage. Berlin: Springer Verlag: pp. 1474-1481
• Frey R, Kaufmann RM, Kasper S (2007) Elektrokrampftherapie. In: F. Holsboer, G. Gründer, O. Benkert (Hrsg.), Handbuch der Psychopharmakotherapie. Heidelberg: Springer Verlag: pp.728-733

• Pjrek E, Winkler D, Kasper S (2006) European College of Neuropsychopharmacology – 18th Congress Clinical Approaches in Bipolar Disorders, 5: 30-31
• Winkler D, Pjrek E, Kasper S (2006) Gender-specific symptoms of depression and anger attacks The Journal of Mens Health & Gender, 3: 19-24
• Winkler D, Pjrek E, Kasper S (2006) Reply to Benazzi F: Evidence for a male or instead for a female depression? Letter to the editor Psychother Psychosom, 75: 193
• Winkler D, Pjrek E, Klein N, Kasper S (2006) Antwort auf Neye H: Kommentar zu Winkler et al. Escitalopram bei berufstätigen Menschen – Ergebnisse einer Anwendungsbeobachtung an 2378 Patienten Psychopharmakotherap, 13: 142-146
• Winkler D, Pjrek E, Klein N, Kasper S (2006) Escitalopram bei berufstätigen Menschen – Ergebnisse einer Anwendungsbeobachtung an 2378 Patienten Psychopharmakotherap, 13: 142-146
• Kasper S, Spadone C, Verpillat P, Angst J (2006) Onset of action of escitalopram compared with other antidepressants: results of a pooled analysis Int Clin Psychopharmacol, 21 (2): 105-110
• Montgomery SA, Tobias K, Zornberg GL, Kasper S, Pande AC. (2006) Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. J Clin Psychiatry, 67 (5): 771-82
• Kasper S, Winkler D (2006) Addressing the limitations of the CATIE study World J Biol Psychiatry, 7 (2): 126-127
• Winkler D, Pjrek E, Kindler J, Heiden A, Kasper S (2006) Validation of a Simplified Definition of Anger Attacks Psychother Psychosom, 75 (2): 103-106
• Mühlbacher M, Konstantinidis A, Kasper S, Eichberger G, Hinterhuber H, Hofmann P, Nimmerrichter A, Schubert H, Egger C, Nickel M, Stuppaeck C (2006) Intravenous Mirtazapine Is Safe and Effective in the Treatment of Depressed Inpatients Neuropsychobiology, 53 (2): 83-87
• Kasper S, Lemming O, de Swart H (2006) Escitalopram in the Long-Term Treatment of Major Depressive Disorder in Elderly Patients Neuropsychobiology, 54 (3): 152-159
• Mossaheb N, Wiesegger G, Amminger G, Kasper S, Tauscher J (2006) Früherkennung und Frühintervention der Schizophrenie Nervenarzt, 77 (1): 23-34
• Winkler D, Ortner R, Pjrek E, Aschauer H, Kasper S (2006) Trazodone-induced cardiac arrhythmias: a report of two cases Hum Psychopharmacol, 21 (1): 61-62
• Kasper S, Lowry A, Hodge A, Bitter I, Dossenbach M (2006) Tardive dyskinesia: Analysis of outpatients with schizophrenia from Africa and the Middle East, Asia, Central and Eastern Europe, and Latin America Schizophr Res, 81 (2-3): 139-143
• Winkler D, Pjrek E, Konstantinidis A, Praschak-Rieder N, Willeit M, Stastny J, Kasper S (2006) Anger attacks in seasonal affective disorder Int J Neuropsychopharmacol, 9 (02): 215
• Kaufmann R, Schreinzer D, Strnad A, Mossaheb N, Kasper S, Frey R (2006) Case report: Intestinal atonia as an unusual symptom of malignant catatonia responsive to electroconvulsive therapy Schizophr Res, 84 (1): 178-179
• Kasper S, Anghelescu I, Szegedi A, Dienel A, Kieser M (2006) Superior efficacy of St John's wort extract WS® 5570 compared to placebo in patients with major depression: a randomized, double-blind, placebo-controlled, multi-center trial [ISRCTN77277298] BMC Med, 4 (1): 14
• Winkler D, Pjrek E, Iwaki R, Kasper S (2006) Treatment of seasonal affective disorder Expert Rev Neurother, 6 (7): 1039-1048
• Kasper S (2006) Optimisation of long-term treatment in schizophrenia: Treating the true spectrum of symptoms Eur Neuropsychopharmacol, 16: S135-S141
• Klein N, Sacher J, Geiss-Granadia T, Attarbaschi T, Mossaheb N, Lanzenberger R, Pötzi C, Holik A, Spindelegger C, Asenbaum S, Dudczak R, Tauscher J, Kasper S (2006) In vivo imaging of serotonin transporter occupancy by means of SPECT and [123I]ADAM in healthy subjects administered different doses of escitalopram or citalopram Psychopharmycol, 188 (3): 263-272
• Attarbaschi T, Kasper S (2006) Behandlungsmöglichkeiten der akuten Manie mit atypischen Antipsychotika Nervenarzt, 77 (11): 1310-1322
• Pjrek E, Winkler D, Konstantinidis A, Willeit M, Praschak-Rieder N, Kasper S (2006) Agomelatine in the treatment of seasonal affective disorder Psychopharmycol, 190 (4): 575-579
• Pjrek E, Winkler D, Abramson D, Konstantinidis A, Stastny J, Willeit M, Praschak-Rieder N, Kasper S (2006) Serum lipid levels in seasonal affective disorder Eur Arch Psychiatry Clin Neurosci, 257 (4): 197-202
• Kasper S (2006) SNRIs–All for one and one for all? Int J Psychiatry Clin Pract, 10 (s2): 4-4
• Kasper S (2006) Anxiety disorders: under-diagnosed and insufficiently treated Int J Psychiatry Clin Pract, 10 (s1): 3-9
• Lee M, Lim S, Cha J, Chung S, Kim K, Kasper S, THE EXECUTIVE COMMITTEE FOR THE KOR (2006) The Korean Medication Algorithm for Major Depressive Disorder (KMA-MDD): Report of the Korean Society of Depressive and Bipolar Disorders Int J Psychiatry Clin Pract, 10 (3): 186-194

• Scharfetter J, Frey R, Strnad A, Kasper S (2006) Katatone Störungen an einer psychiatrischen Intensivpflegestation Journal für Neurologie, Neurochirurgie und Psychiatrie, 3: 34-41
• Naderi-Heiden A, Kasper S (2006) Diagnostik und Therapie der Panikstörung Journal für Neurologie, Neurochirurgie und Psychiatrie, 7: 27-33
• Winkler D, Pjrek E, Klein N, Kasper S (2006) Antwort auf Neye H: Kommentar zu Winkler et al. Escitalopram bei berufstätigen Menschen - Ergebnisse einer Anwendungsbeobachtung an 2378 Patienten Psychopharmakotherap, 13: 253-254

• de Zwaan M, Kasper S (2006) Behandlung von Essstörungen: Psychopharmakotherapie. In: HJ Möller (Hrsg.) , Therapie psychiatrischer Erkrankungen. 3. Auflage. Stuttgart: Thieme: pp. 956-970
• Kasper S, Kaufmann R, Frey R (2006) Behandlung akuter exogener Psychosen. In: HJ Möller (Hrsg.) , Therapie psychiatrischer Erkrankungen. 3. Auflage. Stuttgart: Thieme: pp. 531-543
• Kasper S (2006) Psychiatrische Notfallsituationen. In: HJ Möller (Hrsg.) , Therapie psychiatrischer Erkrankungen. 3. Auflage. Stuttgart: Thieme: pp. 1164-1176
• Kasper S (2006) Behandlung affektiver Erkrankungen - Indikation und Praxis des therapeutischen Schlafentzugs und der Lichttherapie. In: HJ Möller (Hrsg.) , Therapie psychiatrischer Erkrankungen. 3. Auflage. Stuttgart: Thieme: pp. 450-458
• Kasper S, Frey R (2006) Behandlung affektiver Erkrankungen - Indikation und Durchführung der Elektrokrampftherapie (EKT). In: HJ Möller (Hrsg.) , Therapie psychiatrischer Erkrankungen. 3. Auflage. Stuttgart: Thieme: pp. 446-450
• Kasper S (2006) Behandlungspfad/Stufenschema. In: Bandelow B (Hrsg.), GAD-Taschenatlas. Linkenheim-Hochstetten: Aesopus-Verlag: pp.90-95
• Kasper S (2006) Foreword. In: Kasper S (ed.), A new pharmacological approach to the treatment of major depression. Paris: Elsevier: pp. 9-10
• Kasper S (2006) Introduction. In: Kasper S (ed.), A new pharmacological approach to the treatment of major depression. Paris: Elsevier: pp. 19-24
• Kasper S (2006) Depression, Angst und Gedächtnisstörungen im Alter. In: Rosenmayr L, Böhmer F (Hrsg.), Hoffnung Alter. Forschung. Theorie. Praxis. 2.Auflage. Wien: Wiener Universitäts Verlag: pp. 45-58

• Kasper S (2006) A new pharmacological approach to the treatment of major depression. , Paris: Elsevier
• Kasper S, Hauk P (2006) Bipolare Erkrankungen. , Wien: Verlagshaus der Ärzte
• Kasper S, Zohar J, Stein DJ (2006) Decision Making in Psychopharmacology. Ukrainian translation from the English language edition of 2002. , Kiev: Sfera Publishers
• Stuppäck C, Lehofer M, Kapfhammer H, Kasper S (2006) 44 Fragen zu bipolaren Erkrankungen. , Linz: Edition Pro Mente
• Rosenthal NE, Kasper S (2006) Lichttherapie: Das natürliche Programm gegen Stimmungstiefs, Wintertraurigkeit, Depression. , München: Goldmann

• Naderi-Heiden A, Frey R, Presslich O, Frottier P, Willinger U, Blasbichler T, Smetana R, Schmid D, Kasper S (2005) Effect of intravenous magnesium sulphate in reducing irritability and restlessness in pure and polysubstance opiate detoxification Psychiat Res, 135 (1): 53-63
• Winkler D, Pjrek E, Konstantinidis A, Stastny J, Kasper S (2005) Seasonal affective disorder – pathophysiology and clinical management Acta psychiatrica Belgica, 105: 141-148
• Kasper S, Olivieri L, Di Loreto G, Dionisio P (2005) A comparative, randomised, double-blind study of trazodone prolonged-release and paroxetine in the treatment of patients with major depressive disorder. Curr Med Res Opin, 21 (8): 1139-46
• Kasper S, de Swart H, Friis Andersen H (2005) Escitalopram in the treatment of depressed elderly patients Am J Geriatr Psychiatry, 13 (10): 884-891
• Winkler D, Pjrek E, Kasper S (2005) Anger Attacks in Depression – Evidence for a Male Depressive Syndrome Psychother Psychosom, 74 (5): 303-307
• Rainer M, Mucke H, Masching A, Haushofer M, Karger M, Kasper S, Kurz A (2005) Zeitgemäßes Management von nicht kognitiven Symptomen bei Demenz Psychiatr Prax, 32 (1): 31-38
• Kasper S, Stein DJ, Loft H, Nil R (2005) Escitalopram in the treatment of social anxiety disorder: Randomised, placebo-controlled, flexible-dosage study Br J Psychiatry, 186 (3): 222-226
• Heiden A, Kettenbach J, Fischer P, Schein B, Ba-Ssalamah A, Frey R, Naderi M, Gulesserian T, Schmid D, Trattnig S, Imhof H, Kasper S (2005) White matter hyperintensities and chronicity of depression J Psychiatr Res, 39 (3): 285-293
• Naderi-Heiden A, Frey R, Presslich O, Frottier P, Willinger U, Blasbichler T, Smetana R, Schmid D, Kasper S (2005) Effect of intravenous magnesium sulphate in reducing irritability and restlessness in pure and polysubstance opiate detoxification Psychiat Res, 135 (1): 53-63
• Winkler D, Pjrek E, Praschak-Rieder N, Willeit M, Pezawas L, Konstantinidis A, Stastny J, Kasper S (2005) Actigraphy in Patients with Seasonal Affective Disorder and Healthy Control Subjects Treated with Light Therapy Biol Psychiatry, 58 (4): 331-336
• Pjrek E, Winkler D, Dervic K, Aschauer H, Kasper S (2005) Psychosis as a possible side-effect of treatment with glatiramer acetate Int J Neuropsychopharmacol, 8 (3): 487-488
• PRASCHAKRIEDER N, WILLEIT M, ZILL P, WINKLER D, THIERRY N, KONSTANTINIDIS A, MASELLIS M, BASILE V, BONDY B, ACKENHEIL M (2005) A Cys23–Ser23 substitution in the 5-HT receptor gene influences body weight regulation in females with seasonal affective disorder: An Austrian–Canadian collaborative study J Psychiatr Res, 39 (6): 561-567
• Lanzenberger R, Kasper S (2005) NeuroImaging bei schizophrenen Erkrankungen Fortschr Neurol Psychiatr, 73: 51-59
• Letmaier M, Schreinzer D, Reinfried L, Glauninger G, Thierry N, Kapitany T, Kasper S (2005) Typical neuroleptics vs. atypical antipsychotics in the treatment of acute mania in a natural setting Int J Neuropsychopharmacol, 9 (05): 529

• Kasper S, Winkler D (2005) Expertenkommentar zur Schizophreniestudie CATIE Journal für Neurologie, Neurochirurgie und Psychiatrie, 4: 37-39
• Assem-Hilger E, Kasper S (2005) Psychopharmaka und sexuelle Dysfunktion Journal für Neurologie, Neurochirurgie und Psychiatrie, 6: 30-36
• Pjrek E, Winkler D, Kasper S (2005) Pharmacotherapy of seasonal affective disorder CNS Spectr, 10 (8): 664-669
• Pezawas L, Angst J, Kasper S (2005) Recurrent brief depression revisited Int Rev Psychiatry, 17 (1): 63-70

• Kasper S, Pezawas L (2005) Rezidivierende kurze depressive Episoden und Rapid Cycling. In: Bauer M, Berghöfer A, Adli M (Hrsg.), Akute und therapieresistente Depressionen. Pharmakotherapie - Psychotherapie - Innovationen. 2., vollständig überarbeitete und erweiterte Auflage. Heidelberg: Springer: pp. 503-510
• Kasper S (2005) Prinzipien der Psychopharmakotherapie. In: Schölmerich J (Hrsg.), Medizinische Therapie 2005/2006. 2. Auflage. Berlin: Springer: pp. 1311-1317
• Kasper S (2005) Clinical efficacy in depression. In: Müller WE (ed.), St. John s Wort and its active principles in depression and anxiety. Basel-Boston-Berlin: Birkhäuser: pp. 123-131
• Kasper S (2005) Atypical antipsychotics in bipolar disorder. In: Kasper S, Hirschfeld RMA (eds.), Handbook of Bipolar Disorder. New York: Taylor & Francis: pp. 315-329

• Kasper S, Hirschfeld RMA (eds.) (2005) Handbook of Bipolar Disorder. , New York: Taylor and Francis
• Bandelow B, Zohar J, Hollander E, Kasper S, Möller HJ und die WFSBP Task Force on Treatment Guidelines for Anxiety, Obsessive-Compulsive and Posttraumatic Stress Disorders (Ayuso-Gutierrez J, Cassano G, Gorman J, Hindmarch I, Kaiya H, Klein DF, Lader M, Lecrubier Y, Lepine JP, Liebowitz MR, Lopez-Ibor JJ, Marazitti D, Miguel EC, Rickels K, Rupprecht R, Sato M, Sheehan D, Starcevic V, Stein DJ, Uhlenhuth EH, van Ameringen M) (2005) Leitlinien der World Federation of Societies of Biological Psychiatry (WFSBP) für die medikamentöse Behandlung von Angst- und Zwangs- und posttraumatischen Belastungsstörungen. , Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH
• Kasper S, Zohar J, Stein DJ (2005) Decision Making in Psychopharmacology. Greek translation from the English language edition of 2002. , Athen: Vagionaki

• Schosser A, Fuchs K, Leisch F, Bailer U, Meszaros K, Lenzinger E, Willinger U, Strobl R, Heiden A, Gebhardt C, Kasper S, Sieghart W, Hornik K, Aschauer H (2004) Possible linkage of schizophrenia and bipolar affective disorder to chromosome 3q29 J Psychiatr Res, 38 (3): 357-364
• Winkler D, Konstantinidis A, Pjrek E, Kasper S (2004) Effects of light-therapy in seasonal affective disorder – Implications for the treatment of patients with cardiovascular disease Journal of Clinical and Basic Cardiology, 7: 5-7
• Kasper S, Dienel A, Kieser M (2004) Continuation and long-term maintenance treatment with Hypericum extract WS 5570 after successful acute treatment of mild to moderate depression--rationale and study design. Int J Methods Psychiatr Res, 13 (3): 176-183
• Rainer MK, Mucke HA, Krüger-Rainer C, Haushofer M, Kasper S (2004) Zotepine for behavioural and psychological symptoms in dementia: an open-label study CNS Drugs, 18 (1): 49-55
• Van Os J, Altamura AC, Bobes J, Gerlach J, Hellewell JS, Kasper S, Naber D, Robert P (2004) Evaluation of the Two-Way Communication Checklist as a clinical intervention. Results of a multinational, randomised controlled trial Br J Psychiatry, 184: 79-83
• Goodwin GM, Bowden CL, Calabrese JR, Grunze H, Kasper S, White R, Greene P, Leadbetter R (2004) A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry, 65 (3): 432-441
• Hemels ME, Kasper S, Walter E, Einarson TR (2004) Cost-effectiveness analysis of escitalopram: a new SSRI in the first-line treatment of major depressive disorder in Austria Curr Med Res Opin, 20 (6): 869-878
• Hemels ME, Kasper S, Walter E, Einarson TR (2004) Cost-effectiveness of escitalopram versus citalopram in the treatment of severe depression Ann Pharmacother, 38 (6): 954-960
• Kasper S, Brecher M, Fitton L, Jones AM (2004) Maintenance of long-term efficacy and safety of quetiapine in the open-label treatment of schizophrenia. Int Clin Psychopharmacol, 19 (5): 281-289
• Kasper S (2004) Unique mechanism of action for escitalopram: does it hold the promise? Int J Psychiatry Clin Pract, 8 (s1): 15-18
• Thierry N, Willeit M, Praschak-Rieder N, Zill P, Hornik K, Neumeister A, Lenzinger E, Stastny J, Hilger E, Konstantinidis A, Aschauer H, Ackenheil M, Bondy B, Kasper S (2004) Serotonin transporter promoter gene polymorphic region (5-HTTLPR) and personality in female patients with seasonal affective disorder and in healthy controls Eur Neuropsychopharmacol, 14 (1): 53-58
• Kasper S (2004) Quetiapine is effective against anxiety and depressive symptoms in long-term treatment of patients with schizophrenia Depress Anxiety, 20 (1): 44-47
• Wirz-Justice A, Termin M, Oren DA, Goodwin FK, Krippe DF, Whybrow PC, Wisner KL, Wu JC, Lam RW, Berger M, Danilenko KV, Kasper S, Smeraldi E, Takahashi K, Thompson C, van den Hoofdakker RH, (2004) Brightening Depression Science, 303 (5657): 467c-469
• Moscovitch A, Blashko C, Eagles J, Darcourt G, Thompson C, Kasper S, Lane R (2004) A placebo-controlled study of sertraline in the treatment of outpatients with seasonal affective disorder Psychopharmycol, 171 (4): 390-397
• Johansson C, Willeit M, Aron L, Smedh C, Ekholm J, Paunio T, Kieseppä T, Lichtermann D, Praschak-Rieder N, Neumeister A, Kasper S, Peltonen L, Adolfsson R, Partonen T, Schalling M (2004) Seasonal affective disorder and the G-protein β-3-subunit C825T polymorphism Biol Psychiatry, 55 (3): 317-319
• Letmaier M, Schreinzer D, Thierry N, Wolf R, Kasper S (2004) Medikament�se Behandlung akuter Manien Nervenarzt, 75 (3): 249-257
• Schosser A, Fuchs K, Leisch F, Bailer U, Meszaros K, Lenzinger E, Willinger U, Strobl R, Heiden A, Gebhardt C, Kasper S, Sieghart W, Hornik K, Aschauer H (2004) Possible linkage of schizophrenia and bipolar affective disorder to chromosome 3q29 J Psychiatr Res, 38 (3): 357-364
• Bailer U, de Zwaan M, Leisch F, Strnad A, Lennkh-Wolfsberg C, El-Giamal N, Hornik K, Kasper S (2004) Guided self-help versus cognitive-behavioral group therapy in the treatment of bulimia nervosa Int J Eat Disord, 35 (4): 522-537
• Pjrek E, Winkler D, Willeit M, Konstantinidis A, Thierry N, Kasper S (2004) Menstrual disturbances – a rare side-effect of bright-light therapy Int J Neuropsychopharmacol, 7 (2): 239-240
• Pjrek E, Winkler D, Stastny J, Konstantinidis A, Heiden A, Kasper S (2004) Bright light therapy in seasonal affective disorder – does it suffice? Eur Neuropsychopharmacol, 14 (4): 347-351
• Winkler* D, Pjrek* E, Heiden A, Wiesegger G, Klein N, Konstantinidis A, Kasper S (2004) Gender differences in the psychopathology of depressed inpatients Eur Arch Psychiatry Clin Neurosci, 254 (4)
• MONTGOMERY S, Kasper S (2004) ECNP Consensus Meeting, March 2003. Guidelines for the investigation of efficacy in social anxiety disorder Eur Neuropsychopharmacol, 14 (5): 425-433
• Kasper S (2004) Living with bipolar disorder Expert Rev Neurother, 4 (6s2): S9-S15
• Hirschfeld R, Kasper S (2004) A review of the evidence for carbamazepine and oxcarbazepine in the treatment of bipolar disorder Int J Neuropsychopharmacol, 7 (4): 507-522
• RITTMANNSBERGER H, SARTORIUS N, BRAD M, BURTEA V, CAPRARU N, CERNAK P, DERNOVCEK M, DOBRIN I, FRATER R, HASTO J (2004) Changing aspects of psychiatric inpatient treatment Eur Psychiatry, 19 (8): 483-488
• Adam D, Kasper S, Möller H, Singer E (2004) Placebo–controlled trials in major depression are necessary and ethically justifiable Eur Arch Psychiatry Clin Neurosci, 255 (4): 258-260
• Stein D, Kasper S, Andersen E, Nil R, Lader M (2004) Escitalopram in the treatment of social anxiety disorder: Analysis of efficacy for different clinical subgroups and symptom dimensions Depress Anxiety, 20 (4): 175-181

• Leitner I, Bailer U, Letmaier M, Stastny J, Aschauer H, Kasper S (2004) Behandlungsmöglichkeiten der therapieresistenten Depression Journal für Neurologie, Neurochirurgie und Psychiatrie, 5: 28-39
• Kopeinig-Kreissl M, Ramskogler K, Fischer P, Kasper S (2004) Risikofaktor Alter im Straßenverkehr Journal für Neurologie, Neurochirurgie und Psychiatrie, 5: 24-27
• Kaufmann R, Frey R, Battista H, Kasper S (2004) Flunitrazepam und Fahrtüchtigkeit Fortschr Neurol Psychiatr, 72 (9): 503-515
• Zohar J, Kasper S (2004) Myths and facts about post traumatic stress disorder World J Biol Psychiatry, 5 (2): 64-65
• Calabrese JR, Kasper S, Johnson G, Tajima O, Vieta E, Yatham LN, Young AH (2004) International Consensus Group on Bipolar I Depression Treatment Guidelines. J Clin Psychiatry J Clin Psychiatry, 65 (4): 571-579
• de Mendelssohn A, Kasper S, Tauscher J (2004) Neuroimaging in substance abuse disorders Nervenarzt, 75 (7): 651-662
• Grunze H, Kasper S, Goodwin G, Bowden C, Möller HJ, WFSBP Task Force on Treatment Guidelines for Bipolar Disorders. (2004) The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders, part III: maintenance treatment World J Biol Psychiatry, 5 (3): 120-135
• Klein N, Sacher J, Wallner H, Tauscher J, Kasper S (2004) Therapy of treatment resistant depression: focus on the management of TRD with atypical antipsychotics. CNS Spectr, 9 (11): 823-832

• Scharfetter J, Frey R, Kasper S (2004) Biologische Grundlagen der Elektrokonvulsionstherapie. In: Baghai T, Frey R, Kasper S, Möller HJ (Hrsg.), Elektrokonvulsionstherapie. Klinische und wissenschaftliche Aspekte. Wien/New York: Springer: pp. 87-105
• Kasper S (2004) Pharmakodynamik. In: Volz HP, Kasper S, Möller HJ (Hrsg.), Kasuistische Beiträge zur modernen Pharmakotherapie mit Quetiapin. Wiesbaden: Deutscher Universitätsverlag: pp. 368-376
• Kasper S, Winkler D (2004) Research in pharmacotherapy of social anxiety disorder. In: Maj M, Akiskal HS, Lopez-Ibor JJ, Okasha A (eds.), Evidence and Experience in Psychiatry. Phobias. Vol. 7. Chichester: Wiley: pp. 154-155
• Kasper S, Pjrek E (2004) Diagnose und Behandlung der subsyndromalen SAD. In: Kasper S, Möller HJ (Hrsg.), Herbst/Winterdepression und Lichttherapie. Wien: Springer Verlag: pp. 33-40
• Pjrek E, Kasper S (2004) Epidemiologie der saisonal abhängigen Depression (SAD) und ihrer subsyndromalen Form (S-SAD). In: Kasper S, Möller HJ (Hrsg.), Herbst/Winterdepression und Lichttherapie. Wien: Springer Verlag: pp. 23-32
• Winkler D, Heiden A, Kasper S (2004) Die Depression beim Mann. In: Bundesministerium für Soziale Sicherheit, Generationen und Konsumentenschutz (Hrsg.), Psychosoziale und ethische Aspekte der Männergesundheit. Wien: Druckerei des BMSG: pp. 95-99

• Baghai T, Frey R, Kasper S, Möller HJ (2004) Elektrokonvulsionstherapie. Klinische und wissenschaftliche Aspekte. , Wien: Springer Verlag
• Kasper S, Möller HJ (2004) Herbst/Winterdepression und Lichttherapie. , Wien: Springer Verlag
• Volz HP, Kasper S, Möller HJ (2004) Kasuistische Beiträge zur modernen Pharmakotherapie mit Quetiapin. , Wiesbaden: Deutscher Universitätsverlag
• Bauer M, Whybrow PC, Angst J, Versiani M, Möller HJ, WFSBP Task Force on Treatment Guidelines for Unipolar Depressive Disorders (Allain H, Anderson I, Ayuso-Gutierrez JL, Baldwin D, Bech P, Benkert O, Berk M, Bitter I, Bourgeois ML, Burrows G, Cassano G, Cetkovich-Bakmas M, Cookson JC, da Costa D, Gheorghe MD, Grunze H, Higuchi T, Hirschfeld RM, Höschl C, Holsboer-Trachsler E, Kasper S, Katona C, Keller MB, Kulhara P, Kupfer DJ, Lecrubier Y, Leonard B, Licht RW, Lingjaerde O, Lublin H, Mendlewicz J, Mitchell P, Paykel ES, Puzynski S, Rush AJ, Rybakowski JK, Schweitzer I, Unützer J, Vestergaard P, Vieta E, Yamada K) (2004) Biologische Behandlung unipolarer depressiver Störungen. Behandlungsleitlinien der World Federation of Societies of Biological Psychiatry (WFSBP). , Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH

• Pezawas L, Wittchen HU, Pfister H, Angst J, Lieb R, Kasper S (2003) Recurrent brief depressive disorder reinvestigated: a community sample of adolescents and young adults Psychol Med, 33 (3): 407-418
• Johansson C, Willeit M, Levitan R, Partonen T, Smedh C, Del Favero J, Bel Kacem S, Praschak-Rieder N, Neumeister A, Masellis M, Basile V, Zill P, Bondy B, Paunio T, Kasper S, Van Broeckhoven C (2003) The serotonin transporter promoter repeat length polymorphism, seasonal affective disorder and seasonality Psychol Med, 33 (5): 785-792
• Gruber S, Frey R, Mlynárik V, Stadlbauer A, Heiden A, Kasper S, Kemp GJ, Moser E (2003) Quantification of metabolic differences in the frontal brain of depressive patients and controls obtained by 1H-MRS at 3 Tesla Invest Radiol, 38 (7): 403-408
• Kasper S, Resinger E (2003) Cognitive effects and antipsychotic treatment Psychoneuroendocrinology, 28: 27-38
• Winkler D, Pjrek E, Pezawas L, Presslich O, Tauscher J, Kasper S (2003) Relationship between Power Spectra of the Awake EEG and Psychomotor Activity Patterns Measured by Short-Term Actigraphy Neuropsychobiology, 48 (4): 176-181
• Stastny J, Konstantinidis A, Schwarz M, Rosenthal N, Vitouch O, Kasper S, Neumeister A (2003) Effects of tryptophan depletion and catecholamine depletion on immune parameters in patients with seasonal affective disorder in remission with light therapy Biol Psychiatry, 53 (4): 332-337
• El-Giamal N, de Zwaan M, Bailer U, Strnad A, Schüssler P, Kasper S (2003) Milnacipran in the treatment of bulimia nervosa: a report of 16 cases Eur Neuropsychopharmacol, 13 (2): 73-79
• Winkler D, Willeit M, Wolf R, Stamenkovic M, Tauscher J, Pjrek E, Konstantinidis A, Schindler S, Barnas C, Kasper S (2003) Clonazepam in the long-term treatment of patients with unipolar depression, bipolar and schizoaffective disorder Eur Neuropsychopharmacol, 13 (2): 129-134
• Johansson C, Willeit M, Smedh C, Ekholm J, Paunio T, Kieseppä T, Lichtermann D, Praschak-Rieder N, Neumeister A, Nilsson L, Kasper S, Peltonen L, Adolfsson R, Schalling M, Partonen T (2003) Circadian Clock-Related Polymorphisms in Seasonal Affective Disorder and their Relevance to Diurnal Preference Neuropsychopharmacology, 28 (4): 734-739
• Leitner I, Praschak-Rieder N, Willeit M, Kasper S (2003) Quetiapine in a delusional depressed elderly patient: no EPS and a favourable outcome Int J Neuropsychopharmacol, 6 (2): 199-200
• Kasper S (2003) Treatment of depressive symptoms with quetiapine Expert Rev Neurother, 3 (4): 417-423
• Kasper S (2003) Issues in the treatment of bipolar disorder Eur Neuropsychopharmacol, 13: 37-42
• Willeit M, Praschak-Rieder N, Zill P, Neumeister A, Ackenheil M, Kasper S, Bondy B (2003) C825T polymorphism in the G protein β3-Subunit gene is associated with seasonal affective disorder Biol Psychiatry, 54 (7): 682-686
• Kasper S, Lerman M, McQuade R, Saha A, Carson W, Ali M, Archibald D, Ingenito G, Marcus R, Pigott T (2003) Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia Int J Neuropsychopharmacol, 6 (4): 325-337

• Konstantinidis A, Stastny J, Winkler D, Thierry N, Pjrek E, Wimmer R, Heiden A, Kasper S (2003) Diagnose, Ätiologie und Therapie der saisonal abhängigen Depression (SAD) Journal für Neurologie, Neurochirurgie und Psychiatrie, 4: 26-30
• Schreinzer D, Letmaier M, Kasper S (2003) Systematisierte Arzneimittelüberwachung zur Erfassung von Nebenwirkungen - Erfahrungen in Österreich Journal für Neurologie, Neurochirurgie und Psychiatrie, 4: 22-24
• Pjrek E, Winkler D, Konstantinidis A, Thierry N, Kasper S (2003) Aktigraphie als Instrument zur Verlaufskontrolle bei saisonal abhängiger Depression – ein Bericht über zwei Fälle Journal für Neurologie, Neurochirurgie und Psychiatrie, 2: 29-31
• Wiesegger G, Tauscher J, Kasper S (2003) Substanz-P-Antagonismus zur Behandlung von Depression: Ein Wirkprinzip für die Zukunft? Journal für Neurologie, Neurochirurgie und Psychiatrie, 3: 21-23
• Baldwin D, Broich K, Fritze J, Kasper S, Westenberg H, Möller H (2003) Placebo-controlled studies in depression: necessary, ethical and feasible Eur Arch Psychiatry Clin Neurosci, 253 (1): 22-28
• Grunze H, Kasper S, Goodwin G, Bowden C, Baldwin D, Licht RW, Vieta E, Möller HJ; WFSBP Task Force on Treatment Guidelines for Bipolar Disorders. (2003) The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders, Part II: Treatment of Mania World J Biol Psychiatry, 4 (1): 5-13
• Hilger E, Barnas C, Kasper S (2003) Quetiapine in the treatment of borderline personality disorder World J Biol Psychiatry, 4 (1): 42-44
• Willeit M, Praschak-Rieder N, Kasper S (2003) Electroconvulsive therapy as maintenance therapy and for prevention of recurrence in psychiatric disorders and Parkinson disease] Wiener Klinische Wochenschrift, 15 (9): 281-290
• Olié JP, Baylé F, Kasper S (2003) A meta-analysis of randomized controlled trials of tianeptine versus SSRI in the short-term treatment of depression Encephale, 29(4 Pt 1): 322-328
• Kasper S, Zohar J (2003) Broadening the treatment indication: is the term antipsychotic still justified? World J Biol Psychiatry, 4 (4): 144-145
• Winkler D, Kasper S (2003) European College of Neuropsychopharmacology - 16th Congress. 20-24 September 2003, Prague, Czech Republic IDrugs, 6 (11): 1020-1023

• Kasper S (2003) Angststörungen, Zwangsstörung, Reaktionen auf schwere Belastungen und Anpassungsstörungen. In: Gastpar MT, Kasper S, Linden M (Hrsg.), Psychiatrie und Psychotherapie. 2. Auflage. Springer Verlag, Wien New York: pp. 151-190
• Kasper S (2003) Notfälle in der Psychiatrie. In: Gastpar MT, Kasper S, Linden M (Hrsg.), Psychiatrie und Psychotherapie. 2. Auflage. Springer Verlag, Wien New York: pp. 429-442
• Kasper S, Schatzberg A (2003) Development of new treatment options for depression. In: Kasper S, den Boer JA, Sitsen JMA (eds.), Handbook of Depression and Anxiety. Second edition, revised and expanded. New York/Basel: Marcel Dekker: pp. 615-627
• Kasper S (2003) Der Brief des Lord Chandos. Kommentar zu dem Schriftstück von Hugo von Hofmannsthal. In: Köpf G, Faust V (Hrsg.), Psychiatrie in der Literatur. Wiesbaden: Deutscher Universitätsverlag: pp. 122-125

• Kasper S (2003) Sicher therapieren bei bipolaren Störungen. , PM-Verlag, Kössen
• Kasper S, den Boer JA, Sitsen JMA (eds.) (2003) ) Handbook of Depression and Anxiety. Second edition, revised and expanded. , New York/Basel: Marcel Dekker, Inc.
• Gastpar M, Kasper S, Linden M (Hrsg.) (2003) Psychiatrie und Psychotherapie. 2. Auflage. , Wien: Springer Verlag
• Kasper S (2003) Schizophrenia explained. A guide for patients and carers. , St. Albans: Altman Publishing

• Bailer U, Leisch F, Meszaros K, Lenzinger E, Willinger U, Strobl R, Heiden A, Gebhardt C, Döge E, Fuchs K, Sieghart W, Kasper S, Hornik K, Aschauer H (2002) Genome scan for susceptibility loci for schizophrenia and bipolar disorder Biol Psychiatry, 52 (1): 40-52
• Frey R, Schreinzer D, Stimpfl T, Vycudilik W, Berzlanovich A, Kasper S (2002) Fatal poisonings with antidepressive drugs and neuroleptics. Analysis of a correlation with prescriptions in Vienna 1991 to 1997 Nervenarzt, 73 (7): 629-636
• Winkler D, Praschak-Rieder N, Willeit M, Lucht MJ, Hilger E, Konstantinidis A, Stastny J, Thierry N, Pjrek E, Neumeister A, Möller HJ, Kasper S (2002) Seasonal affective depression in 2 German speaking university centers: Bonn, Vienna. Clinical and demographic characteristics Nervenarzt, 73 (7): 637-643
• Pezawas L, Fischer G, Podreka I, Schindler S, Brücke T, Jagsch R, Thurnher M, Kasper S (2002) Opioid Addiction Changes Cerebral Blood Flow Symmetry Neuropsychobiology, 45 (2): 67-73
• Kasper S (2002) Managing reboxetine-associated urinary hesitancy in a patient with major depressive disorder: a case study Psychopharmycol, 159 (4): 445-446
• Konstantinidis A, Stastny J, Ptak-Butta J, Hilger E, Winkler D, Barnas C, Neumeister A, Kasper S (2002) Intravenous mirtazapine in the treatment of depressed inpatients Eur Neuropsychopharmacol, 12 (1): 57-60
• Pezawas L, Stamenkovic M, Aschauer N, Moffat R, Kasper S (2002) Successful Treatment of Recurrent Brief Depression with Reboxetine - A Single Case Analysis Pharmacopsychiatry, 35 (2): 75-76
• Kasper S, Wolf R (2002) Successful treatment of reboxetine-induced urinary hesitancy with tamsulosin Eur Neuropsychopharmacol, 12 (2): 119-122
• Praschak-Rieder N, Willeit M, Winkler D, Neumeister A, Hilger E, Zill P, Hornik K, Stastny J, Thierry N, Ackenheil M, Bondy B, Kasper S (2002) Role of family history and 5-HTTLPR polymorphism in female seasonal affective disorder patients with and without premenstrual dysphoric disorder Eur Neuropsychopharmacol, 12 (2): 129-134
• Tauscher J, Küfferle B, Asenbaum S, Tauscher-Wisniewski S, Kasper S (2002) Striatal dopamine-2 receptor occupancy as measured with [123I]iodobenzamide and SPECT predicted the occurrence of EPS in patients treated with atypical antipsychotics and haloperidol Psychopharmycol, 162 (1): 42-49
• Winkler D, Willeit M, Praschak-Rieder N, Lucht M, Hilger E, Konstantinidis A, Stastny J, Thierry N, Pjrek E, Neumeister A, Möller H, Kasper S (2002) Changes of clinical pattern in seasonal affective disorder (SAD) over time in a German-speaking sample Eur Arch Psychiatry Clin Neurosci, 252 (2): 54-62
• Kasper S, Müller-Spahn F (2002) Intravenous antidepressant treatment: focus on citalopram Eur Arch Psychiatry Clin Neurosci, 252 (3): 105-109
• Tauscher J, Kapur S, Verhoeff N, Hussey D, Daskalakis Z, Tauscher-Wisniewski S, Wilson A, Houle S, Kasper S, Zipursky R (2002) Brain Serotonin 5-HT1A Receptor Binding in Schizophrenia Measured by Positron Emission Tomography and [11C]WAY-100635 Arch Gen Psychiatry, 59 (6): 514
• Kasper S, Olie P (2002) A meta-analysis of randomized controlled trials of tianeptine versus SSRI in the short-term treatment of depression1 Eur Psychiatry, 17: 331-340
• Neumeister A, Konstantinidis A, Stastny J, Schwarz M, Vitouch O, Willeit M, Praschak-Rieder N, Zach J, de Zwaan M, Bondy B, Ackenheil M, Kasper S (2002) Association Between Serotonin Transporter Gene Promoter Polymorphism(5HTTLPR) and Behavioral Responses to Tryptophan Depletion in Healthy Women With and Without Family History of Depression Arch Gen Psychiatry, 59 (7): 613
• Riederer F, Stamenkovic M, Schindler S, Kasper S (2002) Das Tourette-SyndromEine Übersicht Nervenarzt, 73 (9): 805-819
• Brunello N, Mendlewicz J, Kasper S, Leonard B, Montgomery S, Craig Nelson J, Paykel E, Versiani M, Racagni G (2002) The role of noradrenaline and selective noradrenaline reuptake inhibition in depression Eur Neuropsychopharmacol, 12 (5): 461-475
• Volz H, Murck H, Kasper S, Möller H (2002) St John's wort extract (LI 160) in somatoform disorders: results of a placebo-controlled trial Psychopharmycol, 164 (3): 294-300
• Kasper S, Dienel A (2002) Cluster analysis of symptoms during antidepressant treatment with Hypericum extract in mildly to moderately depressed out-patients. A meta-analysis of data from three randomized, placebo-controlled trials Psychopharmycol, 164 (3): 301-308
• Schindler S, Graf A, Fischer P, Tölk A, Kasper S (2002) Paranoid delusions and hallucinations and bright light therapy in Alzheimer's disease Int J Geriatr Psychiatry, 17 (11): 1071-1072
• van Os J, Altamura A, Bobes J, Owens D, Gerlach J, Hellewell J, Kasper S, Naber D, Tarrier N, Robert P (2002) 2-COM: an instrument to facilitate patient-professional communication in routine clinical practice Acta Psychiatr Scand, 106 (6): 446-452

• Bailer U, Aschauer HN, Kasper S (2002) Genetik der Schizophrenie Journal für Neurologie, Neurochirurgie und Psychiatrie, 3: 25-31
• Hilger E, Kasper S (2002) Kognitive Symptomatik bei schizophrener Erkrankung: Diagnostik und Pharmakotherapie Journal für Neurologie, Neurochirurgie und Psychiatrie, 4: 17-22
• Kasper S, Heiden A (2002) Begleitdepression Jatros Neurologie & Psychiatrie , 10/2002: 1-5
• Kasper S (2002) Editorial Jatros Neurologie & Psychiatrie , 03/2002: 3
• Gupta R, Kumar R, Kasper S (2002) Physical signs in psychiatry: a step towards evidence-based medicine Int J Psychiatry Clin Pract, 6 (2): 69-72
• Allgulander C, Kasper S (2002) Coping with somatic comorbidities: striving for complete recovery Psychopharmacol Bull, 36 Suppl 2: 103-111
• Baldwin DS, Evans DL, Hirschfeld RM, Kasper S (2002) Can we distinguish anxiety from depression? Psychopharmacol Bull, 36 Suppl 2 : 158-165
• Grunze H, Kasper S, Goodwin G, Bowden C, Baldwin D, Licht R, Vieta E, Möller HJ; WFSBP Task Force on Treatment Guidelines for Bipolar Disorders. (2002) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of bipolar disorders. Part I: Treatment of bipolar depression. World J Biol Psychiatry, 3 (3): 115-124
• Kasper S, Tauscher J, Willeit M, Stamenkovic M, Neumeister A, Küfferle B, Barnas C, Stastny J, Praschak-Rieder N, Pezawas L, de Zwaan M, Quiner S, Pirker W, Asenbaum S, Podreka I, Brücke T (2002) Receptor and transporter imaging studies in schizophrenia, depression, bulimia and Tourette's disorder--implications for psychopharmacology World J Biol Psychiatry, 3 (3): 133-146
• Kasper S, Stamenkovic M, Letmaier M, Schreinzer D (2002) Atypical antipsychotics in mood disorders Int Clin Psychopharmacol, 17 Suppl 3: 1-10
• Hirschfeld RM, Montgomery SA, Aguglia E, Amore M, Delgado PL, Gastpar M, Hawley C, Kasper S, Linden M, Massana J, Mendlewicz J, Möller HJ, Nemeroff CB, Saiz J, Such P, Torta R, Versiani M (2002) Partial response and nonresponse to antidepressant therapy: current approaches and treatment options J Clin Psychiatry, 63 (9): 826-837
• Bandelow B, Zohar J, Hollander E, Kasper S, Möller HJ; WFSBP Task Force on Treatment Guidelines for Anxiety, Obsessive-Compulsive and Posttraumatic Stress Disorders (2002) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders World J Biol Psychiatry, 3 (4): 171-199
• Hilger E, Praschak-Rieder N, Willeit M, Stastny J, Konstandinidis A, Neumeister A, Kasper S (2002) Pharmacotherapy of seasonal depression Nervenarzt, 73 (1): 22-9
• Quiner S, Letmaier M, Barnas C, Heiden A, Kasper S (2002) Transcranial magnetic stimulation (TMS)--from diagnostic procedure to therapy Wiener Klinische Wochenschrift, 114 (5-6): 181-6
• Pezawas L, Stamenkovic M, Jagsch R, Ackerl S, Putz C, Stelzer B, Moffat RR, Schindler S, Aschauer H, Kasper S (2002) A longitudinal view of triggers and thresholds of suicidal behavior in depression J Clin Psychiatry, 63 (10): 866-873
• Kasper S (2002) Dopaminergic deficit and the role of amisulpride in the treatment of schizophrenia Int Clin Psychopharmacol, 17 Suppl 4 : 19-26

• Winkler D, Pjrek E, Kasper S (2002) Male depression. Clinical picture, diagnosis and treatment. In: Szymczynski GA, Progress in Andrology Andromed Ltd., Bydgoszcz
• Kasper S, Zohar J (2002) Pharmacotherapy of unipolar depression. In: Kasper S, Zohar J, Stein DJ (eds.), Decision Making in Psychopharmacology. London: Martin Dunitz: pp. 1-11
• Kasper S, Zohar J (2002) Pharmacotherapy of bipolar depression. In: Kasper S, Zohar J, Stein DJ (eds.), Decision Making in Psychopharmacology. London: Martin Dunitz: pp. 13-23
• Kasper S, Zohar J (2002) Pharmacotherapy of schizophrenia. In: Kasper S, Zohar J, Stein DJ (eds.), Decision Making in Psychopharmacology. London: Martin Dunitz: pp. 25-34
• Müller-Spahn F, Kasper S (2002) Pharmacotherapy of dementia of the Alzheimer’s type. In: Kasper S, Zohar J, Stein DJ (eds.), Decision Making in Psychopharmacology. London: Martin Dunitz: pp. 81-105
• Kasper S (2002) Serotonin-selektive Antidepressiva (SSRI, DSA) – Klinik – Indikationen: Allgemeines, Citalopram/Escitalopram, Paroxetin, Sertralin. In: P. Riederer, G. Laux, W. Pöldinger (Hrsg.), Neuro-Psychopharmaka. Ein Therapie-Handbuch. Band 3: Antidepressiva, Phasenprophylaktika und Stimmungsstabilisierer. Zweite, neu bearbeitete Auflage. Wien-New York: Springer: pp. 249-255, 261-276, 291-305
• Kasper S (2002) Aminpräkursoren - Klinik. In: P. Riederer, G. Laux, W. Pöldinger (Hrsg.), Neuro-Psychopharmaka. Ein Therapie-Handbuch. Band 3: Antidepressiva, Phasenprophylaktika und Stimmungsstabilisierer. Zweite, neu bearbeitete Auflage. Wien-New York: Springer: pp. 641-649
• Kasper S (2002) Bipolar disorder: a new field for rational polypharmacy. In: Maj M (ed.), Bipolar Disorder. Evidence and Experience in Psychiatry. Chichester: Wiley & Sons, Ltd.: pp. 275-276
• Thierry N, Barnas C, Kasper S (2002) Zur Biologie der Dysthymie. In: Hofmann P (Hrsg.), Dysthymie. Diagnostik und Therapie der chronisch depressiven Verstimmung. Wien-New York: Springer: pp. 33-38
• Kasper S (2002) Clinical studies on mood disorder. In: Okuma T, Kanba S, Inoue Y (eds.), Recent Advances in the Research of Affective Disorder in Japan. Elsevier Press: pp. 125-130
• Heiden A, Kasper S (2002) Antidepressive Wirksamkeit bei schwerer Depression: moderne und traditionelle Antidepressiva im Vergleich. In: Möller HJ, Müller WE, Rüther E (Hrsg.), Moderne Antidepressiva. Stuttgart: Thieme Verlag: pp. 49-60
• Zohar J, Kasper S, Stein DJ (2002) Pharmacotherapy of social anxiety disorder. In: Kasper S, Zohar J, Stein DJ (eds.), Decision Making in Psychopharmacology. London: Martin Dunitz: pp. 47-56
• Zohar J, Kasper S, Stein DJ (2002) Pharmacotherapy of post-traumatic stress disorder. In: Kasper S, Zohar J, Stein DJ (eds.), Decision Making in Psychopharmacology. London: Martin Dunitz: pp. 57-68
• Zohar J, Kasper S, Stein DJ (2002) Pharmacotherapy of obsessive-compulsive disorder. In: Kasper S, Zohar J, Stein DJ (eds.), Decision Making in Psychopharmacology. London: Martin Dunitz: pp. 69-79
• Kasper S (2002) Serotonin-selektive Antidepressiva (SSRI, DSA) – Expertimentelle und klinische Pharmakologie: Escitalopram. In: P. Riederer, G. Laux, W. Pöldinger (Hrsg.), Neuro-Psychopharmaka. Ein Therapie-Handbuch. Band 3: Antidepressiva, Phasenprophylaktika und Stimmungsstabilisierer. Zweite, neu bearbeitete Auflage. Wien-New York: Springer: pp. 229-233
• Kasper S, Laux G, Riedel M, Müller N, Möller HJ (2002) Serotonin-selektive Antidepressiva (SSRI, DSA) – Klinik – Dosierung. In: P. Riederer, G. Laux, W. Pöldinger (Hrsg.), Neuro-Psychopharmaka. Ein Therapie-Handbuch. Band 3: Antidepressiva, Phasenprophylaktika und Stimmungsstabilisierer. Zweite, neu bearbeitete Auflage. Wien-New York: Springer: pp. 281-282
• Kasper S, Laux G, Riedel M, Müller N, Möller HJ (2002) Serotonin-selektive Antidepressiva (SSRI, DSA) – Klinik – Unerwünschte Wirkungen, Kontraindikationen, Überdosierung, Intoxikation. In: P. Riederer, G. Laux, W. Pöldinger (Hrsg.), Neuro-Psychopharmaka. Ein Therapie-Handbuch. Band 3: Antidepressiva, Phasenprophylaktika und Stimmungsstabilisierer. Zweite, neu bearbeitete Auflage. Wien-New York: Springer: pp. 282-291
• Kasper S (2002) Antidepressants for better quality of life. In: Maj M, Sartorius D (eds.), WPA Series - Evidence and Experience in Psychiatry, Volume 1, Second Edition - Depressive Disorders. Comment on the paper of Per Bech: Pharmacological treatment of depressive disorders: a review. Chichester, New York, Weinheim, Brisbane, Singapore, Toronto: John Wiley & Sons Ltd.: pp.146-148

• Kasper S, Zohar J, Stein DJ (eds.) (2002) Decision Making in Psychopharmacology. , London: Martin Dunitz
• Kasper S (ed.) on behalf of the BEAM panel (Agren H, Bourgeois M, Cassano G, Chengappa R, Cookson J, Elgie R, Goodwin G, Kasper S, Marneros A, Mendlewicz J, Montgomery S, Morselli PL, Sacchetti E, Sachs G, Suppes T, van Gent EM, Vieta E, Yamawaki S, Yatham LN) (2002) Clinical overview – Module 2. Recognizing bipolar disorder. , Complete Medical Communications (CMC) Publishing, Macclesfield, UK
• Yatham LN (ed.) on behalf of the BEAM panel (Agren H, Bourgeois M, Cassano G, Chengappa R, Cookson J, Elgie R, Goodwin G, Kasper S, Marneros A, Mendlewicz J, Montgomery S, Morselli PL, Sacchetti E, Sachs G, Suppes T, van Gent EM, Vieta E, Yamawaki S, Yatham LN) (2002) Clinical overview – Module 1. Introducing bipolar disorder. , Complete Medical Communications (CMC) Publishing, Macclesfield, UK
• Kasper S (ed.) on behalf of the BEAM panel (Agren H, Bourgeois M, Cassano G, Chengappa R, Cookson J, Elgie R, Goodwin G, Kasper S, Marneros A, Mendlewicz J, Montgomery S, Morselli PL, Sacchetti E, Sachs G, Suppes T, van Gent EM, Vieta E, Yamawaki S, Yatham LN) (2002) Treating and managing bipolar disorder. A guide for patients. , Complete Medical Communications (CMC) Publishing, Macclesfield, UK
• BEAM panel (Agren H, Bourgeois M, Cassano G, Chengappa R, Cookson J, Elgie R, Goodwin G, Kasper S, Marneros A, Mendlewicz J, Montgomeryi PL, Sacchetti E, Sachs G, Suppes T, van Gent EM, Vieta E, Yamawaki S, Yatham LN) (2002) Bipolar disorder. Bipolar opinion leader update programme slide kit. , Complete Medical Communications (CMC) Publishing, Macclesfield, UK
• BEAM panel (Agren H, Bourgeois M, Cassano G, Chengappa R, Cookson J, Elgie R, Goodwin G, Kasper S, Marneros A, Mendlewicz J, Montgomery S, Morselli P, Sacchetti E, Sachs G, Suppes T, van Gent EM, Vieta E, Yamawaki S, Yatham LN) (2002) Diary for patients. , Complete Medical Communications (CMC) Publishing, Macclesfield, UK
• Kasper S, Möller HJ, Müller-Spahn F (2002) Depression. Diagnose und Pharmakotherapie. 2., überarbeitete Auflage. , Stuttgart: Thieme Verlag

• Stamenkovic M, Schindler S, Asenbaum S, Neumeister A, Willeit M, Willinger U, de Zwaan M, Riederer F, Aschauer H, Kasper S (2001) No change in striatal dopamine re-uptake site density in psychotropic drug naive and in currently treated Tourette’s disorder patients: a [123I]-β-CIT SPECT-study Eur Neuropsychopharmacol, 11 (1): 69-74
• Neumeister A, Willeit M, Praschak-Rieder N, Asenbaum S, Stastny J, Hilger E, Pirker W, Konstantinidis A, Kasper S (2001) Dopamine transporter availability in symptomatic depressed patients with seasonal affective disorder and healthy controls. Psychol Med, : 31(8):1467-73
• Barnas C, Quiner S, Tauscher J, Hilger E, Willeit M, Küfferle B, Asenbaum S, Brücke T, Rao ML, Kasper S (2001) In vivo (123)I IBZM SPECT imaging of striatal dopamine 2 receptor occupancy in schizophrenic patients. Psychopharmycol, : 157(3):236-42
• Hilger E, Willeit M, Praschak-Rieder N, Stastny J, Neumeister A, Kasper S (2001) Reboxetine in seasonal affective disorder: an open trial. Eur Neuropsychopharmacol, : 11(1):1-5
• Pezawas L, Kasper S (2001) Paroxetine in panic disorder with agoraphobia Int J Psychiatry Clin Pract, 5 (4): 279-281
• Montgomery SA, Kasper S, Stein DJ, Bang Hedegaard K, Lemming OM (2001) Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder Int Clin Psychopharmacol, 16 (2): 75-86
• Kasper S, Quiner S, Barnas C, Fabisch H, Haushofer M, Sackel C, König P, Lingg A, Platz T, Rittmannsberger H, Stuppäck C, Willeit M, Zapotoczky HG (2001) Zotepine in the treatment of acute hospitalized schizophrenic episodes Int Clin Psychopharmacol, 16 (3): 163-8
• Frey R, Heiden A, Scharfetter J, Schreinzer D, Blasbichler T, Tauscher J, Felleiter P, Kasper S (2001) Inverse relation between stimulus intensity and seizure duration: implications for ECT procedure J ECT, 17 (2): 102-8
• Kasper S, Rosillon D, Duchesne I (2001) Risperidone olanzapine drug outcomes studies in schizophrenia (RODOS): efficacy and tolerability results of an international naturalistic study Int Clin Psychopharmacol, 16 (4): 179-87
• Kasper S, Jones M, Duchesne I (2001) Risperidone olanzapine drug outcomes studies in schizophrenia (RODOS): health economic results of an international naturalistic study Int Clin Psychopharmacol, 16 (4): 189-96
• Stamenkovic M, Blasbichler T, Riederer F, Pezawas L, Brandstätter N, Aschauer HN, Kasper S (2001) Fluoxetine treatment in patients with recurrent brief depression Int Clin Psychopharmacol, 16 (4): 221-6
• Rychlik R, Siedentop H, von den Driesch V, Kasper S (2001) General practice research study of St. Johns Wort extract WS 5572. Normally 600 mg per day is enough MMW Fortschr Med, 143 (47): 48
• Rychlik R, Siedentop H, von den Driesch V, Kasper S (2001) St. John's wort extract WS 5572 in minor to moderately severe depression. Effectiveness and tolerance of 600 and 1200 mg active ingredient daily Fortschr Med Orig, 119 (3-4): 119-28
• Ruether E, Husmann R, Kinzler E, Diabl E, Klingler D, Spatt J, Ritter R, Schmidt R, Taneri Z, Winterer W, Koper D, Kasper S, Rainer M, Moessler H (2001) A 28-week, double-blind, placebo-controlled study with Cerebrolysin in patients with mild to moderate Alzheimer's disease. Int Clin Psychopharmacol Int Clin Psychopharmacol, 16 (5): 253-63
• Letmaier M, Schreinzer D, Wolf R, Kasper S (2001) Topiramate as a mood stabilizer Int Clin Psychopharmacol, 16 (5): 295-8
• Neumeister A, Willeit M, Praschak-Rieder N, Asenbaum S, Stastny J, Hilger E, Pirker W, Konstantinidis A, Kasper S (2001) Dopamine transporter availability in symptomatic depressed patients with seasonal affective disorder and healthy controls Psychol Med, 31 (8): 1467-73
• Stein DJ, Montgomery SA, Kasper S, Tanghoj P (2001) Predictors of response to pharmacotherapy with citalopram in obsessive-compulsive disorder Int Clin Psychopharmacol, 16 (6): 357-61
• Stamenkovic M, Aschauer H, Riederer F, Schindler S, Leisch F, Resinger E, Neumeister A, Hornik K, Kasper S (2001) Study of Family History in Seasonal Affective Disorder Neuropsychobiology, 44 (2): 65-69
• Hilger E, Willeit M, Praschak-Rieder N, Stastny J, Neumeister A, Kasper S (2001) Reboxetine in seasonal affective disorder: an open trial Eur Neuropsychopharmacol, 11 (1): 1-5
• Stamenkovic M, Schindler S, Asenbaum S, Neumeister A, Willeit M, Willinger U, de Zwaan M, Riederer F, Aschauer H, Kasper S (2001) No change in striatal dopamine re-uptake site density in psychotropic drug naive and in currently treated Tourette’s disorder patients: a [123I]-β-CIT SPECT-study Eur Neuropsychopharmacol, 11 (1): 69-74
• Tauscher J, Pirker W, Willeit M, de Zwaan M, Bailer U, Neumeister A, Asenbaum S, Lennkh C, Praschak-Rieder N, Brücke T, Kasper S (2001) [123I] β-CIT and single photon emission computed tomography reveal reduced brain serotonin transporter availability in bulimia nervosa Biol Psychiatry, 49 (4): 326-332
• Praschak-Rieder N, Willeit M, Neumeister A, Hilger E, Stastny J, Thierry N, Lenzinger E, Kasper S (2001) Prevalence of premenstrual dysphoric disorder in female patients with seasonal affective disorder J Affect Disord, 63 (1-3): 239-242
• Schreinzer D, Frey R, Stimpfl T, Vycudilik W, Berzlanovich A, Kasper S (2001) Different fatal toxicity of neuroleptics identified by autopsy Eur Neuropsychopharmacol, 11 (2): 117-124
• Tauscher J, Verhoeff NP, Christensen BK, Hussey D, Meyer JH, Kecojevic A, Javanmard M, Kasper S, Kapur S (2001) Serotonin 5-HT1A Receptor Binding Potential Declines with Age as Measured by [11C]WAY-100635 and PET Neuropsychopharmacology, 24 (5): 522-530
• Kasper S, Resinger E (2001) Panic disorder: the place of benzodiazepines and selective serotonin reuptake inhibitors Eur Neuropsychopharmacol, 11 (4): 307-321
• Tauscher J, Baby RM, Javanmard M, Chistensen BK, Kasper S, Kapur S (2001) Inverse Relationship Between Serotonin 5-HT1A Receptor Binding and Anxiety: A [11C]WAY-100635 PET Investigation in Healthy Volunteers Am J Psychiatry, 158 (8): 1326-1328
• Barnas C, Quiner S, Tauscher J, Hilger E, Willeit M, Küfferle B, Asenbaum S, Brücke T, Rao M, Kasper S (2001) In vivo 123I IBZM SPECT imaging of striatal dopamine 2 receptor occupancy in schizophrenic patients Psychopharmycol, 157 (3): 236-242
• Kirchheiner J, Brosen K, Dahl M, Gram L, Kasper S, Roots I, Sjoqvist F, Spina E, Brockmoller J (2001) CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages Acta Psychiatr Scand, 104 (3): 173-192
• Kasper S, Tauscher J, Heiden A (2001) Quetiapine: efficacy and tolerability in schizophrenia Eur Neuropsychopharmacol, 11: S405-S413
• Graf A, Wallner C, Schubert V, Willeit M, Wlk W, Fischer P, Kasper S, Neumeister A (2001) The effects of light therapy on mini-mental state examination scores in demented patients Biol Psychiatry, 50 (9): 725-727
• Neumeister A, Konstantinidis A, Praschak-Rieder N, Willeit M, Hilger E, Stastny J, Kasper S (2001) Monoaminergic function in the pathogenesis of seasonal affective disorder Int J Neuropsychopharmacol, 4 (04)

• Glauninger G, Kapitany T, Baumgartner C, Kasper S (2001) Die Psychosen bei Epilepsie Journal für Neurologie, Neurochirurgie und Psychiatrie, 2: 47-57
• Letmaier M, Schreinzer D, Wolf R, Kasper S (2001) Topiramat als Phasenprophylaktikum – ein Fallbericht Journal für Neurologie, Neurochirurgie und Psychiatrie, 4: 42-45
• Kasper S, Schreinzer D (2001) Depression als Nebenwirkung einer nicht-psychopharmakologischen Pharmakotherapie Jatros Neurologie & Psychiatrie , Supplement September 2001: 46-54
• Kasper S (Hrsg.) (2001) Begleitdepression. Körperliche Erkrankung und Depression Jatros Neurologie & Psychiatrie , Supplement September 2001
• Kasper S (2001) Social integration of the depressed patient J Clin Psychiatry, 62: 387-388
• Pezawas L, Stamenkovic M, Kasper S (2001) Rezidivierende kurze depressive Störung – Übersicht und eigene klinische Erfahrungen zu einer unterdiagnostizierten Depressionsform Journal für Neurologie, Neurochirurgie und Psychiatrie, 2 (1): 37-48
• Pezawas L, Stamenkovic M, Kasper S (2001) Recurrent brief depressive episodes. Epidemiology, clinical aspects, diagnosis and therapy Nervenarzt, 72 (3): 169-80
• Kasper S (2001) Hypericum perforatum--a review of clinical studies Pharmacopsychiatry, 34 Suppl 1: 51-5
• Kasper SF, Resinger E (2001) Efficacy of noradrenergic-selective agents in the treatment of neuropsychiatric diseases CNS Spectr, 6 (8): 710-3
• Frey R, Schreinzer D, Heiden A, Kasper S (2001) Use of electroconvulsive therapy in psychiatry Nervenarzt, 72 (9): 661-76

• Kasper S, Hilger E, Willeit M, Neumeister A, Praschak-Rieder N, Heßelmann B, Habeler A (2001) Drug Therapy. In: Partonen T, Magnusson A (eds.), Seasonal Affective Disorder: practice and research. New York: Oxford University Press: pp. 85-93
• Neumeister A, Konstantinidis A, Praschak-Rieder N, Willeit M, Hilger E, Stastny J, Kasper S (2001) Monoamines. In: Partonen T, Magnusson A (eds.), Seasonal Affective Disorders: practice and research. New York: Oxford University Press: pp. 201-217
• Kasper S, Frey R, Schreinzer D (2001) Safety and tolerability of old and new antidepressants. In: den Boer JA, Westenberg HGM (eds.), Focus on Psychiatry. Antidepressants: Selectivity or multiplicity? Amsterdam, Benecke: pp. 157-169

• Kasper S, Carlsson A (eds.) (2001) Selective Serotonin Reuptake Inhibitors 1990-2000. A decade of developments. , Lundbeck Publishing
• Kasper S (2001) Antipsychotika in Klinik und Praxis. , Basel: ComMed Verlag

• Bailer U, Leisch F, Meszaros K, Lenzinger E, Willinger U, Strobl R, Gebhardt C, Gerhard E, Fuchs K, Sieghart W, Kasper S, Hornik K, Aschauer H (2000) Genome Scan for Susceptibility Loci for Schizophrenia Neuropsychobiology, 42 (4): 175-182
• Meszaros K, Lenzinger E, Hornik K, Füreder T, Stompe T, Willinger U, Heiden A, Fathi N, Gerhard E, Fuchs K, Sieghart W, Kasper S, Aschauer H (2000) Association study of schizophrenia spectrum disorders and dopamine D3 receptor gene: is schizoaffective disorder special? Psychiat Res, 96 (2): 179-183
• Stamenkovic M, Schindler S, Aschauer H, de Zwaan M, Willinger U, Resinger E, Kasper S (2000) Effective open-label treatment of Touretteʼs disorder with olanzapine Int Clin Psychopharmacol, 15 (1): 23-28
• Willeit M, Praschak-Rieder N, Neumeister A, Pirker W, Asenbaum S, Vitouch O, Tauscher J, Hilger E, Stastny J, Brücke T, Kasper S (2000) [123I]-beta-CIT SPECT imaging shows reduced brain serotonin transporter availability in drug-free depressed patients with seasonal affective disorder. Biol Psychiatry, 47(6): 482-9
• Hale AS, Azorin JM, Kasper S, Maier W, Syvälahti E, Van der Burght M, Sloth-Nielsen M, Wehnert A (2000) Sertindole is associated with a low level of extrapyramidal symptoms in schizophrenic patients: results of a phase III trial Int J Psychiatry Clin Pract, 4: 47-54
• El-Giamal N, de Zwaan M, Bailer U, Lennkh C, Schüssler P, Strnad A, Kasper S (2000) Reboxetine in the treatment of bulimia nervosa: a report of seven cases Int Clin Psychopharmacol, 15 (6): 351-6
• Stamenkovic M, Schindler SD, Aschauer HN, De Zwaan M, Willinger U, Resinger E, Kasper S (2000) Effective open-label treatment of tourette's disorder with olanzapine Int Clin Psychopharmacol, 15 (1): 23-8
• Vesely C, Küfferle B, Brücke T, Kasper S (2000) Remission of severe tardive dyskinesia in a schizophrenic patient treated with the atypical antipsychotic substance quetiapine Int Clin Psychopharmacol, 15 (1): 57-60
• Pezawas L, Quiner S, Moertl D, Tauscher J, Barnas C, Küfferle B, Wolf R, Kasper S (2000) Efficacy, cardiac safety and tolerability of sertindole: a drug surveillance Int Clin Psychopharmacol, 15 (4): 207-14
• Bailer U, Fischer P, Küfferle B, Stastny J, Kasper S (2000) Occurrence of mirtazapine-induced delirium in organic brain disorder Int Clin Psychopharmacol, 15 (4): 239-43
• Gebhardt C, Leisch F, Schüssler P, Fuchs K, Stompe T, Sieghart W, Hornik K, Kasper S, Aschauer HN (2000) Non-association of dopamine D4 and D2 receptor genes with personality in healthy individuals Psychiat Gen, 10 (3): 131-7
• Angst J, Kasper S, Weiller E (2000) Recurrent brief depression: A frequent syndrome in clinical practice Int J Psychiatry Clin Pract, 4 (3): 195-199
• Naber D, Kasper S (2000) The importance of treatment acceptability to patients Int J Psychiatry Clin Pract, 4 (1): 25-34
• Altamura A, Bobes J, Owens D, Gerlach J, Hellewell J, Kasper S, Naber D, Tarrier N, Os J (2000) Principles of Practice from the European Expert Panel on the Contemporary Treatment of Schizophrenia Int J Psychiatry Clin Pract, 4 (1): 1-11
• Neumeister A, Pirker W, Willeit M, Praschak-Rieder N, Asenbaum S, Brücke T, Kasper S (2000) Seasonal variation of availability of serotonin transporter binding sites in healthy female subjects as measured by [123I]-2β-carbomethoxy-3β- (4-iodophenyl)tropane and single photon emission computed tomography Biol Psychiatry, 47 (2): 158-160
• Willeit M, Praschak-Rieder N, Neumeister A, Pirker W, Asenbaum S, Vitouch O, Tauscher J, Hilger E, Stastny J, Brücke T, Kasper S (2000) [123I]-β-CIT SPECT imaging shows reduced brain serotonin transporter availability in drug-free depressed patients with seasonal affective disorder Biol Psychiatry, 47 (6): 482-489
• Kasper S, Giamal N, Hilger E (2000) Reboxetine: the first selective noradrenaline re-uptake inhibitor Expert Opin Pharmacother, 1 (4): 771-782
• Kasper S, Müller-Spahn F (2000) Review of quetiapine and its clinical applications in schizophrenia Expert Opin Pharmacother, 1 (4): 783-801
• Montgomery S, Schatzberg A, Guelfi J, Kasper S, Nemeroff C, Swann A, Zajecka J (2000) Pharmacotherapy of depression and mixed states in bipolar disorder J Affect Disord, 59: S39-S56
• Brunello N, den Boer J, Judd L, Kasper S, Kelsey J, Lader M, Lecrubier Y, Lepine J, Lydiard R, Mendlewicz J, Montgomery S, Racagni G, Stein M, Wittchen H (2000) Social phobia: diagnosis and epidemiology, neurobiology and pharmacology, comorbidity and treatment J Affect Disord, 60 (1): 61-74
• Tauscher J, Tauscher-Wisniewski S, Kasper S (2000) Treatment of Patients With Delirium Am J Psychiatry, 157 (10): 1711-1711
• Gombas W, Fischer G, Jagsch R, Eder H, Okamoto I, Schindler S, Müller C, Ferenci P, Kasper S (2000) Prevalence and Distribution of Hepatitis C Subtypes in Patients with Opioid Dependence Eur Addict Res, 6 (4): 198-204

• Kasper S (2000) Diagnose und Therapie der uni- und bipolaren Depression Journal für Neurologie, Neurochirurgie und Psychiatrie, 1: 7-16
• Kasper S, Schulz V (2000) St. Johns wort extract as plant antidepressant Praxis, 89 (51-52): 2169-77
• Hilger E, Kasper S (2000) Atypical neuroleptics: new approaches to drug therapy of schizophrenic disorders Wiener Klinische Wochenschrift, 112 (24): 1031-8
• Hirschfeld RM, Montgomery SA, Keller MB, Kasper S, Schatzberg AF, Möller HJ, Healy D, Baldwin D, Humble M, Versiani M, Montenegro R, Bourgeois M (2000) Social functioning in depression: a review J Clin Psychiatry, 61 (4): 268-75
• Bailer U, de Zwaan M, Schüssler P, el-Giamal N, Strnad A, Lennkh C, Kasper S (2000) Diagnosis and therapy of eating disorders Wiener Klinische Wochenschrift, 112 (20): 865-75

• Kasper S, Volz HP (2000) Pharmakotherapie. In: Möller HJ, Kasper S (Hrsg.), Die Rolle der Kognition in der Therapie schizophrener Störungen. Wiesbaden: Deutscher Universitätsverlag: pp.189-202
• Neumeister A, Kasper S (2000) Seasonal affective disorder. In: Steiner M. Yonkers KA, Eriksson E (eds.), Mood Disorders in Women. M. Dunitz Publishers, London: pp.151-167
• Kasper S, Schatzberg A (2000) Future directions in antidepressants and mood stabilizing agents. In: Buckley P, Waddington J (eds.), Schizophrenia and mood disorders. The new drug therapies in clinical practice. Butterworth & Heinemann, Oxford, Auckland, Boston, Johannisburg, Melbourne, New Delhi: pp.212-219
• Kasper S (2000) Depression in der Allgemeinarztpraxis - weit verbreitet, aber schlecht erkannt und behandelt? Vorwort. In: Wittchen HU, Höfler N, Meister W (Hrsg), Depressionen in der Allgemeinarztpraxis: Die bundesweite Depressionsstudie. Schattauer Verlag, Stuttgart: V-VI
• Kasper S, Stamenkovic M, Pezawas L (2000) Recurrent Brief Depression - Diagnosis, epidemiology and potential pharmacological options. In: Adis International, Auckland, Managing Depressive Disorders. Adis International, Auckland: pp. 29-36
• Kasper S, Leitner I (2000) Nichtmedikamentöse Therapie - Phytotherapie, Lichttherapie, Schlafentzugstherapie, Elektrokrampftherapie. In: Böhmer F, Zapotoczky HG (Hrsg.), Depression im höheren Lebensalter. Manstein Verlags GesmbH, Wien: pp.89-94
• Kasper S, Hilger E (2000) Wirkungen und Nebenwirkungen der Psychopharmakotherapie. In: Böhmer F, Zapotoczky HG (Hrsg.), Depression im höheren Lebensalter. Manstein Verlags GesmbH, Wien: pp.77-82
• Bailer U, Kasper S (2000) Therapieresistente Depressionen - ein therapeutisches Dilemma?. In: Peter K (Hrsg.), Spektrum psychiatrischer Arbeit. Springer, Wien, New York: pp. 219-229
• Kasper S, Quiner S, Pezawas L, Barnas C, Aschauer HN, Küfferle B (2000) The efficacy of sertindole on positive and negative symptoms of schizophrenia. In: Sacchetti E, Span PF, Novel antipsychotics: facts and promises at the turn of the millennium Excerpta Medica – Elsevier Group, Amsterdam, Netherlands: 47-55

• Kasper S (2000) Soziale Phobie - Diagnostik und Pharmakologie. , Wiesbaden: Deutscher Universitätsverlag
• Kasper S (2000) Sicher therapieren mit Neuroleptika. 3. Ausgabe. , PM-Verlag, Kössen
• Kasper S (Hrsg.) (2000) Depressionen – Diagnostik und Therapie. Behandlungsmöglichkeiten mit Johanniskraut. , Urban und Vogel, München
• Möller HJ, Kasper S (Hrsg.) (2000) Die Rolle der Kognition in der Therapie schizophrener Störungen. , Wiesbaden: Deutscher Universitätsverlag

• Heiden A, Willinger U, Scharfetter J, Meszaros K, Kasper S, Aschauer H (1999) Anticipation in schizophrenia Schizophr Res, 35 (1): 25-32
• Scharfetter J, Chaudhry H, Hornik K, Fuchs K, Sieghart W, Kasper S, Aschauer H (1999) Dopamine D3 receptor gene polymorphism and response to clozapine in schizophrenic Pakistani patients Eur Neuropsychopharmacol, 10 (1): 17-20
• Lenzinger E, Neumeister A, Praschak-Rieder N, Fuchs K, Gerhard E, Willeit M, Sieghart W, Kasper S, Hornik K, N. Aschauer H (1999) Behavioral effects of tryptophan depletion in seasonal affective disorder associated with the serotonin transporter gene? Psychiat Res, 85 (3): 241-246
• Tauscher J, Küfferle B, Asenbaum S, Fischer P, Pezawas L, Barnas C, Tauscher-Wisniewski S, Brücke T, Kasper S (1999) In vivo 123I IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol Psychopharmycol, 141 (2): 175-81
• Tauscher J, Pirker W, de Zwaan M, Asenbaum S, Brücke T, Kasper S (1999) In vivo visualization of serotonin transporters in the human brain during fluoxetine treatment Eur Neuropsychopharmacol, 9 (1-2): 177-9
• Kasper S, Hale A, Azorin JM, Möller HJ (1999) Benefit-risk evaluation of olanzapine, risperidone and sertindole in the treatment of schizophrenia Eur Arch Psychiatry Clin Neurosci, 249 Suppl 2: II1-II14
• Tateyama M, Kudo I, Hashimoto M, Abe Y, Kainuma A, Yoshimura K, Asai M, Bartels M, Kasper S (1999) Is paranoid schizophrenia the most common subtype? Comparison of subtype diagnoses by Japanese and European psychiatrists, using the summaries of the same patients Psychopathology, 32 (2): 98-106
• Fischer G, Gombas W, Eder H, Jagsch R, Stühlinger G, Aschauer HN, Kasper S (1999) Buprenorphine vs. methadone as maintenance treatment for opioid dependence Nervenarzt, 70 (9): 795-802
• Neumeister A, Habeler A, Praschak-Rieder N, Willeit M, Kasper (1999) Tryptophan depletion: a predictor of future depressive episodes in seasonal affective disorder? Int Clin Psychopharmacol, 14 (5): 313-5
• Bagli M, Süverkrüp R, Quadflieg R, Höflich G, Kasper S, Möller HJ, Langer M, Barlage U, Rao ML (1999) Pharmacokinetic-pharmacodynamic modeling of tolerance to the prolactin-secreting effect of chlorprothixene after different modes of drug administration J Pharmacol Exp Ther, 291 (2): 547-54
• Bailer U, De Zwaan M, Kasper S (1999) Atypical eating disorder in a male patient Int J Psychiatry Clin Pract, 3 (2): 137-139
• Heiden A, Willinger U, Scharfetter J, Meszaros K, Kasper S, Aschauer H (1999) Anticipation in schizophrenia Schizophr Res, 35 (1): 25-32
• Lennkh C, de Zwaan M, Bailer U, Strnad A, Nagy C, El-Giamal N, Wiesnagrotzki S, Vytiska E, Huber J, Kasper S (1999) Osteopenia in anorexia nervosa: specific mechanisms of bone loss J Psychiatr Res, 33 (4): 349-356
• Fischer G, Gombas W, Eder H, Jagsch R, Peternell A, Stuhlinger G, Pezawas L, Aschauer H, Kasper S (1999) Buprenorphine versus methadone maintenance for the treatment of opioid dependence Addition, 94 (9): 1337-1347
• Heiden A, Frey R, Presslich O, Blasbichler T, Smetana R, Kasper S (1999) Treatment of severe mania with intravenous magnesium sulphate as a supplementary therapy Psychiat Res, 89 (3): 239-246

• Kasper S, Aschauer H, Ortwein-Swoboda G, Volc D, Leblhuber F, Rehak P, Angerer M (1999) Die Langzeittherapie depressiver Patienten mit Fluoxetin Jatros Neurologie & Psychiatrie , Sonderdruck 7: 1-10
• Kasper S (1999) Pharmakotherapie depressiver Syndrome bei Frauen Jatros Neurologie & Psychiatrie , Sonderdruck 1999: 18-25
• Kasper S (1999) Bridging the gap between psychopharmacology and clinical symptoms Int J Psychiatry Clin Pract, 3 (Suppl. 2): 17-20
• Kasper S (1999) Nachruf Professor Viktor E. Frankl Nervenarzt, 70: 81-82
• Heßelmann B, Habeler A, Praschak-Rieder N, Willeit M, Neumeister A, Kasper S (1999) Mirtazapine in seasonal affective disorder (SAD): A preliminary report Human Psychopharmacology Clinical and Experimental, 14: 59-62
• Montgomery S, Lecrubier Y (1999) Is severe depression a separate Indikation? Chair: SA Montgomery, Y. Lecrubier. Participants: E. Abadie, M. Ackenheil, J. Angst, P. Bech, P. Bouka, M. Briley, S. Eisen, J.-D. Guelfi, S. Kasper, J. Keogeorgos, B. Picon, R.M. Pinder, A. Puech, A. Sitzen, C.R. Soldatos, J.M. Van Ree, B.J. Van Zwieten-Boot.Rapporteur: D.B. Montgomery.1 Eur Neuropsychopharmacol, 9 (3): 259-264
• Kasper S, Schulz V (1999) John's wort extract as a phytogenic antidepressant Wien Med Wochenschr, 149 (8-10): 191-6
• Kasper S, Pezawas L (1999) Depression and anxiety Wien Med Wochenschr, 149 (18): 494-502
• Praschak-Rieder N, Willeit M, Neumeister A, Hilger E, Kasper S (1999) Therapeutic sleep deprivation and phototherapy Wien Med Wochenschr, 149 (18): 520-4
• Kasper S (1999) First-episode schizophrenia: the importance of early intervention and subjective tolerability J Clin Psychiatry, 60 Suppl 23: 5-9
• Kasper S, Tauscher J, Küfferle B, Barnas C, Pezawas L, Quiner S (1999) Dopamine- and serotonin-receptors in schizophrenia: results of imaging-studies and implications for pharmacotherapy in schizophrenia Eur Arch Psychiatry Clin Neurosci, 249 Suppl 4: 83-9
• Neumeister A, Praschak-Rieder N, Willeit M, Stastny J, Kasper S (1999) Monoamine depletion in non-pharmacological treatments for depression Adv Exp Med Biol, 467: 29-33
• Kasper S (1999) From symptoms to social functioning: differential effects of antidepressant therapy Int Clin Psychopharmacol, 14 Suppl 1: 27-31
• Lennkh C, de Zwaan M, Bailer U, Strnad A, Nagy C, el Giamal N, Vytiska E, Kasper S (1999) Osteoporosis in anorexia nervosa. New aspects of pathogenesis and therapy Nervenarzt, 70 (9): 823-9

• Kasper S (1999) Antidepressants for Better Quality of Life. In: Maj M, Sartorius D (eds.), WPA Series. Evidence and Experience in Psychiatry. Volume 1. Depressive Disorder. Comment to the paper of Per Bech. Choice and duration of treatment. Antidepressants for Better Quality of Life. Chichester: John Wiley and Sons Ltd.: pp.145-147
• Kasper S (1999) Vorwort zu Depressionen und Psychopharmakotherapie. In: PMI Verlag, QualitätsMedizin programmed. Band I. Frankfurt: PMI Verlag
• Liebowitz MR, Kasper S (1999) Anxiety Disorders. In: Halbreich U (Hrsg.), Curriculum on Mental Health and Psychopharmacology for Primary Care Physicians and Psychiatrists-Clinicians. Buffalo: WPA Section on Interdisciplinary Collaboration
• Stokes P, Halbreich U, Kasper S (1999) Depression. In: Halbreich U (Hrsg.), Curriculum on Mental Health and Psychopharmacology for Primary Care Physicians and Psychiatrists-Clinicians. Buffalo: WPA Section on Interdisciplinary Collaboration
• Kasper S (1999) Violent patient in the community. In: Lader MH, Naber D (eds.), Difficult Clinical Problems in Psychiatry. M. Dunitz Publishers, London: pp.199-211
• Neumeister A, Stastny J, Praschak-Rieder N, Willeit M, Kasper S (1999) Light treatment in depression (SAD, s-SAD & non-SAD). In: Holick MF, Jung EG (eds.), Biologic Effects of Light 1998. Kluwer Academic Press: pp.409-416
• Kasper S, Hilger E (1999) Vor- und Nachteile des Einsatzes von neuen Antidepressiva bei älteren Patienten. In: Laux G, Müller W (Hrsg.), Altersdepression: Erkennen und Behandeln. LinguaMed Verlag, Neu-Isenburg: pp. 83-94

• Fischer G, Kasper S (1999) Therapiestandards der Opiatabhängigkeit. , Druckerei Edelbacher, Wien

• Tateyama M, Asai M, Hashimoto M, Bartels M, Kasper S (1998) Transcultural study of schizophrenic delusions. Tokyo versus Vienna and Tübingen (Germany) Psychopathology, 31 (2): 59-68
• Danos P, Kasper S, Grünwald F, Klemm E, Krappel C, Broich K, Höflich G, Overbeck B, Biersack HJ, Möller HJ (1998) Pathological regional cerebral blood flow in opiate-dependent patients during withdrawal: a HMPAO-SPECT study Neuropsychobiology, 37 (4): 194-9
• Danos P, Van Roos D, Kasper S, Brömel T, Broich K, Krappel C, Solymosi L, Möller HJ (1998) Enlarged cerebrospinal fluid spaces in opiate-dependent male patients: a stereological CT study Neuropsychobiology, 38 (2): 80-3
• Stamenkovic M, Pezawas L, de Zwaan M, Aschauer HN, Kasper S (1998) Mirtazapine in recurrent brief depression Int Clin Psychopharmacol, 13 (1): 39-40
• Eder H, Fischer G, Gombas W, Jagsch R, Stühlinger G, Kasper S (1998) Comparison of buprenorphine and methadone maintenance in opiate addicts Eur Addict Res, 4 Suppl 1: 3-7
• Neumeister A, Praschak-Rieder N, Hesselmann B, Vitouch O, Rauh M, Barocka A, Kasper S (1998) Effects of tryptophan depletion in fully remitted patients with seasonal affective disorder during summer Psychol Med, 28 (2): 257-64
• Fischer P, Tauscher J, Küfferle B, Kasper S (1998) Weak antidepressant response after buspirone augmentation of serotonin reuptake inhibitors in refractory severe depression Int Clin Psychopharmacol, 13 (2): 83-6
• Kasper S, Tauscher J, Küfferle B, Barnas C, Hesselmann B, Asenbaum S, Podreka I, Brücke T (1998) Sertindole and dopamine D2 receptor occupancy in comparison to risperidone, clozapine and haloperidol - a 123I-IBZM SPECT study Psychopharmycol, 136 (4): 367-73
• Heiden A, de Zwaan M, Frey R, Presslich O, Kasper S (1998) Paroxetine in a patient with obsessive-compulsive disorder, anorexia nervosa and schizotypal personality disorder J Psychiatry Neurosci, 23 (3): 179-80
• Ruhrmann S, Kasper S, Hawellek B, Martinez B, Höflich G, Nickelsen T, Möller HJ (1998) Effects of fluoxetine versus bright light in the treatment of seasonal affective disorder Psychol Med, 28 (4): 923-33
• Lennkh C, Fischer P, Küfferle B, Kasper S (1998) Occurrence of trazodone-induced delirium Int Clin Psychopharmacol, 13 (5): 225-8
• Pezawas LM, Fischer G, Diamant K, Schneider C, Schindler SD, Thurnher M, Ploechl W, Eder H, Kasper S (1998) Cerebral CT findings in male opioid-dependent patients: stereological, planimetric and linear measurements Psychiat Res, 83 (3): 139-47
• Bailer U, Praschak-Rieder N, Pezawas L, Kasper S (1998) Mirtazapine in inpatient treatment of depressed patients Wiener Klinische Wochenschrift, 110 (18): 646-50
• Hirschfeld R, Keller M, Bourgeois M, Baldwin D, Healy D, Humble M, Kasper S, Montgomery S (1998) Focus on social functioning in depression Int J Psychiatry Clin Pract, 2 (4): 241-243
• Kasper S, Tauscher J, Küfferle E, Hesselmann B, Barnas C, Brücke T (1998) IBZM-SPECT imaging of dopamine D2 receptors with typical and atypical antipsychotics Eur Psychiatry, 13 (1): 9s-14s
• Neumeister A, Praschak-Rieder N, Heßelmann B, Vitouch O, Rauh M, Barocka A, Tauscher J, Kasper S (1998) Effects of Tryptophan Depletion in Drug-Free Depressed Patients Who Responded to Total Sleep Deprivation Arch Gen Psychiatry, 55 (2): 167
• Neumeister A, Turner E, Matthews J, Postolache T, Barnett R, Rauh M, Vetticad R, Kasper S, Rosenthal N (1998) Effects of Tryptophan Depletion vs Catecholamine Depletion in Patients With Seasonal Affective Disorder in Remission With Light Therapy Arch Gen Psychiatry, 55 (6): 524
• Broich K, Grünwald F, Kasper S, Klemm E, Biersack H, Möller H (1998) D 2 -Dopamine Receptor Occupancy measured by IBZM-SPECT in Relation to Extrapyramidal Side Effects Pharmacopsychiatry, 31 (05): 159-162
• Tauscher J, Fischer P, Neumeister A, Rappelsberger P, Kasper S (1998) Low frontal electroencephalographic coherence in neuroleptic-free schizophrenic patients Biol Psychiatry, 44 (6): 438-447
• Frey R, Metzler D, Fischer P, Heiden A, Scharfetter J, Moser E, Kasper S (1998) Myo-inositol in depressive and healthy subjects determined by frontal 1H-magnetic resonance spectroscopy at 1.5 tesla J Psychiatr Res, 32 (6): 411-420

• Kasper S (1998) Pharmakotherapie der Panikstörung. In: Kasper S (Hrsg.) Depression und Angst. Jatros Neurologie & Psychiatrie , : 6-12
• Kasper S (Hrsg.) (1998) Depression und Angst Jatros Neurologie & Psychiatrie ,
• Kasper S, Küfferle B, Tauscher J, Barnas C, Brücke T (1998) Receptor imaging studies in schizophrenia and their clinical relevance Psychiatry Res, 83: 37-55
• Ballenger JC, Davidson JR, Lecrubier Y, Nutt DJ, Baldwin DS, den Boer JA, Kasper S, Shear MK (1998) Consensus statement on panic disorder from the International Consensus Group on Depression and Anxiety J Clin Psychiatry, 59 Suppl 8: 47-54
• Montgomery SA, Kasper S (1998) Side effects, dropouts from treatment and cost consequences Int Clin Psychopharmacol, 13 Suppl 2: 1-5
• Kasper S (1998) How much do novel antipsychotics benefit the patients? Int Clin Psychopharmacol, 13 Suppl 3: 71-7
• Hasse-Sander I, Müller H, Schurig W, Kasper S, Möller HJ (1998) Effects of electroconvulsive therapy on cognitive functions in therapy-refractory depression Nervenarzt, 69 (7): 609-16
• Montgomery SA, Kasper S (1998) Depression: a long-term illness and its treatment Int Clin Psychopharmacol, 13 Suppl 6: 23-6
• Kasper S, Küfferle B (1998) Comments on "Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders" by Tran and Associates J Clin Psychopharmacol, 18 (4): 353-6
• Kasper S (1998) Social phobia: the nature of the disorder J Affect Disord, 50 Suppl 1: 3-9
• Kasper S (1998) Risperidone and olanzapine: optimal dosing for efficacy and tolerability in patients with schizophrenia Int Clin Psychopharmacol, 13 (6): 253-62

• Kasper S, Neumeister A, Praschak-Rieder N, Heßelmann B, Willeit M, Habeler A (1998) Light therapy for other conditions than seasonal affective disorder (SAD). In: Hönigsmann H, Knobler R, Trautinger F, Jori G, Landmarks in Photobiology. Milano: OEMF spa: pp 520-524
• Neumeister A, Praschak-Rieder N, Heßelmann B, Kasper S (1998) Serotonergic activity in seasonal affective disorder and light therapy. In: Hönigsmann H, Knobler R, Trautinger F, Jori G, Landmarks in Photobiology. Milano: OEMF spa: pp 516-519
• Kasper S, Neumeister A (1998) Non-pharmacological treatments for depression - focus on sleep deprivation and light therapy. In: Briley M, Montgomery S (eds.), Antidepressant Therapy—at the dawn of the third millennium. Martin Dunitz, London: pp. 255-278
• Kasper S (1998) Sind Depressionen und Schizophrenien aufgrund moderner Untersuchungsergebnisse als organische Psychosen anzusehen? . In: Klapfer H, Zapotoczky HG, Drlik G, Lux M, Hofmann P, Organische Psychosen. III. Conventum Psychiatricum Internationale Graz, 17.-19.11.1995. Verlag zur Förderung von Wissenschaft an der Psychiatrischen Universitätsklinik Graz: pp 41-42

• Briley M (ed.) and the Scientific Advisory Board (Ansseas M, Cassano GB, Deakin JF, Figueira L, Holsboer-Trachsler E, Kasper S, von Knorring L, Lecrubier Y, Leonard B, Lopez-Ibor J, Möller HJ, van Praag H, Sechter D) (1998) Is full recovery from depression possible?. , London: Martin Dunitz
• Kasper S (1998) Troubles anxieux. Diagnostic et pharmacothérapie. , München: Medizin Verlag GmbH
• Kasper S (1998) Angsterkrankungen: Diagnostik und Pharmakotherapie. , München: Medizin Verlag GmbH
• Fischer G, Kasper S (Hrsg.) (1998) Schwangerschaft, Drogen und Therapie. , Druckerei Edelbacher, Wien

• Möller HJ, Bäuml J, Ferrero F, Fuger J, Geretsegger C, Kasper S, Kissling W, Schubert H (1997) Risperidone in the treatment of schizophrenia: results of a study of patients from Germany, Austria, and Switzerland Eur Arch Psychiatry Clin Neurosci, 247 (6): 291-6
• Kasper S (1997) Hypericum perforatum in psychiatric practice Nervenarzt, 68 (2 Suppl): 8
• Vesely C, Fischer P, Goessler R, Kasper S (1997) Mania associated with serotonin selective reuptake inhibitors. J Clin Psychiatry J Clin Psychiatry, 58 (2): 88
• Kasper S, Hesselmann B, Wein W (1997) Maintenance therapy with 20 mg fluoxetine. Results of an administration study of 1,737 depressed patients Wiener Klinische Wochenschrift, 109 (6): 197-201
• Neumeister A, Praschak-Rieder N, Hesselmann B, Vitouch O, Rauh M, Barocka A, Kasper S (1997) Rapid tryptophan depletion in drug-free depressed patients with seasonal affective disorder Am J Psychiatry, 154 (8): 1153-5
• Tauscher J, Küfferle B, Asenbaum S, Brücke T, Kasper S (1997) Previous treatment as a confounding variable in studies with novel antipsychotics: two cases of high dopamine-2 receptor occupancy with quetiapine Psychopharmycol, 133 (1): 102-5
• Praschak-Rieder N, Neumeister A, Hesselmann B, Willeit M, Barnas C, Kasper S (1997) Suicidal tendencies as a complication of light therapy for seasonal affective disorder: a report of three cases J Clin Psychiatry, 58 (9): 389-92
• Küfferle B, Tauscher J, Asenbaum S, Vesely C, Podreka I, Brücke T, Kasper S (1997) IBZM SPECT imaging of striatal dopamine-2 receptors in psychotic patients treated with the novel antipsychotic substance quetiapine in comparison to clozapine and haloperidol Psychopharmycol, 133 (4): 323-8
• Kasper S, Praschak-Rieder N, Tauscher J, Wolf R (1997) A risk-benefit assessment of mirtazapine in the treatment of depression Drug Saf, 17 (4): 251-64
• Ibatoullina E, Praschak-Rieder N, Kasper S (1997) Severe atypical symptoms without depression in SAD: effects of bright light therapy J Clin Psychiatry, 58 (11): 495
• Kasper S, Jobson K (1997) First european meeting for diseases algorithms on the psychopharmacology of psychiatric Int J Psychiatry Clin Pract, 1 (s1): S1-S1
• Wehnert A, Hale A, Kasper S, Moller H, Campbell R, Stilwell C, Sloth-Nielsen M (1997) EPOS: Increasing our understanding of the treatment of schizophrenia; Start of a prospective referenced cohort study of sertindole in clinical practice Int J Psychiatry Clin Pract, 1 (3): 197-202
• Kasper S, Barnas C, Heiden A, Volz H, Laakmann G, Zeit H, Pfolz H (1997) Pramipexole as adjunct to haloperidol in schizophrenia Eur Neuropsychopharmacol, 7 (1): 65-70
• Neumeister A, Praschak-Rieder N, Heßelmann B, Vitouch O, Rauh M, Barocka A, Tauscher J, Kasper S (1997) Effects of Tryptophan Depletion on Drug-Free Patients With Seasonal Affective Disorder During a Stable Response to Bright Light Therapy Arch Gen Psychiatry, 54 (2): 133
• Kasper S, Zivkov M, Roes K, Pols A (1997) Pharmacological treatment of severely depressed patients: a meta-analysis comparing efficacy of mirtazapine and amitriptyline Eur Neuropsychopharmacol, 7 (2): 115-124
• Kasper S (1997) Treatment of Seasonal Affective Disorder (SAD) with Hypericum Extract Pharmacopsychiatry, 30 (S 2): 89-93

• Kasper S, Heiden A (1997) Gemeinsamkeiten und Unterschiede der SSRIs Jatros Neurologie & Psychiatrie , Sonderausgabe 05/1997: 11-4, 19
• Kasper SD (1997) Diagnostik und Therapie der Angst-/Panikerkrankung Jatros Neurologie & Psychiatrie , 05/1997: 32-33
• Kasper S, König P (Hrsg.) (1997) Paroxetin zur Therapie von Angst und Depression Jatros Neurologie & Psychiatrie , Sonderausgabe
• Kasper S (1997) Efficacy of antidepressants in the treatment of severe depression: the place of mirtazapine J Clin Psychopharmacol, 17 Suppl 1: 19S-28S
• Tauscher J, Neumeister A, Fischer P, Frey R, Kasper S (1997) Electroconvulsive therapy in clinical practice Nervenarzt, 68 (5): 410-6
• Neumeister A, Praschak-Rieder N, Hesselmann B, Tauscher J, Kasper S (1997) The tryptophan depletion test. Basic principles and clinical relevance Nervenarzt, 68 (7): 556-62
• Lenzinger E, Diamant K, Vytiska-Binstorfer E, Kasper S (1997) Premenstrual dysphoric disorder. An overview of diagnosis, epidemiology and therapeutic approaches Nervenarzt, 68 (9): 708-18
• Lennkh C, De Zwaan M, Kasper S (1997) New aspects of diagnosis and pharmacotherapy of eating disorders Int J Psychiatry Clin Pract, 1 (1): 21-35
• Zohar J, Ayuso-Gutierrez J, D'Haenen H, Honig A, Iancu I, Jobson K, Kasper S (1997) Treatment of obsessive compulsive disorder: Algorithms for pharmacotherapy Int J Psychiatry Clin Pract, 1 (s1): S17-S23
• Kasper S, Bech P, Dejonghe F, De Sousa M, Dinan T, Guelfi J, Higuchi T, Larsen J, Lecrubier J, Lerer B, Neumeister A, Papadimitriou G, Paykel E, Poldinger W, Svestka J, Walter H (1997) Treatment of unipolar major depression: Algorithms for pharmacotherapy Int J Psychiatry Clin Pract, 1 (s1): S5-S7

• Kasper S (1997) Therapie der Negativsymptome - ist sie unterschiedlich zur Depressionstherapie. In: Kasper S (Hrsg.), Depression und Psychose. Jatros Universimed VerlagsgesmbH, Wien: pp. 21-27
• Kasper S (1997) Long-term treatment of depression with antidepressants. Evidence from clinical trials, prediction and practical guidelines. In: Honig A, van Praag HM, Depression, Neurobiological, Psychopathological and Therapeutic Advances. J. Wiley & Sons Ltd. Chichester: pp 499-518
• Kasper S, Praschak-Rieder N (1997) Diagnosis and treatment of subsyndromal seasonal affective disorder (S-SAD).. In: Judd L, Saletu B, Filip V, Basic and Clinical Science of Mental and Addictive Disorders, Bibl Psychiatr. No. 167. S. Karger, Basel: pp 11-20

• Kasper S (1997) Blickpunkt Sertralin. Blaue Reihe. , Stuttgart: Aesopus-Verlag
• Kasper S (1997) Angsterkrankungen erkennen und beurteilen. , Frankfurt: Medizinisch-wissenschaftliche Schriftenreihe
• Gröger H, Gabriel E, Kasper S (1997) On the history of psychiatry in Vienna. , Wien: Christian Brandstätter-Verlag
• Kasper S (Hrsg.) (1997) Depression und Psychose. , Wien: Jatros Universimed VerlagsgesmbH
• Gröger H, Gabriel E, Kasper S (1997) Zur Geschichte der Psychiatrie in Wien. , Wien: Christian Brandstätter-Verlag

• Meszaros K, Lenzinger E, Füreder T, Hornik K, Willinger U, Stompe T, Heiden A, Resinger E, Fathi N, Gerhard E, Fuchs K, Miller-Reiter E, Pfersmann V, Sieghart W, Aschauer H, Kasper S (1996) Schizophrenia and the dopamine-β-hydroxylase gene Psychiat Gen, 6 (1): 17-22
• Meszaros K, Lenzinger E, Füreder T, Hornik K, Willinger U, Stompe T, Heiden AM, Resinger E, Fathi N, Gerhard E, Fuchs K, Miller-Reiter E, Pfersmann V, Sieghart W, Aschauer HN, Kasper S (1996) Schizophrenia and the dopamine-beta-hydroxylase gene: results of a linkage and association study. Psychiat Gen, 6 (1): 17-22
• Schneider C, Fischer G, Diamant K, Hauk R, Pezawas L, Lenzinger E, Kasper S (1996) Pregnancy and drug dependence Wiener Klinische Wochenschrift, 108 (19): 611-614
• Fischer G, Presslich O, Diamant K, Schneider C, Pezawas L, Kasper S (1996) Oral morphine-sulphate in the treatment of opiate dependent patients Alcoholism, 32: 35-43
• Klemm E, Danos P, Grünwald F, Kasper S, Möller HJ, Biersack HJ (1996) Temporal lobe dysfunction and correlation of regional cerebral blood flow abnormalities with psychopathology in schizophrenia and major depression--a study with single photon emission computed tomogra Psychiat Res, 68 (1): 1-10
• Küfferle B, Brücke T, Topitz-Schratzberger A, Tauscher J, Gössler R, Vesely C, Asenbaum S, Podreka I, Kasper S (1996) Striatal dopamine-2 receptor occupancy in psychotic patients treated with risperidone Psychiat Res, 68 (1): 23-30
• Schneider C, Fischer G, Diamant K, Hauk R, Pezawas L, Lenzinger E, Kasper S (1996) Pregnancy and drug dependence Wiener Klinische Wochenschrift, 108(19): 611-4
• Stamenkovic M, Schindler S, Kasper S (1996) Therapy of post-stroke depression with fluoxetine. A pilot project Nervenarzt, 67(1): 62-7
• Klemm E, Grünwald F, Kasper S, Menzel C, Broich K, Danos P, Reichmann K, Krappel C, Rieker O, Briele B, Hotze AL, Möller HJ, Biersack HJ (1996) 123I]IBZM SPECT for imaging of striatal D2 dopamine receptors in 56 schizophrenic patients taking various neuroleptics Am J Psychiatry, 153(2): 183-90
• Bagli M, Rao ML, Höflich G, Kasper S, Langer M, Barlage U, Beneke M, Süverkrüp R, Möller HJ (1996) Pharmacokinetics of chlorprothixene after single intravenous and oral administration of three galenic preparations Arzneimittelforschung, 46(3): 247-50
• Stamenkovic M, Schindler S, Kasper S (1996) Poststroke depression and fluoxetine Am J Psychiatry, 153(3): 247-50
• Meszaros K, Kasper S (1996) Psychopathological phenomena in long-term follow-up of acute psychosis after preventive mefloquinine (Lariam) administration Nervenarzt, 67(5): 404-6
• Lesch OM, Walter H, Freitag H, Heggli DE, Leitner A, Mader R, Neumeister A, Passweg V, Pusch H, Semler B, Sundrehagen E, Kasper S (1996) Carbohydrate-deficient transferrin as a screening marker for drinking in a general hospital population Alcohol Alcohol., 31 (3): 249-56
• Lesch OM, Walter H, Antal J, Heggli DE, Kovacz A, Leitner A, Neumeister A, Stumpf I, Sundrehagen E, Kasper S (1996) Carbohydrate-deficient transferrin as a marker of alcohol intake: a study with healthy subjects Alcohol Alcohol., 31 (3): 265-71
• Neumeister A, Goessler R, Lucht M, Kapitany T, Bamas C, Kasper S (1996) Bright light therapy stabilizes the antidepressant effect of partial sleep deprivation Biol Psychiatry, 39 (1): 16-21
• Oren D, Levendosky A, Kasper S, Duncan C, Rosenthal N (1996) Circadian profiles of cortisol, prolactin, and thyrotropin in seasonal affective disorder Biol Psychiatry, 39 (3): 157-170
• Rao M, Ruhrmann S, Retey B, Liappis N, Fuger J, Kraemer M, Kasper S, Möller H (1996) Low Plasma Thyroid Indices of Depressed Patients are Attenuated by Antidepressant Drugs and Influence Treatment Outcome Pharmacopsychiatry, 29 (05): 180-186

• Kasper S (1996) Neue Antipsychotika Jatros Neurologie & Psychiatrie , 06/1996: 24-27
• Kasper S (1996) Treatment options in severe depression J Clin Psychiatry, 57: 556-558
• Kasper S, Schindler S, Neumeister A (1996) Risk of suicide in depression and its implication for psychopharmacological treatment Int Clin Psychopharmacol, 11 (2): 71-9
• Kasper S, Pletan Y, Solles A, Tournoux A (1996) Comparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with major depression: a summary of clinical trial results Int Clin Psychopharmacol, 11 Suppl 4: 35-9

• Kasper S (1996) Notfälle in der Psychiatrie. In: Psychiatrie. Lehrbuch mit Repetitorium. In: Gastpar MT, Kasper S, Linden M (Hrsg.), Psychiatrie. Lehrbuch mit Repertorium. Berlin, Walter de Gruyter u. Co.: pp. 357-370
• Fischer G, Diamant K, Schneider C, Pezawas L, Presslich O, Podreka I, Brücke T, Thurnherr M, Kasper S (1996) Hirn-SPECT Untersuchung bei opiatabhängigen Patienten. In: Möller HJ, Müller-Spahn F, Kurtz G (Hrsg.), Aktuelle Perspektiven der Biologischen Psychiatrie. Wien: Springer Verlag: pp. 694-696
• Kapitany T, Meszaros K, Aschauer H, Schindler S, Barnas C, Fuchs K, Sieghart W, Kasper S (1996) Genotypisierung des Cyp 2D6-Polymorphismus in einer Gruppe chronisch schizophrener Patienten mit therapeutisch ungünstigem Verlauf. In: Möller HJ, Müller-Spahn F, Kurtz G (Hrsg.), Aktuelle Perspektiven der Biologischen Psychiatrie. Wien: Springer Verlag: pp. 483-485
• Neumeister A, Gössler R, Rieder N, Lucht M, Kasper S (1996) Rückfallverhütung nach Schlafentzug. In: Möller HJ, Müller-Spahn F, Kurtz G (Hrsg.), Aktuelle Perspektiven der Biologischen Psychiatrie. Wien: Springer Verlag: pp. 466-469
• Stamenkovic M, Schindler S, Kasper S (1996) Therapie der Poststroke-Depression mit Fluoxetin: Ein Pilotprojekt. In: Möller HJ, Müller-Spahn F, Kurtz G (Hrsg.), Aktuelle Perspektiven der Biologischen Psychiatrie. Wien: Springer Verlag: pp. 117-119
• Kasper S, Höflich G (1996) Somatotherapie bei Zwangsstörungen. In: Peters UH, Schifferdecker M, Krahl A (Hrsg.), 150 Jahre Psychiatrie Jubiläumswerk der DGPN. Köln: Eigenverlag: pp. 138-141
• Kasper S, Möller HJ (1996) Diagnostik und Therapie der Angst- Panikerkrankungen. In: Peters UH, Schifferdecker M, Krahl A (Hrsg.), 150 Jahre Psychiatrie Jubiläumswerk der DGPN. Köln: Eigenverlag: pp. 310-312
• Broich K, Kasper S, Grünwald F, Danos P, Klemm E, Biersack HJ, Möller HJ (1996) Darstellung von Dopamin D2-Rezeptoren mittels 123J-IBZM-Spect bei psychiatrischen Fragestellungen. In: Peters UH, Schifferdecker M, Krahl A (Hrsg.), 150 Jahre Psychiatrie Jubiläumswerk der DGPN. Köln: Eigenverlag: pp. 519-520
• Höflich G, Kasper S, Rao ML, Scholl HP, Ruhrmann S, Danos P, Möller HJ (1996) Ansprechen auf Elektrokrampftherapie und hormonelle Parameter bei Patienten mit therapieresistenter Depression. In: Peters UH, Schifferdecker M, Krahl A (Hrsg.), 150 Jahre Psychiatrie Jubiläumswerk der DGPN. Köln: Eigenverlag: pp. 469-471
• Rao ML, Andres AH, Fuger J, Ruhrmann S, Kasper S, Ostrowitzki S, Möller HJ (1996) Biologische Verlaufsparameter unter psychiatrischer Therapie. In: Peters UH, Schifferdecker M, Krahl A (Hrsg.), 150 Jahre Psychiatrie Jubiläumswerk der DGPN. Köln: Eigenverlag: pp. 458-464
• Kasper S, Scholl HP, Danos P, Höflich G, Horn R, Möller HJ (1996) Therapiebedingte Veränderungen, die durch eine quantitative EEG-Auswertung erfaßt werden können. In: Peters UH, Schifferdecker M, Krahl A (Hrsg.), 150 Jahre Psychiatrie Jubiläumswerk der DGPN. Köln: Eigenverlag: pp. 472-474
• Martinez B, Höflich G, Rao ML, Eichert V, Assion HJ, Kasper S (1996) Veränderungen der serotonergen Aktivität bei Zwangspatienten: Neuroendokrinologische Ergebnisse beim Clomipramin-Stimulationstest. In: Möller HJ, Müller-Spahn F, Kurtz G (Hrsg.), Aktuelle Perspektiven der Biologischen Psychiatrie. Wien: Springer Verlag: pp. 387-389
• Wagner E, Presslich O, Fischer G, Frey R, Diamant K, Schneider C, Kasper S (1996) Der Einsatz von Morphinsulfatpentahydrat in der Detoxifikationsbehandlung Opiatabhängige. In: Möller HJ, Müller-Spahn F, Kurtz G (Hrsg.), Aktuelle Perspektiven der Biologischen Psychiatrie. Wien: Springer Verlag: pp. 374-377
• Höflich G, Martinez B, Klemm E, Kasper S, Biersack HJ, Möller HJ (1996) HMPAO-SPECT bei Patienten mit Zwangserkrankungen. In: Möller HJ, Müller-Spahn F, Kurtz G (Hrsg.), Aktuelle Perspektiven der Biologischen Psychiatrie. Wien: Springer Verlag: pp. 390-392
• van den Hoofdakker RH, Gordijn MCM, Neumeister A, Kasper S (1996) Schlafentzug bei Therapieresistenz auf Antidepressiva. In: Kasper S, Möller HJ (Hrsg.), Therapeutischer Schlafentzug. Klinik und Wirkmechanismen. Wien-New York: Springer Verlag: pp 107-122
• Neumeister A, Lucht M, Kasper S (1996) Kombination von Schlafentzug und Lichttherapie zur Behandlung depressiver Störungen. In: Kasper S, Möller HJ (Hrsg.), Therapeutischer Schlafentzug. Klinik und Wirkmechanismen. Wien-New York: Springer Verlag: pp 69-80
• Grass F, Kasper S (1996) Biophotons, CNS and the possible role of pigments and fluorescent substances. In: Holick MF, Jung EG, Biological Effects of Light 1995. Walter de Gruyter u. Co, Berlin, New York: pp 148-151
• Schindler S, Kapitany T, Barnas C, Kasper S (1996) Nebenwirkungen der Lichttherapie bei der Behandlung psychiatrischer Erkrankungen. In: Möller HJ, Müller-Spahn F, Kurtz G (Hrsg.), Aktuelle Perspektiven der Biologischen Psychiatrie. Wien: Springer Verlag: pp 232-236
• Rieder N, Schindler S, Neumeister A, Stuppäck C, Benke T, Stamenkovic M, Barnas C, Kasper S (1996) Manisch-depressive Zustandsbilder im Anschluß an Hirnläsionen: 2 Fallbeschreibungen. In: Möller HJ, Müller-Spahn F, Kurtz G (Hrsg.), Aktuelle Perspektiven der Biologischen Psychiatrie. Wien: Springer Verlag: pp 228-231
• Barnas C, Wolf R, Schindler S, Dietzel M, Kasper S (1996) Clonazepam zur Prophylaxe affektiver Erkrankungen. In: Möller HJ, Müller-Spahn F, Kurtz G (Hrsg.), Aktuelle Perspektiven der Biologischen Psychiatrie. Wien: Springer Verlag: pp 253-256
• Meszaros K, Pfersmann V, Resinger E, Stamenkovic M, Willinger U, Aschauer H, Kasper S (1996) Die Diagnose der rezidivierenden kurzdauernden Depression bei einem ambulanten Patientengut. In: Möller HJ, Müller-Spahn F, Kurtz G (Hrsg.), Aktuelle Perspektiven der Biologischen Psychiatrie. Wien: Springer Verlag: pp 209-211
• Topitz-Schratzberger A, Küfferle B, Gössler R, Vesely C, Tauscher J, Barnas C, Heiden A, Brücke T, Asenbaum S, Kasper S (1996) IBZM-SPECT zur Darstellung der D2-Rezeptorokkupanz unter Risperidon. In: Möller HJ, Müller-Spahn F, Kurtz G (Hrsg.), Aktuelle Perspektiven der Biologischen Psychiatrie. Wien: Springer Verlag: pp 675-677
• Kasper S, Neumeister A, Rieder N, Hesselmann B, Ruhrmann S (1996) Serotonergic mechanisms in the pathophysiology and treatment of seasonal affective disorder. In: Holick MF, Jung EG, Biological Effects of Light 1995. Walter de Gruyter u. Co, Berlin, New York: pp 325-331
• Neumeister A, Rieder-Praschak N, Heßelmann B, Glück J, Rao ML, Kasper S (1996) Effect of tryptophan depletion in seasonal depressives who responded to light therapy. In: Holick MF, Jung EG, Biological Effects of Light 1995. Walter de Gruyter u. Co, Berlin, New York: pp 424-425
• Kasper S (1996) Therapeutischer Schlafentzug und antidepressive Medikation. In: Kasper S, Möller HJ (Hrsg.), Therapeutischer Schlafentzug. Klinik und Wirkmechanismen. Wien-New York: Springer Verlag: pp 101-106
• Kasper S, Ruhrmann S, Heßelmann B, Rao ML, Möller HJ (1996) Metabolismustheorie des therapeutischen Schlafentzugs. In: Möller HJ, Müller-Spahn F, Kurtz G (Hrsg.), Aktuelle Perspektiven der Biologischen Psychiatrie. Wien: Springer Verlag: pp 460-465
• Kasper S, Fischer G, Danos P, Grünwald F, Klemm E, Biersack HJ, Presslich O, Podreka I, Brücke T, Möller HJ (1996) HMPAO-SPECT bei Störungen durch Opioide und multiplen Substanzgebrauch. In: Möller HJ, Müller-Spahn F, Kurtz G (Hrsg.), Aktuelle Perspektiven der Biologischen Psychiatrie. Wien: Springer Verlag: pp 728-731
• Ruhrmann S, Kasper S, Rao ML, Hawellek B, Möller HJ (1996) Beziehungen zwischen serotonergen Parametern und Lichttherapie bei saisonal-abhängiger Depression. In: Möller HJ, Müller-Spahn F, Kurtz G (Hrsg.), Aktuelle Perspektiven der Biologischen Psychiatrie. Wien: Springer Verlag: pp 202-205
• Ruhrmann S, Kasper S, Hawellek B, Biersack HJ, Möller HJ (1996) Veränderung von Schilddrüsenparametern unter Fluoxetin und Lichttherapie. In: Möller HJ, Müller-Spahn F, Kurtz G (Hrsg.), Aktuelle Perspektiven der Biologischen Psychiatrie. Wien: Springer Verlag: pp 198-201
• Gössler R, Kasper S (1996) EEG Veränderungen depressiver Patienten unter antidepressiver Therapie - Ergebnisse einer Doppelblindstudie. In: Möller HJ, Müller-Spahn F, Kurtz G (Hrsg.), Aktuelle Perspektiven der Biologischen Psychiatrie. Wien: Springer Verlag: pp 568-570
• Gössler R, Pirker W, Kasper S, Asenbaum S, Walter H, Angelberger P, Podreka I, Brücke T (1996) In-vivo Darstellung der 5HT-Wiederaufnahmeblockade. In: Möller HJ, Müller-Spahn F, Kurtz G (Hrsg.), Aktuelle Perspektiven der Biologischen Psychiatrie. Wien: Springer Verlag: pp 143-146
• Vesely C, Gössler R, Fischer P, Kasper S (1996) Manische Symptome unter antidepressiver Therapie mit selektiven Serotoninwiederaufnahmehemmern. In: Möller HJ, Müller-Spahn F, Kurtz G (Hrsg.), Aktuelle Perspektiven der Biologischen Psychiatrie. Wien: Springer Verlag: pp 217-220
• Heiden A, Meszaros K, Lenzinger E, Fuchs K, Fathi N, Gerhard E, Miller-Reiter E, Willinger U, Resinger E, Stompe T, Pfersmann V, Sieghart W, Aschauer H, Kasper S (1996) Schizophrenie und DNS-Polymorphismen am Dopamin-ß-Hydroxylase Gen. In: Möller HJ, Müller-Spahn F, Kurtz G (Hrsg.), Aktuelle Perspektiven der Biologischen Psychiatrie. Wien: Springer Verlag: pp 480-482
• Kasper S (1996) Angststörungen, Zwangsstörungen, Reaktion auf schwere Belastungen und Anpassungsstörungen. In: Gastpar MT, Kasper S, Linden M (Hrsg.), Psychiatrie. Lehrbuch mit Repertorium. Berlin, Walter de Gruyter u. Co.: p 134-165
• Kasper S (1996) Praktische Hinweise zur Langzeitbehandlung affektiver Störungen. In: Drlik G, Hofmann P, Kulhanek F, Melisch B, Zapotoczky HG (Hrsg.), Dosisäquivalenzen der Neuroleptika und Antidepressiva, II Graz, Conventum Psychiatricum Internationale Graz 1993, Verlag Verein zur Förderung von Wissenschaft an der Psychiatrischen Klinik Graz: pp. 37-40

• Gastpar MT, Kasper S, Linden M (1996) Psychiatrie. Lehrbuch mit Repetitorium. , Walter de Gruyter & Co., Berlin
• Kasper S, Möller HJ (1996) Therapeutischer Schlafentzug. Klinik und Wirkmechanismen. , Springer Verlag, Wien - New York

• Kolbinger HM, Höflich G, Hufnagel A, Möller HJ, Kasper S (1995) Transcranial magnetic stimulation (TMS) in the treatment of major depression - a pilot study Human Psychopharmacology Clinical and Experimental, 10: 305-310
• Klemm E, Roth A, Möller HJ, Biersack HJ Kasper S (1995) Involvement of mesial-temporal structures in rapid cycling mood disorders? Human Psychopharmacology Clinical and Experimental, 10: 475-480
• Kasper S, Stamenkovic M, Fischer G (1995) Recurrent Brief Depression CNS Drugs, 4 (3): 222-229
• Bagli M, Höflich G, Rao ML, Langer M, Baumann P, Kolbinger M, Barlage U, Kasper S, Möller HJ (1995) Bioequivalence and absolute bioavailability of oblong and coated levomepromazine tablets in CYP2D6 phenotyped subjects Int J Clin Pharmacol Ther, 33(12): 646-52
• Nelson JC, Docherty JP, Henschen GM, Kasper S, Nierenberg AA, Ward NG (1995) Algorithms for the treatment of subtypes of unipolar major depression Psychopharmacol Bull, 31(3): 457-82
• Pirker W, Asenbaum S, Kasper S, Walter H, Angelberger P, Koch G, Pozzera A, Deecke L, Podreka I, Brücke T (1995) beta-CIT SPECT demonstrates blockade of 5HT-uptake sites by citalopram in the human brain in vivo. J Neutral Transm Gen Sect, 100(3): 247-56
• Kasper S, Möller HJ, Montgomery SA, Zondag E (1995) Antidepressant efficacy in relation to item analysis and severity of depression: a placebo-controlled trial of fluvoxamine versus imipramine Int Clin Psychopharmacol, 4: 3-12
• Montgomery SA, Kasper S (1995) Comparison of compliance between serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis Int Clin Psychopharmacol, 4: 33-40
• eng CT, Akerman D, Cordás TA, Kasper S, Vieira AH (1995) Seasonal affective disorder in a tropical country: a case report Psychiat Res, 56(1): 11-5
• Schindler S, Barnas C, Leitner H, Kapitany T, Kasper S (1995) Trigeminal neuralgic syndrome after bright light therapy Am J Psychiatry, 152(8): 1237
• Kasper S, Jung B (1995) Psychiatrically relevant side effects of non-psychopharmacological pharmacotherapy Nervenarzt, 66(9): 649-61
• Kasper S (1995) Clinical efficacy of mirtazapine: a review of meta-analyses of pooled data Int Clin Psychopharmacol, 10(4): 25-35
• Höflich G, Kasper S, Karl-Werner B, Hans-Peter S, Hans-Jürgen M (1995) Maintenance ECT for treatment of therapy-resistant paranoid schizophrenia and Parkinson's disease Biol Psychiatry, 37 (12): 892-894
• Möller H, Kasper S, Müller H, Kissling W, Fuger J, Ruhrmann S (1995) A Controlled Study of the Efficacy and Safety of Mianserin and Amitriptyline in Depressive Inpatients Pharmacopsychiatry, 28 (06): 249-252

• Brunello N, Burrows G, Jönsson B, Judd LL, Kasper S, Keller M, Kupfer D, Lecrubier Y, Mendlewicz J, Montgomery SA, Nemeroff CB, Preskorn SH, Racagni G, Rush AJ (1995) Critical issues in the treatment of affective disorders Depression, 3: 187-198
• Kasper S, Heiden A (1995) Do SSRIs differ in their antidepressant efficacy? Human Psychopharmacology Clinical and Experimental, 10: 163-171
• Kasper S, Lepine JP, Mendlewicz J, Montgomery SA, Rush AJ (1995) Efficacy, safety and indications for tricyclic and newer antidepressants. Depression, 2: 127-137
• Beaumont G, Kasper S, O'Hanlon J, Mendlewicz J (1995) Antidepressant side effect and adverse reactions. Depression, 2: 138-144
• Kasper S, Möller HJ (1995) Antidepressive Psychopharmakotherapie. Selektive Serotonin-Wiederaufnahmehemmer (SSRI) als neues Wirkprinzip. Deutsches Ärzteblatt, 92: A-428-434
• Tauscher J, Schindler S, Rappelsberger P, Kasper S (1995) EEG-Veränderungen bei schizophrenen Erkrankungen - eine kritische Übersicht Fortschr Neurol Psychiatr, 63 (04): 162-169

• Miller-Reiter E, Presslich O, Fodor G, Frey R, Kasper S (1995) ) Magnesium as an aid in opioid detoxification and withdrawal. In: Smetana R (ed.), Advances in Magnesium Research 1. Magnesium in Cardiology. John Libbey: London-Paris-Rom-Sidney: pp. 242-246
• Kasper S (1995) Sind Depressionen und Schizophrenien aufgrund moderner Untersuchungsergebnisse als organische Psychosen anzusehen?. In: Klapfer H, Zapotoczky HG, Drlik G, Lux M, Hofmann P (Hrsg.), Organische Psychosen. III. Conventum Psychiatricum Internationale Graz Verlag zur Förderung von Wissenschaft an der Psychiatrischen Universitätsklinik Graz: pp. 41-42
• Kasper S, Kapitany T, Neumeister A, Rieder N (1995) Der antidepressive Effekt der Lichttherapie. In: Helmchen H, Hippius H (Hrsg.), Psychiatrie für die Praxis 21. München: Medizin Verlag München (MMV): pp. 163-168
• Danos P, Kasper S, Klemm E, Grünwald F, Krappel C, Broich K, Höflich G, Overbeck B, Biersack HJ, Möller HJ (1995) HMPAO-SPECT findings in opioid polydrug users - preliminary results.. In: Grünwald F, Kasper S, Biersack HJ, Möller HJ (Hrsg.), Brain SPECT imaging in psychiatry. Berlin: De Gruyter Verlag: pp. 59-71
• Kasper S, Rieder N (1995) Die Begleitmedikation bei schizophrenen Erkrankungen. In: Hinterhuber H, Fleischhacker W, Meise U (Hrsg.), Die Behandlung der Schizophrenien: State of the Art. Innsbruck: VIP Verlag: pp. 185-196
• Kasper S (1995) Psychopharmakotherapie der Altersdepression. In: Kasper S (Hrsg.), Depression und Demenz. Wien: Informator Verlag: pp. 4-11
• Kasper S (1995) Pharmakologische Behandlung von Angststörungen. In: Zapotoczky HG, Kasper S, Biebl W (Hrsg.), Leitfaden zur Therapieführung eines Angstpatienten. Wien: Upjohn
• Miller-Reiter E, Presslich O, Fodor G, Frey R, Kasper S (1995) Magnesium as an aid in opioid detoxification and withdrawal. In: Smetana R (ed.), Advances in Magnesium Research 1. Magnesium in Cardiology. John Libbey: London-Paris-Rom-Sidney: pp 242-246
• Broich K, Kasper S, Danos P, Möller HJ, Grünwald F, Klemm E, Biersack HJ, Alavi A (1995) IBZM-SPECT during neuroleptic treatment. In: Grünwald F, Kasper S, Biersack HJ, Möller HJ, Brain SPECT imaging in psychiatry. De Gruyter Verlag Berlin: pp 193-202
• Kasper S (1995) Neue psychopharmakologische Strategien bei der Behandlung von Angsterkrankungen. In: Kasper S, Möller HJ (Hrsg.), Angst- und Panikerkrankungen Jena, G. Fischer Verlag: pp. 331-347
• Kasper S, Neumeister A (1995) Übersicht über die Ergebnisse klinischer Studien mit Risperidon. In: Fleischhacker WW, Hinterhuber H, König P (Hrsg.), Die Behandlung schizophrener Erkrankungen - Neue Entwicklungen Innsbruck, VIP-Verlag: pp. 33-45
• Kasper S (1995) Biological aspects of late-life depression. In: Hofmann P, Wieselmann G, Zapotoczky HG (Hrsg.), Proceedings of the International Conference on Aging, Depression and Dementia Wien, Verlag Wilhelm Maudrich: pp. 127-131
• Klemm E, Grünwald F, Overbeck B, Menzel C, Rieker O, Briele B, Hotze AL, Biersack HJ, Danos P, Kasper S, Broich K, Krappel C, Möller HJ (1995) Temporal lobe involvement in schizophrenia and major depression: 99m Tc-HMPAO-SPECT findings and their correlation to psychopathology. In: Grünwald F, Kasper S, Biersack HJ, Möller HJ (Hrsg.), Brain SPECT imaging in psychiatry. Berlin: De Gruyter Verlag: pp. 73-81
• Kasper S, Ruhrmann S, van den Hoofdakker RH (1995) Therapeutic sleep deprivation in patients resistant to antidepressants. In: Marcher JP, Crocq MA, Nedelec JF (eds.), New prospects in psychiatry. The bio-clinical interface Paris, John Libbey Eurotext: pp. 127-137

• Croy A, Dal-Bianco P, Danielczyk W, Deisenhammer E, Fischer P, Grünberger J, Kasper S, Luthringshausen G, Pammer E, Ransmayr G, Schäfer C, Seitelberger F, Thuile C. Zapotoczky HG (1995) Morbus Alzheimer. Rechtzeitig erkennen - richtig behandeln. , Manstein Verlag, Wien.
• Kasper S, Möller HJ (1995) Angst- und Panikerkrankungen. , G. Fischer Verlag, Jena
• Wittchen HU, Bullinger-Naber M, Dorfmüller M, Hand I, Kasper S, Katschnig H, Linden M, Margraf J, Möller HJ, Naber D, Pöldinger W, van de Roemer A (1995) Angst. Angsterkrankungen, Behandlungsmöglichkeiten. , S. Karger, Basel, Freiburg
• Wittchen HU, Möller HJ, Vossen A, Hautzinger M, Kasper S, Heuser I (1995) Depression. Wege aus der Krankheit. , S. Karger, Basel, Freiburg
• Grünwald F, Kasper S, Biersack HJ, Möller HJ (1995) Brain SPECT imaging in psychiatry. , De Gruyter Verlag Berlin

• Neumeister A, Kapitany T, Rieder N, Kasper S (1994) Fall/winter depression and its therapy Wiener Klinische Wochenschrift, 106(21): 665-70
• Kasper S (1994) Diagnosis, epidemiology and therapy of seasonal depression Nervenarzt, 65(1): 69-72
• Kasper S, Ruhrmann S, Haase T, Möller HJ (1994) Evidence for a seasonal form of recurrent brief depression (RBD-seasonal) Eur Arch Psychiatry Clin Neurosci, 244(4): 205-10
• Höflich G, Burghof KW, Kasper S, Möller HJ (1994) Electroconvulsive therapy in comorbidity of treatment refractory paranoid hallucinatory psychoses with Parkinson disease Nervenarzt, 65(3): 202-5
• Scholl HP, Kasper S, Danos P, Höflich G, Möller HJ (1994) elective serotonin reuptake inhibitors in treatment of compulsive symptoms within the scope of schizophrenia Nervenarzt, 65(7): 4478-81
• Kasper S, Kasper A (1994) Long-term treatment of affective disorders Nervenarzt, 65(9): 577-89
• Kapitany T, Kasper S (1994) Endocrine changes within the scope of psychiatric diseases Internist, 35(9): 823-31
• Martinez B, Kasper S, Ruhrmann S, Möller HJ. (1994) Hypericum in the treatment of seasonal affective disorders J Geriatr Psychiatry Neurol, 1: 29-33
• Danos P, Kasper S, Scholl H, Kaiser J, Ruhrmann S, Hoflich G, Möller H (1994) Clinical Response to Sleep Deprivation and Auditory-Evoked Potentials - Preliminary Results Pharmacopsychiatry, 27 (02): 70-71
• Möller H, Fuger J, Kasper S (1994) Efficacy of New Generation Antidepressants: Meta-Analysis of Imipramine-Controlled Studies Pharmacopsychiatry, 27 (06): 215-223
• Stamenkovic M, Aschauer H, Kasper S (1994) Risperidone for Tourette's syndrome Landet, 344 (8936): 1577-1578

• Kasper S, Schindler S, Neumeister A (1994) Le risque de suicide dans la dépression et ses implications pour le traitement psychopharmacologique (Risk of suicide in depression and its implications for psychopharmacological treatment). Neuro-psy, 12: 46-55
• Kasper S, Kapitany T, Neumeister A, Rieder N (1994) Der antidepressive Effekt der Lichttherapie. MMW Fortschr Med, 136: 160-162
• Kasper S, Grünwald I, Danos P, Walter H, Klemm E, Brücke T, Podreka I, Biersack HJ (1994) Die Bedeutung der Hirn-SPECT in der Psychiatrie. Der Nuklearmediziner, 17: 309-326
• Kasper S, Höflich G, Scholl HP, Möller HJ (1994) Safety and antidepressant efficacy of selective serotonin re-uptake inhibitors. Human Psychopharmacology Clinical and Experimental, 9: 1-12
• Kasper S, Höflich G (1994) Pharmakotherapie der Zwangsstörung. TW Neurologie und Psychiatrie , 8: 168-178
• Kasper S, Walter H (1994) Schmerz und Depression. TW Neurologie und Psychiatrie , 8 (Heft 7/8): 347-354

• Kasper S (1994) Vorwort für die Übersetzung des Buches von R. Abrams: Elektrokonvulsionstherapie (EKT). In: Abrams R, Elektrokonvulsionstherapie (EKT) Lake Bluff: Somatils Inc.
• van den Hoofdakker RH, Gordijn MCM, Kasper S (1994) Sleep deprivation in refractory depression: current strategies and future directions. In: Nolen WA, Zohar J, Roose SP, Amsterdam JD (Hrsg.), Refractory depression current strategies and future directions. Chichester: John Wiley and Sons Ltd: pp. 129-142
• Broich K, Kasper S, Danos P, Grünwald F, Laux G, Möller HJ (1994) "Frontale Hypoperfusion" mittels SPECT bei schizophrener Minussymptomatik. In: Möller HJ, Laux G (Hrsg.), Fortschritte in der Diagnostik und Therapie schizophrener Minussymptomatik Springer: pp. 163-170
• Kasper S, Neumeister A (1994) Epidemiology of seasonal affective disorders (SAD) and its subsyndromal form (S-SAD). In: Beigel A, Lobez Ibor JJ, Costa e Silva JA (Hrsg) , Past, Present and Future of Psychiatry. IX Singapore, New Jersey, World Scientific: pp. 300-305
• Kasper S (1994) Neurobiology and new psychopharmacological strategies for treatment of anxiety disorders. In: Darcourt G, Mendlewicz J, Racagni G, Brunello N (Hrsg.) , Current therapeutical approaches to panic and other anxiety disorders Basel, Int Acad Biomed Drug Res. Karger-Verlag: pp. 15-35
• Kasper S, Ruhrmann S, Schuchardt HM (1994) The effects of light therapy in treatment indications other than seasonal affective disorder (SAD). In: Holick MF, Jung EG (Hrsg.), Biologic effects of light 1993 Berlin, New York, De Gruyter &Co: pp. 206-218
• Kasper S, Danos P, Höflich G, Möller HJ (1994) Behandlungsergebnisse mit präsynaptischen und postsynaptischen Dopamin-Agonisten bei Minussymptomatik. In: Möller HJ, Laux G (Hrsg.), Fortschritte in der Diagnostik und Therapie schizophrener Minussymptomatik Springer: pp. 221-239

• Kasper S (1994) Der sichere Umgang mit Antidepressiva. , PM-Verlag, Kössen
• Kasper S, Buchkremer G, Dilling H, Gaebel W, Hautzinger M, Holsboer-Trachsler E, Linden M, Möller HJ, Pöldinger W, Wittchen HU, Wolfersdorf M (1994) Depressive Störungen erkennen und behandeln. , S. Karger, Basel, Freiburg

• Martinez B, Kasper S, Ruhrmann S, Möller HJ (1993) Hypericum in der Behandlung von saisonal abhängigen Depressionen. Nervenheilkunde, 12: 302-307
• Höflich G, Kasper S, Hufnagel A, Ruhrmann S, Möller HJ (1993) Application of transcranial magnetic stimulation for treatment of drug-resistant major depression - a report of two cases. Human Psychopharmacology Clinical and Experimental, 8: 361-365
• Scholl HP, Kasper S, Höflich G, Danos P, Ruhrmann S, Horn R, Möller HJ (1993) Kontralaterale Akzentuierung langsamer Aktivität im EEG nach Elektrokrampftherapie mit unilateraler Reizung Biologische Psychiatrie der Gegenwart, : pp. 210-212
• Kasper S (1993) New experiences with phototherapy: seasonal depression (SAD) and further indications Schweiz Arch. Neurol. Psychiatr., 144(6): 539-60
• Kasper S (1993) The rationale for long-term antidepressant therapy Int Clin Psychopharmacol, 8(4): 225-35
• Kasper S, Dötsch M, Kick H, Vieira A, Möller HJ (1993) Plasma concentrations of fluvoxamine and maprotiline in major depression: implications on therapeutic efficacy and side effects Eur Neuropsychopharmacol, 3(1): 13-21
• Menzel C, Grünwald F, Klemm E, Broich K, Kasper S, Reichmann K, Hotze AL, Biersack HJ (1993) Brain SPECT with 123I-labelled iodobenzamide (IBZM): aspects of semiquantitative evaluation Nuklearmedizin, 32(5): 227-30

• Kasper S (1993) Is severe depression a different illness? The pharmacological evidence. Eur Neuropsychopharmacol, 3: 215-217
• Kasper S, Ruhrmann S (1993) Angst- und Panikstörungen, Diagnostik und Therapie. Arzneimitteltherapie, 11: 118-128
• Grünwald F, Biersack HJ, Danos P, Kasper S (1993) SPECT bei psychiatrischen Erkrankungen. Der Nuklearmediziner, 2 (16): 135-142
• Kasper S (1993) Neue Erfahrungen mit der Lichttherapie: Saisonal abhängige Depressionen und weitere Indikationsgebiete. Schweiz Arch. Neurol. Psychiatr., 144: 539-560

• Rao ML, Fuger J, Ruhrmann S, Andres AH, Kasper S, Deister A, Möller HJ (1993) Einfluß von endogenen und exogenen Liganden auf serotonerge Aktivität bei psychiatrischen Patienten und gesunden Probanden. In: Baumann P (Hrsg.), Biologische Psychiatrie der Gegenwart Wien, New York, Springer : pp. 181-185
• Danos P, Kasper S, Grünwald F, Klemm E, Broich K, Overbeck B, Höflich G, Scholl HP, Biersack HJ, Möller HJ (1993) Psychiatrische Diagnostik und Psychopathologie bei HMPAO-SPECT. In: Baumann P (Hrsg.), Biologische Psychiatrie der Gegenwart Wien, New York, Springer : pp. 482-484
• Danos P, Kasper S, Grünwald F, Broich K, Overbeck B, Höflich G, Krappel C, Biersack HJ, Möller HJ (1993) Pathologische CT- und SPECT-Befunde bei Heroinsucht. In: Baumann P (Hrsg.), Biologische Psychiatrie der Gegenwart Wien, New York, Springer : pp. 551-554
• Horn R, Ries F, Höflich G, Kasper S, Scholl HP, Möller HJ (1993) Intrakranielle hämodynamische Veränderungen während Elektrokrampftherapie. In: Baumann P (Hrsg.), Biologische Psychiatrie der Gegenwart Wien, New York, Springer : pp. 213-216
• Horn R, Kasper S, Eichert V, Möller HJ (1993) EEG-Mapping bei Alzheimer Patienten unter Behandlung mit Velnacrine (HP-029). In: Baumann P (Hrsg.), Biologische Psychiatrie der Gegenwart Wien, New York, Springer : pp. 422-425
• Broich K, Kasper S, Grünwald F, Danos P, Klemm E, Biersack HJ, Möller HJ (1993) Darstellung von Dopamin-D2-Rezeptoren mittels 123J-IBZM-SPECT bei schizophrenen Patienten. In: Baumann P (Hrsg.), Biologische Psychiatrie der Gegenwart Wien, New York, Springer : pp. 511-513
• Ruhrmann S, Kasper S, Höflich G, Hawellek B, Danos P, Möller H (1993) Objektivierung der quantitativen Lichtexposition während Lichttherapie durch kontinuierliche photometrische Aufzeichnung. In: Baumann P (Hrsg.), Biologische Psychiatrie der Gegenwart Wien, New York, Springer : pp. 268-271
• Höflich G, Kasper S, Rao ML, Ruhrmann S, Danos P, Scholl HP, Möller HJ (1993) Pharmakokinetik und hormonelle Veränderungen unter peroraler und Medikation von Levomepromazin. In: Baumann P (Hrsg.), Biologische Psychiatrie der Gegenwart Wien, New York, Springer : pp. 679-681
• Höflich G, Hasse-Sander I, Kasper S, Ruhrmann S, Danos P, Scholl HP, Möller HJ (1993) Einfluß von Levomepromazin auf psychometrische Parameter bei gesunden Probanden. In: Baumann P (Hrsg.), Biologische Psychiatrie der Gegenwart Wien, New York, Springer : pp. 682-684
• Kasper S, Höflich G, Ruhrmann S, Rao ML, Danos P, Scholl HP, Möller HJ (1993) Hormonelle Verlaufsparameter unter Elektrokrampftherapie bei Patientinnen mit therapieresistenter Depression. In: Baumann P (Hrsg.), Biologische Psychiatrie der Gegenwart Wien, New York, Springer : pp. 186-190
• Grünwald F, Danos P, Kasper S, Reichmann K, Briele B, Klemm E, Rieker O, Shih WJ, Möller HJ, Biersack HJ (1993) CT in psychiatric diseases. In: Höfer R, Bergmann H, Sinzinger H (Hrsg), Radioaktive Isotope in Klinik und Forschung Stuttgart, New York, Schattauer Verlag: pp. 122-125
• Kasper S, Ruhrmann S (1993) Leitlinien zur Diagnostik und Therapie der Angst/Panikstörungen. In: Kasper S, Möller HJ (Hrsg.), Angst- und Panikerkrankungen, Diagnose - Therapie Gräfelfing, SMV Verlag: pp. 137-152
• Kasper S, Möller HJ (1993) Praxisorientiertes Angstprogramm (PAAP) - ein Fortbildungsprogramm für den Allgemeinarzt zum Thema Angststörung. In: Kasper S, Möller HJ (Hrsg.), Angst- und Panikerkrankungen, Diagnose - Therapie Gräfelfing, SMV Verlag: pp. 153-159
• Kasper S, Höflich G, Scholl HP, Möller HJ (1993) Sicherheit und antidepressive Wirksamkeit von spezifischen Serotonin-Wiederaufnahmehemmern (SSRIs). In: Lungershausen E, Joraschky P, Barocka A (Hrsg.), Depression, Neue Perspektiven der Diagnostik und Therapie Berlin, Heidelberg, New York, Springer : pp. 163-182
• Scholl HP, Kasper S (1993) Die Bedeutung neurophysiologischer Methoden bei der Vorhersage des Therapieerfolges auf Neuroleptika bei schizophrenen Patienten. In: Möller HJ (Hrsg.), Therapierestistenz unter Neuroleptikabehandlung New York, Springer: pp. 49-67
• Kasper S, Danos P, Scholl HP, Ruhrmann S, Höflich G, Möller HJ (1993) Quantitatives EEG und Ansprechen auf therapeutischen Schlafentzug bei depressiven Patienten. In: Baumann P (Hrsg.), Biologische Psychiatrie der Gegenwart Wien, New York, Springer : pp. 217-220
• Kasper S, Möller HJ (1993) National Anxiety Awareness Program (NAAP). Ein Fortbildungsprogramm für den Allgemeinarzt. In: Holsboer F, Philipp M. (Hrsg), Angststörungen. Pathogenese Diagnostik Therapie Gräfelfing, SMVerlag : pp. 59-66
• Kasper S, Ruhrmann S (1993) Schmerz aus psychiatrischer Sicht. In: Möller HJ, Przuntek H (Hrsg.) , Therapie im Grenzgebiet von Psychiatrie und Neurologie Berlin, Heidelberg, New York, Springer Verlag: pp. 179-197
• Kasper S (1993) Akute exogene Psychosen. In: Möller HJ (Hrsg.) , Therapie psychiatrischer Erkrankungen Stuttgart: Enke Verlag: pp. 363-373
• Kasper S (1993) Indikation und Praxis des therapeutischen Schlafentzugs und der Lichttherapie. In: HJ Möller (Hrsg.) , Therapie psychiatrischer Erkrankungen Stuttgart,Enke Verlag: pp. 318-325
• Kasper S, Nedopil N (1993) Klinik der Aminpräkursoren. In: Riederer P, Laux G, Pöldinger W (Hrsg.) , Neuro-Psychopharmaka Wien, New York, Springer Verlag: pp.446-453

• Wittchen HU, Bullinger-Naber M, Hand I, Kasper S, Katschnig H, Linden M, Margraf J, Möller HJ, Naber D, Pöldinger W, van de Roemer A (1993) Was Sie schon immer über Angst wissen wollten. , S. Karger, Basel, Freiburg
• Wittchen HU, Aldenhoff J, Bullinger-Naber M, Hand I, Kasper S, Katschnig H, Linden M, Margraf J, Möller HJ, Naber D, Pöldinger W (1993) Wie informiere ich meine Patienten über Angst?. , S. Karger, Basel, Freiburg
• Kasper S, Möller HJ (1993) Angst- und Panikerkrankungen, Diagnose - Therapie. , SMV Verlag Gräfelfing

• Kasper S, Fuger J (1992) Clinical profile of selective serotonin re-uptake inhibitors New prospects in psychiatry, The bio-clinical interface I, Developments in psychiatry, : pp. 313-338
• Kasper S, Wehr TA (1992) The role of sleep and wakefulness in the genesis of depression and mania Encephale, 1: 45-50
• Kasper S, Ruhrmann S, Haase T, Möller HJ (1992) Recurrent brief depression and its relationship to seasonal affective disorder Eur Arch Psychiatry Clin Neurosci, 242(1): 20-6
• Kasper S, Fuger J, Möller HJ (1992) Comparative efficacy of antidepressants Drugs, 2: 11-22
• Kasper S, Fuger J, Zinner HJ, Bäuml J, Möller HJ (1992) Early clinical results with the neuroleptic roxindole (EMD 49,980) in the treatment of schizophrenia--an open study Eur Neuropsychopharmacol, 2(1): 91-5
• Ruhrmann S, Kasper S (1992) Seasonal depression. Phototherapy and psychopharmacologic approaches Eur Neuropsychopharmacol, 15(10): 293-9
• Höflich G, Kasper S, Möller HJ (1992) Successful treatment of seasonal compulsive syndrome with phototherapy Nervenarzt, 63(11): 701-4
• Kasper S, Fuger J, Zinner H, Bäuml J, Möller H (1992) Early clinical results with the neuroleptic roxindole (EMD 49 980) in the treatment of schizophrenia — an open study Eur Neuropsychopharmacol, 2 (1): 91-95
• Höflich G, Kasper S, Danos P, Schmidt R (1992) Thyroid hormones, body temperature, and antidepressant treatment Biol Psychiatry, 31 (8): 859-862

• Ruhrmann S, Kasper S (1992) Saisonal abhängige Depression - Lichttherapie und psychopharmakologische Ansätze. Medizinische Monatsschrift für Pharmazeuten, 15: 293-299
• Danos P, Kasper S, Grünwald F, Klemm E, Broich K, Overbeck B, Biersack HJ, Möller HJ (1992) HMPAO-SPECT bei psychiatrischen Erkrankungen - Erste Ergebnisse. Nervenheilkunde, (Sonderheft, 108. Wanderversammlung Südwestdeutscher Neurologen und Psychiater, 13.-14.6.1992): 17-19
• Kasper S, Ruhrmann S (1992) (1992) Lichttherapie zur Behandlung saisonal abhängiger Depressionen (SAD). Pso-Magazin / Wissenschaftliches Beiheft , 7: 26-44

• Biersack HJ, Klemm E, Grünwald F, Danos P, Overbeck B, Kasper S (1992) Brain SPECT in psychiatry. In: Biersack HJ, Klemm E, Grünwald F, Danos P, Overbeck B, Kasper S (Hrsg.), Proceedings of the Fifth Asia and Oceania Congress of Nuclear Medicine and Biology. Amsterdam: Elsevier: pp. 89-101
• Höflich G, Kasper S, Hufnagel A, Schmidt R (1992) Veränderung von Schilddrüsenhormonen unter antidepressiver Behandlung bei Patienten mit Major Depression. In: Gaebel W, Laux G (Hrsg.), Biologische Psychiatrie - Synopsis 1990/91 Berlin, Heidelberg, Springer : pp. 457-459
• Kasper S, Sack DA, Wehr TA (1992) Therapeutischer Schlafentzug und Resistenz auf Antidepressiva - Neuroendokrinologische und klinische Befunde. In: Gaebel W, Laux G (Hrsg.), Biologische Psychiatrie - Synopsis 1990/91 Berlin, Heidelberg, Springer : pp. 446-448
• Klemm E, Roth A, Kasper S, Möller HJ, Penin H, Grünwald F, Biersack HJ (1992) Hinweise auf eine temporo-mesiale Funktionsstörung bei Rapid-cycling-Zyklothymie. In: Gaebel W, Laux G (Hrsg.), Biologische Psychiatrie - Synopsis 1990/91 Berlin, Heidelberg, Springer : pp. 308-310
• Biersack HJ, Grünwald F, Klemm E, Danos P, Kasper S, Overbeck B (1992) SPECT Imaging in mood disorders and schizophrenia. In: Limuris GS, Shukla SK (Hrsg.), Braindiagnostics and radionuclids Athen, Mediterra-Publishers : pp. 103-107
• Kasper S (1992) Einfluß des Tageslichtes auf die seelische Gesundheit. In: G. Huber (Hrsg.), Verantwortung für die Zukunft. Klima- und Umweltforschung an der Universität Bonn Bonn, Bornemann Verlag: pp. 263-264
• Kasper S (1992) Neuroendokrinologie und Schizophrenie. In: Steinberg R (Hrsg.) , Schizophrenie Klingenmünster, Tilia Verlag : pp. 114-129
• Kasper S, Wehr TA, Rosenthal NE (1992) Reduzierte Amplitude zircadianer Hormonprofile bei Patienten mit saisonal abhängiger Depression (SAD). In: Gaebel W, Laux G (Hrsg.), Biologische Psychiatrie - Synopsis 1990/91 Berlin, Heidelberg, Springer : pp. 356-359
• Kasper S, Eichert V, Horn R, Höflich G, Möller HJ (1992) Mapping von EEG und EP unter therapeutischem Schlafentzug bei Patienten mit Major Depression - Erste Ergebnisse. In: Gaebel W, Laux G (Hrsg.), Biologische Psychiatrie - Synopsis 1990/91 Berlin, Heidelberg, Springer : pp. 285-288

• Joseph-Vanderpool JR, Rosenthal NE, Chrousos GP, Wehr TA, Skwerer R, Kasper S, Gold PW (1991) Abnormal pituitary-adrenal response to corticotropin-releasing hormone in patients with seasonal affective disorder: clinical and pathophysiological implications J Clin Endocrinol Metab, 72: 1382-1387
• Kasper S, Rosenthal NE, Barberi S, Williams A, Tamarkin L, Rogers SL, Pillemer SR. (1991) mmunological correlates of seasonal fluctuations in mood and behavior and their relationship to phototherapy Psychiat Res, 36(3): 253-64
• Wehr TA, Giesen HA, Schulz PM, Anderson JL, Joseph-Vanderpool JR, Kelly K, Kasper S, Rosenthal NE (1991) Contrasts between symptoms of summer depression and winter depression J Affect Disord, 23(4): 173-83
• Hardin T, Wehr T, Brewerton T, Kasper S, Berrettini W, Rabkin J, Rosenthal N (1991) Evaluation of seasonality in six clinical populations and two normal populations J Psychiatr Res, 25 (3): 75-87
• Kasper S, Kick H, Voll G, Vieira A (1991) Therapeutic sleep deprivation and antidepressant medication in patients with major depression Eur Neuropsychopharmacol, 1 (2): 107-111

• Ballus Pascual CB, Beaumont G, Figueira ML, Larsen JK, Kasper S (1991) Langzeitbehandlung der Depression. Blickpunkt Depression, 7: 13-17
• Kasper S (1991) Chronobiologie und Depressionsbehandlung. Die Medizinische Welt, 42: 896-903
• Fleischhacker WW, Kasper S (1991) Timing of phototherapy and occurance of mania. Biol Psychiatry, 29: 1156-1160
• Kasper S (1991) Quo vadis S-SAD? Comment on draft report of the SLBTR scientific and clinical advisory work group. Light Treatment and Biological Rhythms, 3: 16-18
• Kasper S, Fuger J (1991) Seasonal affective disorder (SAD) and phototherapy: Clinical description and theoretical considerations. Mini-review. Bulletin du Groupe d Etude des Rythmes biologiques, 23: 35-46
• Kasper S (1991) Saisonal abhängige Depressionen (SAD) und Phototherapie ZFA, 67: 1976-1984

• Kasper S, Ruhrmann S, Höflich G, Möller HJ (1991) Therapeutic sleep deprivation and antidepressive medication. In: , Biological Psychiatry Elsevier BV: pp. 800-803
• Kasper S (1991) Biorhythmische Aspekte bei depressiven Erkrankungen. In: H. Hippius, W. Pöldinger (Hrsg.), Phantasie und Wirklichkeit: Fluvoxamin Berlin, Heidelberg, New York, Springer : pp. 95-97
• Hefner G, Elger CE, Hufnagel A, Kappler S, Kasper S (1991) Psychiatrische und psychosoziale Erhebungen bei pharmakoresistenten Epilepsiepatienten mit komplex-partiellen Anfallsleiden vor und nach Temporallappenresektion. In: Scheffer D (Hrsg.), Epilepsie 90 Einhorn Presse Verlag: pp. 152-156

• Kasper S (1991) Jahreszeit und Befindlichkeit in der Allgemeinbevölkerung. Eine Mehrebenenuntersuchung zur Epidemiologie, Biologie und therapeutischen Beeinflußbarkeit (Lichttherapie) saisonaler Befindlichkeitsschwankungen. Monographien aus dem Gesamtgebiete der Psychiatrie, Band 66. Springer Verlag, Springer Verlag, Heidelberg, New York

• Rosenthal NE, Levendosky AA, Skwerer RG, Joseph-Vanderpool JR, Kelly KA, Hardin T, Kasper S, DellaBella P, Wehr TA (1990) Effects of light treatment on core body temperature in seasonal affective disorder Biol Psychiatry, 27(1): 39-50
• Rosen LN, Targum SD, Terman M, Bryant MJ, Hoffman H, Kasper SF, Hamovit JR, Docherty JP, Welch B, Rosenthal NE (1990) Prevalence of seasonal affective disorder at four latitudes Psychiat Res, 31(2): 131-44
• Kasper S, Rogers SL, Madden PA, Joseph-Vanderpool JR, Rosenthal NE (1990) The effects of phototherapy in the general population J Affect Disord, 18(3): 211-9
• Kasper S, Kamo T (1990) Seasonality in major depressed inpatients J Affect Disord, 19(4): 243-8
• Kasper S, Vieira A, Schmidt R, Richter P (1990) Multiple Hormone Responses to Stimulation with dl-Fenfluramine in Patients with Major Depression before and after Antidepressive Treatment Pharmacopsychiatry, 23 (02): 76-84
  | Weblink |
• Kasper S, Voll G, Vieira A, Kick H (1990) Response to Total Sleep Deprivation Before and During Treatment with Fluvoxamine or Maprotiline in Patients with Major Depression - Results of a Double-Blind Study Pharmacopsychiatry, 23 (03): 135-142
  | Weblink |

• Kasper S, Wehr TA, Bartko JJ, Gaist PA, Rosenthal NE (1990) Epidemiologische Ergebnisse bei saisonalen Veränderungen der Stimmung und des Verhaltens. Psychiatry Digest (BRD), 4: 7-9
• Kasper S, Wehr TA, Bartko JJ, Gaist PA, Rosenthal NE (1990) Epidemiologic findings of seasonal changes in mood and behavior Psychiatry Digest (GB), 2: 11-12
• Kamo T, Kasper S (1990) Current perspectives of seasonal affective disorders Japanese Journal of Clinical Psychiatry , 19: 103-111

• Kasper S (1990) Saisonale Befindlichkeitsschwankungen in der Allgemeinbevölkerung, deren biologische Grundlagen und der therapeutische Effekt der Phototherapie. Habilitationsschrift, Medizinische Fakultät der Universität Bonn,

• Kasper S (1990) Schlafentzugstherapie - eine Chance bei Antidepressiva-Nonresponse?. In: Möller HJ (Hrsg.), Therapieresistenz unter Antidepressiva-Behandlung Heidelberg,Springer Verlag: pp. 149-166
• Mundt C, Kasper S (1990) Skalen zur Erfassung schizophrener Minussympromatik im Vergleich. In: Möller H.J., Pelzer E. (Hrsg.), Neuere Ansätze zur Diagnostik und Therapie schizophrener Minussymptomatik Heidelberg,Springer Verlag: pp. 47-57
• Kasper S, Hennemann-Hohenfried U (1990) Zirkadiane und saisonale Rhythmen immunologischer Funktionen bei affektiven Störungen. In: Kaschka WP und Aschauer HN (Hrsg.), Psychoimmunologie Stuttgart New York,Thieme Verlag: pp. 64-74
• Kasper S, Wehr TA, Rosenthal NE (1990) Zur Epidemiologie und Biologie saisonal abhängiger Depressionsformen (SAD). In: Lungershausen E, Kaschka WP, Witkowski RJ (Hrsg), Affektive Psychosen Stuttgart Schattauer Verlag : pp 97-102

• Kasper S, Vieira A (1989) Stimulation with dl-Fenfluramine and antidepressive medication in major depressed inpatients Pharmacopsychiatry, 22: 201
• Giambra LM, Rosenberg E, Kasper S, Yee W, Sack DA (1989) A circadian rhythm in the frequency of spontaneous task-unrelated images and thoughts Journal of imagination, cognition, and personality , 8: 309-314
• Souêtre E, Rosenthal NE, Kasper S, Wehr TA. (1989) Effects of light in depressive syndromes Presse med, 18(2): 53-4
• Mundt C, Kasper S, Huerkamp M (1989) The diagnostic specificity of negative symptoms and their psychopathological context Br J Psychiatry, 7: 32-6
• Bartko J, Kasper S (1989) Seasonal changes in mood and behavior: A cluster analytic approach Psychiat Res, 28 (2): 227-239
• Kasper S, Rogers SLB, Yancey A, Schulz PM, Skwerer RG, Rosenthal NE (1989) Phototherapy in Individuals With and Without Subsyndromal Seasonal Affective Disorder Arch Gen Psychiatry, 46 (9): 837
• Kasper S, Wehr TA, Bartko JJ, Gaist PA, Rosenthal NE (1989) Epidemiological Findings of Seasonal Changes in Mood and Behavior Arch Gen Psychiatry, 46 (9): 823

• Kasper S, Kamo T (1989) Zur Saisonalität bei stationär behandelten depressiven Patienten Psycho, 15: 408-411
• Kasper S (1989) Saisonal abhängige Depressionen (SAD) Deutsches Ärzteblatt, 86: B-554

• Kasper S (1989) Beurteilung der Hypothalamus-Hypophysen-Nebennierenrindenfunktion bei psychiatrischen Patienten durch die Betamethason induzierte Cortisol-Suppressibilität Promotionsschrift, Medizinische Fakultät der Universität Bonn,

• Skwerer RG, Jacobsen FM, Duncan CC, Kelly KA, Sack DA, Tamarkin L, Gaist PA, Kasper S, Rosenthal NE (1989) Neurobiology of seasonal affective disorder and phototherapy. In: Rosenthal NE, Blehar M (Hrsg.), Seasonal affective disorders and phototherapy New York,Guilford Press: pp. 311-332
• Rosenthal NE, Kasper S, Schulz P, Wehr TA (1989) New concepts and developments in seasonal affective disorder. In: C Thompson and T. Silverstone (eds.), Seasonal affective disorder London,CNS Clinical Neuroscience: pp. 97-132
• Wehr TA, Giesen HA, Schulz PM, Joseph-Vanderpool JR, Kasper S, Kelly KA, Rosenthal NE (1989) Summer depression: description of the syndrome and comparison with winter depression. In: Rosenthal NE, Blehar M (Hrsg.), Seasonal affective disorders and phototherapy New York,Guilford Press: pp. 55-63
• Kasper S, Rogers S, Yancey A, Skwerer RG, Schulz PM, Rosenthal NE (1989) Psychological effects of light therapy in normals. In: Rosenthal NE, Blehar M (Hrsg.), Seasonal affective disorders and phototherapy New York,Guilford Press: pp. 260-270
• Kasper S, Sack DA, Wehr TA (1989) Therapeutischer Schlafentzug und Energiehaushalt. In: Pflug B, B Lemmer (Hrsg.) , Chronobiologie und Chronopharmakologie, Antidepressiva - Schlafentzug - Licht. Gustav Fischer Verlag: pp. 53-79
• Kasper S, Rosenthal NE (1989) Anxiety and depression in seasonal affective disorders. In: Kendall PC, Watson D (Hrsg.), Anxiety and depression: distinctive and overlapping features San Diego, Academic Press: pp 341-375

• Kasper S, Vieira A, Wehr TA, Schmidt R, Kick H, Voll G, Murphy DL (1988) Serotonergically induced hormonal responses and the antidepressant effect of total sleep deprivation in patients with major depression Psychopharmacol Bull, 24(3): 450-3
• Schulz PM, Goldberg S, Wehr TA, Sack DA, Kasper S, Rosenthal NE (1988) Personality as a dimension of summer and winter depression Psychopharmacol Bull, 24(3): 476-83
• Kasper S, Vecsei P, Richter P, Haack D, Diebold K, Katzinski L (1988) Judgement of the hypothalamic-pituitary-adrenocortical function in psychiatric patients by betamethasone-induced cortisol suppressibility. J Neural Transm, 74(3): 161-74
• Kasper S, Wehr TA, Rosenthal NE (1988) Season-related forms of depression. II. Modification by phototherapy and biological results Nervenarzt, 59(4): 20014
• Kasper S, Wehr TA, Rosenthal NE (1988) Season-related forms of depression. I. Principles and clinical description of the syndrome Nervenarzt, 59(4): 191-9
• Kasper S, Katzinski L, Lenarz T, Richter P (1988) Auditory evoked potentials and total sleep deprivation in depressed patients Psychiat Res, 25(1): 91-100
• Skwerer RG, Jacobsen FM, Duncan CC, Kelly KA, Sack DA, Tamarkin L, Gaist PA, Kasper S, Rosenthal NE (1988) Neurobiology of seasonal affective disorder and phototherapy J Biol Rhythms, 3(2): 135-54
• Kasper S, Sack DA, Wehr TA, Kick H, Voll G, Vieira A (1988) Nocturnal TSH and prolactin secretion during sleep deprivation and prediction of antidepressant response in patients with major depression Biol Psychiatry, 24(6): 631-41
• Kasper S, Rogers S, Yancey A, Schulz P, Skwerer R, Rosenthal N (1988) Phototherapy in Subsyndromal Seasonal Affective Disorder (S-SAD) and "Diagnosed" Controls Pharmacopsychiatry, 21 (06): 428-429

• Kasper S, Rosenthal NE (1988) Jahreszeiten der Depression Selecta, 8: 506-515

• Mundt C, Kasper S (1988) Sind negative und Basissymptome spezifisch für Schizophrenie?. In: Böker F, Weig W (Hrsg), Aktuelle Kernfragen in der Psychiatrie. Springer Verlag : pp 122-127
• Kasper S, Katzinski L, Lenarz T, Richter P (1988) Frühe und späte akustisch evozierte Potentiale bei endogen depressiven Patienten und therapeutischer Schlafentzug. In: Beckmann H und Laux G (Hrsg), Biologische Psychiatrie, Synopsis 1986/87 Springer Verlag : pp 310-314

• Kasper S, Kick H (1987) Occipitally accented asymmetry in the EEG of schizophrenic patients Nervenarzt, 58(6): 369-73
• Mundt C, Kasper S (1987) Schizophrenia specificity of negative and basic symptoms Nervenarzt, 58(8): 489-95

• Kasper S, Vieira A, Voll G, Kick H (1987) Prädiktiver Wert der Beurteilung des serotonergen Systems Fortschritte in der Pharmakotherapie/Advances in pharmacotherapy, 3: 112-124

• Kasper S, Richter P, Diebold K, Haak D, Vieira A (1986) Betamethason-induzierte Cortisol-Suppressibilität in der psychiatrischen Diagnostik Psycho, 12: 387-388
• Kasper S, Mundt C (1986) Diagnostische Spezifität der sogenannten Negativsymptome, Basissymptome bzw. verminderte Intentionalität. Erste Ergebnisse Psycho, 12: 385-386

• Kasper S (1986) Bericht und Kommentar über: "3rd biannual winter workshop on schizophrenia" in Schladming, Österreich, 26.-31.1.1986 Nervenarzt, 57: 548-549
• Kasper S (1986) Bemerkungen zur Arbeit von F. Holsboer und O. Benkert, Neuroendokrinologische und endokrinologische Forschung bei depressiven Patienten Nervenarzt, 57: 124

• Kasper S, Moises HW, Beckmann H (1983) Dexamethasone suppression test combined with total sleep deprivation in depressed patients Psychiatr Clin, 16(1): 17-25
• Häfner H, Kasper S (1983) Emergency in general medicine (50). Acute life-threatening catatonia ZFA, 59(11): 665-6
• Kasper S, Beckmann H (1983) Dexamethasone suppression test in a pluridiagnostic approach: its relationship to psychopathological and clinical variables Acta Psychiatr Scand, 68(1): 31-7

• Beckmann H, Kasper S (1983) Serotonin-Vorstufen als Antidepressiva: Eine Übersicht Fortschr Neurol Psychiatr, 51 (05): 176-182

• Moises HW, Kasper S, Beckmann H (1982) Trazodon und Amitriptylin im Vergleich (Eine Doppelblindstudie bei stationären Patienten) Arzneimittelforschung/Drug Research, 32: 875
• Gattaz WF, Kasper S, Propping P, Friedl W, Beckmann H (1982) Relevance of sex difference for Mao-activity in schizophrenics Arzneimittelforschung/Drug Research, 32: 895
• Kasper S, Moises HW, Beckmann H (1982) Erweiterter Dexamethason-Suppressionstest als Maß für die Sensibilität des Hypothalamus-Hypophysen-Nebennierenrinden-Systems Arzneimittelforschung/Drug Research, 32: 882
• Kasper S, Gattaz WF, Schmitt R, Beckmann H (1982) Stressbedingte Wachstumshormon- und Cortisol-Ausschüttung bei schizophrenen Patienten im Vergleich zu Kontrollen Arzneimittelforschung/Drug Research, 32: 896
• Häfner H, Kasper S (1982) Acute life-threatening catatonia Nervenarzt, 53(7): 385-94

• Kasper S, Beckmann H (1982) Klinische Bedeutsamkeit des Dexamethason-Suppressionstests bei endogen depressiven Patienten Psycho, 1: 72-73

• Gattaz WF, Kasper S (1982) MAO-Bestimmung bei schizophrenen Patienten: Geschlechtsunterschiede. In: Beckmann H (Hrsg.), Biologische Psychiatrie. Fortschritte psychiatrischer Forschung Stuttgart:Thieme: pp 175-181

• Gattaz WF, Kasper S, Ewald R, Beckmann H (1981) HLA, schizophrenias and arthropathies Psychiatr Clin, 14(1): 49-55
• Gattaz WF, Kasper S, Propping P, Friedl W, Beckmann H (1981) Low platelet MAO activity and schizophrenia: sex differences Acta Psychiatr Scand, 64(2): 167-74
  | Weblink |
• Gattaz* W, Kasper S, Kohlmeyer** K, Beckmann H (1981) Die kraniale Computertomographie in der Schizophrenieforschung Fortschr Neurol Psychiatr, 49 (07): 286-291
  | Weblink |
• Moises H, Kasper S, Beckmann H (1981) Trazodone and Amitriptyline in Treatment of Depressed Inpatients Pharmacopsychiatry, 14 (05): 167-171
  | Weblink |
• Kasper S, Moises H, Beckmann H (1981) The Anticholinergic Biperiden in Depressive Disorders Pharmacopsychiatry, 14 (06): 195-198
  | Weblink |

• Gattaz WF, Kasper S, Ewald RW, Beckman H (1980) Arthropathies and schizophrenia Lancet, 2(8193): 536-537
  | Weblink |
• Gattaz WF, Kasper S, Beckmann H (1980) HL-A-antigens, schizophrenia and brain atrophy Br J Psychiatry, 137: 398-399
  | Weblink |